NDC,PRODUCTTYPENAME,PROPRIETARYNAME,PROPRIETARYNAMESUFFIX,NONPROPRIETARYNAME,DOSAGEFORMNAME,ROUTENAME,STARTMARKETINGDATE,ENDMARKETINGDATE,MARKETINGCATEGORYNAME,APPLICATIONNUMBER,LABELERNAME,SUBSTANCENAME,ACTIVE_NUMERATOR_STRENGTH,ACTIVE_INGRED_UNIT,PHARM_CLASSES,DEASCHEDULE,NDC_EXCLUDE_FLAG,LISTING_RECORD_CERTIFIED_THROUGH,PRIMARY_ICD10,ALL_ICD10_MAPPINGS,MAPPING_CONFIDENCE
0067-0109,HUMAN OTC DRUG,Theraflu,Severe Congestion Relief Cooling Nasal Mist,Oxymetazoline HCl,SPRAY,NASAL,20250601,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,OXYMETAZOLINE HYDROCHLORIDE,0.5,mg/mL,"Imidazolines [CS], Increased Sympathetic Activity [PE], Vasoconstriction [PE], Vasoconstrictor [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0110,HUMAN OTC DRUG,Theraflu,Severe Congestion Relief Nasal Mist,Oxymetazoline HCl,SPRAY,NASAL,20250601,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,OXYMETAZOLINE HYDROCHLORIDE,0.5,mg/mL,"Imidazolines [CS], Increased Sympathetic Activity [PE], Vasoconstriction [PE], Vasoconstrictor [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0111,HUMAN OTC DRUG,Theraflu,Severe Cold Relief Soft Chews,"Acetaminophen, Dextromethorphan HBr","TABLET, CHEWABLE",ORAL,20240619,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE,325; 10,mg/1; mg/1,"Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0112,HUMAN OTC DRUG,Theraflu,Severe Cold Relief Nighttime Soft Chews,"Acetaminophen, Diphenhydramine HCl","TABLET, CHEWABLE",ORAL,20240930,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE,325; 12.5,mg/1; mg/1,"Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0114,HUMAN OTC DRUG,Theraflu-D Flu Relief Max Strength plus Nasal Decongestant,Nighttime,"Acetaminophen, Chlorpheniramine maleate, Dextromethorphan HBr, Pseudoephedrine HCl",SYRUP,ORAL,20240619,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE,1000; 4; 30; 60,mg/30mL; mg/30mL; mg/30mL; mg/30mL,"Adrenergic alpha-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0115,HUMAN OTC DRUG,Theraflu-D Flu Relief Max Strength plus Nasal Decongestant,,"Acetaminophen, Dextromethorphan HBr, Pseudoephedrine HCl",SYRUP,ORAL,20240619,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE,1000; 30; 60,mg/30mL; mg/30mL; mg/30mL,"Adrenergic alpha-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0117,HUMAN OTC DRUG,Gas-X,Extra Strength,Simethicone,"TABLET, CHEWABLE",ORAL,20120101,,OTC MONOGRAPH DRUG,M002,Haleon US Holdings LLC,"DIMETHICONE, UNSPECIFIED",125,mg/1,Skin Barrier Activity [PE],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0118,HUMAN OTC DRUG,Gas-X,Total Relief Maximum Strength,"Calcium carbonate, Simethicone","TABLET, CHEWABLE",ORAL,20220203,,OTC MONOGRAPH DRUG,M001,Haleon US Holdings LLC,"CALCIUM CARBONATE; DIMETHICONE, UNSPECIFIED",750; 250,mg/1; mg/1,Skin Barrier Activity [PE],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0119,HUMAN OTC DRUG,Gas-X,Total Relief Maximum Strength,"Calcium carbonate, Simethicone","TABLET, CHEWABLE",ORAL,20220203,,OTC MONOGRAPH DRUG,M001,Haleon US Holdings LLC,CALCIUM CARBONATE; DIMETHICONE,750; 250,mg/1; mg/1,Skin Barrier Activity [PE],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0122,HUMAN OTC DRUG,Theraflu,Severe Cold Relief Combo Pack,"acetaminophen, dextromethorphan hbr, diphenhydramine hcl",KIT,,20240415,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0123,HUMAN OTC DRUG,Theraflu,Severe Cold Relief Combo Pack,"acetaminophen, dextromethorphan hbr, diphenhydramine hcl",KIT,,20240601,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-0129,HUMAN OTC DRUG,Gas-X,Extra Strength,Simethicone,"TABLET, CHEWABLE",ORAL,20120101,,OTC MONOGRAPH DRUG,M002,Haleon US Holdings LLC,"DIMETHICONE, UNSPECIFIED",125,mg/1,Skin Barrier Activity [PE],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2000,HUMAN OTC DRUG,Excedrin,Extra Strength Pain Reliever,"Acetaminophen, Aspirin (NSAID), and Caffeine","TABLET, FILM COATED",ORAL,20060927,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2001,HUMAN OTC DRUG,Excedrin,Extra Strength Pain Reliever,"Acetaminophen, Aspirin (NSAID), and Caffeine","TABLET, FILM COATED",ORAL,20190315,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2002,HUMAN OTC DRUG,Excedrin,Extra Strength Headache,"Acetaminophen, Aspirin (NSAID), Caffeine","TABLET, FILM COATED",ORAL,20240101,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2003,HUMAN OTC DRUG,Excedrin,Extra Strength Headache,"Acetaminophen, Aspirin (NSAID), Caffeine","TABLET, FILM COATED",ORAL,20240101,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2021,HUMAN OTC DRUG,Excedrin,Extra Strength Geltabs,"Acetaminophen, Asprin, Caffeine","TABLET, COATED",ORAL,20110913,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2035,HUMAN OTC DRUG,Excedrin,Migraine Geltabs,"Acetaminophen, Asprin, Caffeine","TABLET, COATED",ORAL,20110913,,NDA,NDA020802,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2039,HUMAN OTC DRUG,EXCEDRIN,MIGRAINE,"Acetaminophen, Aspirin (NSAID) and Caffeine","TABLET, FILM COATED",ORAL,20100215,,NDA,NDA020802,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2040,HUMAN OTC DRUG,Excedrin,Migraine,"Acetaminophen, Aspirin, and Caffeine","TABLET, FILM COATED",ORAL,20200930,,NDA,NDA020802,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2042,HUMAN OTC DRUG,Excedrin,Migraine Relief,"Acetaminophen, Aspirin (NSAID), Caffeine","TABLET, FILM COATED",ORAL,20240101,,NDA,NDA020802,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2056,HUMAN OTC DRUG,Excedrin PM Triple Action Caplets,,"Acetaminophen, Aspirin (NSAID) and Diphenhydramine Citrate","TABLET, COATED",ORAL,20140924,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; DIPHENHYDRAMINE CITRATE,250; 250; 38,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-2086,HUMAN OTC DRUG,4 Way,Fast Acting,Phenylephrine hydrochloride,SPRAY,NASAL,20100101,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,PHENYLEPHRINE HYDROCHLORIDE,10,mg/mL,"Adrenergic alpha1-Agonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-3998,HUMAN OTC DRUG,Lamisil,AT,TERBINAFINE HYDROCHLORIDE,CREAM,TOPICAL,20050810,20251130,NDA,NDA020980,Haleon US Holdings LLC,TERBINAFINE HYDROCHLORIDE,10,mg/g,"Allylamine Antifungal [EPC], Allylamine [CS]",,N,,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0067-6094,HUMAN OTC DRUG,Theraflu,PowerPods Daytime Severe Cold,"ACETAMINOPHEN, DEXTROMETHORPHAN, PHENYLEPHRINE","POWDER, FOR SOLUTION",ORAL,20180728,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 20; 10,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6095,HUMAN OTC DRUG,THERAFLU,POWERPODS NIGHTTIME SEVERE COLD,"ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PHENYLEPHRINE HCL","POWDER, FOR SOLUTION",ORAL,20180728,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 25; 10,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6274,HUMAN OTC DRUG,Gas-X,Ultra Strength AntiGas Softgels,Simethicone,"CAPSULE, LIQUID FILLED",ORAL,20070901,,OTC MONOGRAPH DRUG,M002,Haleon US Holdings LLC,DIMETHICONE,180,mg/1,Skin Barrier Activity [PE],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6275,HUMAN OTC DRUG,Gas-X,Extra Strength Softgels,Simethicone,"CAPSULE, LIQUID FILLED",ORAL,20110912,,OTC MONOGRAPH DRUG,M001,Haleon US Holdings LLC,"DIMETHICONE, UNSPECIFIED",125,mg/1,Skin Barrier Activity [PE],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6283,HUMAN OTC DRUG,Gas-X,Maximum Strength Softgels,Simethicone,"CAPSULE, LIQUID FILLED",ORAL,20190310,,OTC MONOGRAPH DRUG,M001,Haleon US Holdings LLC,DIMETHICONE,250,mg/1,Skin Barrier Activity [PE],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6426,HUMAN OTC DRUG,THERAFLU,MULTI-SYMPTOM SEVERE COLD,"ACETAMINOPHEN, DEXTROMETHORPHAN HBr, PHENYLEPHRINE HCl","POWDER, FOR SOLUTION",ORAL,20140701,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,500; 20; 10,mg/237mL; mg/237mL; mg/237mL,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6800,HUMAN OTC DRUG,Theraflu Severe Cold Relief Daytime Berry Burst,,"Acetaminophen, Dextromethorphan HBr, Phenylephrine Hydrochloride",POWDER,ORAL,20220120,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 20; 10,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6801,HUMAN OTC DRUG,Theraflu Severe Cold relief Nighttime,,"Acetaminophen, Diphenhydramine Hydrochloride, Phenylephrine Hydrochloride",POWDER,ORAL,20220120,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE,500; 25; 10,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6802,HUMAN OTC DRUG,THERAFLU,Severe Cold Relief Daytime,"ACETAMINOPHEN, DEXTROMETHORPHAN HBr, PHENYLEPHRINE HCl","POWDER, FOR SOLUTION",ORAL,20230120,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,500; 20; 10,mg/237mL; mg/237mL; mg/237mL,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6803,HUMAN OTC DRUG,Theraflu,Severe Cold Relief Nighttime,"ACETAMINOPHEN, DIPHENHYDRAMINE HCl, PHENYLEPHRINE HCl","POWDER, FOR SOLUTION",ORAL,20230120,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 25; 10,mg/237mL; mg/237mL; mg/237mL,"Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-6804,HUMAN OTC DRUG,Theraflu Severe Cold Relief Daytime and Theraflu Severe Cold Relief Nighttime,,"Acetaminophen, Dextromethorphan HBr, Phenylephrine HCl, Diphenhydramine HCl",KIT,,20230120,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-7917,HUMAN OTC DRUG,Theraflu,Daytime Severe Cold and Cough,"ACETAMINOPHEN, DEXTROMETHORPHAN, PHENYLEPHRINE","POWDER, FOR SOLUTION",ORAL,20120924,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 20; 10,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-7918,HUMAN OTC DRUG,THERAFLU,NIGHTTIME SEVERE COLD AND COUGH,"ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PHENYLEPHRINE HCL","POWDER, FOR SOLUTION",ORAL,20140701,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 25; 10,mg/237mL; mg/237mL; mg/237mL,"Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-7919,HUMAN OTC DRUG,Theraflu Multi-Symptom Severe Cold and Theraflu Nighttime Severe Cold and Cough,,"Acetaminophen, Dextromethorphan HBr, Phenylephrine HCl, Diphenhydramine HCl",KIT,,20160101,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-7921,HUMAN OTC DRUG,Theraflu Flu Relief Max Strength,Daytime,"Acetaminophen, Dextromethorphan HBr",POWDER,ORAL,20220615,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE,1000; 30,mg/1; mg/1,"Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-7922,HUMAN OTC DRUG,Theraflu Flu Relief Max Strength,Nighttime,"Acetaminophen, Chlorpheniramine maleate, Dextromethorphan HBr",POWDER,ORAL,20220615,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE,1000; 4; 30,mg/1; mg/1; mg/1,"Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-7923,HUMAN OTC DRUG,Theraflu Flu Relief Max Strength,Daytime Nighttime Combo Pack,"Acetaminophen, Dextromethorphan HBr, and Acetaminophen, Chlorpheniramine maleate, Dextromethorphan HBr",KIT,,20220615,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8125,HUMAN OTC DRUG,Theraflu ExpressMax,Daytime Nighttime Value Pack,"Acetaminophen, Dextromethorphan HBr, Phenylephrine HCl and Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl",KIT,,20150715,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8127,HUMAN OTC DRUG,Theraflu ExpressMax,Daytime Severe Cold and Cough,"Acetaminophen, Dextromethorphan HBr, Phenylephrine HCl",SYRUP,ORAL,20150715,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 20; 10,mg/30mL; mg/30mL; mg/30mL,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8129,HUMAN OTC DRUG,Theraflu ExpressMax,Nighttime Severe Cold and Cough,"Acetaminophen, Diphenhydramine HCl, Phenylephrine HCl",SYRUP,ORAL,20150715,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 25; 10,mg/30mL; mg/30mL; mg/30mL,"Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8132,HUMAN OTC DRUG,Theraflu ExpressMax Severe Cold and Flu Syrup,,"Acetaminophen, Dextromethorphan HBr, Guaifenesin, Phenylephrine HCl",SYRUP,ORAL,20170707,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE,650; 20; 400; 10,mg/1; mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8136,HUMAN OTC DRUG,Theraflu ExpressMax,Daytime Severe Cold and Cough,"acetaminophen, dextromethorphan HBr, phenylephrine HCl","TABLET, FILM COATED",ORAL,20160705,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,325; 10; 5,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8137,HUMAN OTC DRUG,Theraflu ExpressMax,Nighttime Severe Cold and Cough,"acetaminophen, diphenhydramine HCl, phenylephrine HCl","TABLET, FILM COATED",ORAL,20160705,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE,325; 12.5; 5,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8139,HUMAN OTC DRUG,Excedrin,Tension Headache,"Acetaminophen, Caffeine","TABLET, FILM COATED",ORAL,20161215,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; CAFFEINE,500; 65,mg/1; mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Methylxanthine [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8140,HUMAN OTC DRUG,EX-LAX,REGULAR STRENGTH CHOCOLATED STIMULANT LAXATIVE,SENNOSIDES,"TABLET, CHEWABLE",ORAL,20170801,,OTC MONOGRAPH DRUG,M007,Haleon US Holdings LLC,SENNOSIDES,15,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8141,HUMAN OTC DRUG,EX-LAX,REGULAR STRENGTH STIMULANT LAXATIVE,SENNOSIDES,TABLET,ORAL,20170701,,OTC MONOGRAPH DRUG,M007,Haleon US Holdings LLC,SENNOSIDES,15,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8142,HUMAN OTC DRUG,EX-LAX,MAXIMUM STRENGTH STIMULANT LAXATIVE,SENNOSIDES,PILL,ORAL,20170701,,OTC MONOGRAPH DRUG,M007,Haleon US Holdings LLC,SENNOSIDES,25,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8143,HUMAN OTC DRUG,Perdiem,,"Sennosides, stimulant laxative",TABLET,ORAL,20170701,,OTC MONOGRAPH DRUG,M007,Haleon US Holdings LLC,SENNOSIDES,15,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8145,HUMAN OTC DRUG,Theraflu ExpressMax Severe Cold and Flu Caplets,,"Acetaminophen, Dextromethorphan HBr, Guaifenesin, Phenylephrine HCl","TABLET, COATED",ORAL,20170717,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE,325; 10; 200; 5,mg/1; mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8147,HUMAN OTC DRUG,Excedrin PM Triple Action Caplets and Excedrin Tension Headache,,"Acetaminophen, Aspirin (NSAID), Caffeine, and Diphenhydramine Citrate",KIT,,20170601,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8148,HUMAN OTC DRUG,Excedrin PM Triple Action Caplets and Excedrin Extra Strength Pain Reliever,,"Acetaminophen, Aspirin (NSAID), Caffeine, and Diphenhydramine Citrate",KIT,,20180501,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8151,HUMAN OTC DRUG,Excedrin Extra Strength and Excedrin Tension Headache,,"Acetaminophen, Aspirin (NSAID), and Caffeine",KIT,,20180930,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8152,HUMAN OTC DRUG,Voltaren,Arthritis Pain,diclofenac sodium,GEL,TOPICAL,20200513,,NDA,NDA022122,Haleon US Holdings LLC,DICLOFENAC SODIUM,10,mg/g,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Prostaglandin Production [PE], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0067-8153,HUMAN OTC DRUG,Voltaren,Arthritis Pain,diclofenac sodium,KIT,,20200513,,NDA,NDA022122,Haleon US Holdings LLC,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8154,HUMAN OTC DRUG,Voltaren,Arthritis Pain,diclofenac sodium,KIT,,20250219,,NDA,NDA022122,Haleon US Holdings LLC,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8161,HUMAN OTC DRUG,Theraflu Flu Relief Maximum Strength,Daytime Nighttime Combo Pack,"Acetaminophen, Dextromethorphan HBr and Acetaminophen, Chlorpheniramine maleate, Dextromethorphan HBr",KIT,,20220627,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8200,HUMAN OTC DRUG,Theraflu Multi-Symptom Severe Cold and Theraflu Nighttime Severe Cold and Cough,,"Acetaminophen, Dextromethorphan HBr, Phenylephrine HCl, Diphenhydramine HCl",KIT,,20160101,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8201,HUMAN OTC DRUG,EXCEDRIN,MIGRAINE,"Acetaminophen, Aspirin (NSAID) and Caffeine","TABLET, FILM COATED",ORAL,20100215,,NDA,NDA020802,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8202,HUMAN OTC DRUG,Excedrin,Extra Strength Pain Reliever,"Acetaminophen, Aspirin (NSAID), and Caffeine","TABLET, FILM COATED",ORAL,20200309,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8203,HUMAN OTC DRUG,Excedrin,Extra Strength Pain Reliever,"Acetaminophen, Aspirin (NSAID), and Caffeine","TABLET, FILM COATED",ORAL,20210115,,OTC MONOGRAPH DRUG,M013,Haleon US Holdings LLC,ACETAMINOPHEN; ASPIRIN; CAFFEINE,250; 250; 65,mg/1; mg/1; mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8204,HUMAN OTC DRUG,Theraflu Flu Relief Max Strength,Daytime,"Acetaminophen, Dextromethorphan HBr",SYRUP,ORAL,20220627,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE,1000; 30,mg/30mL; mg/30mL,"Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8205,HUMAN OTC DRUG,Theraflu Flu Relief Max Strength,Nighttime,"Acetaminophen, Chlorpheniramine maleate, Dextromethorphan HBr",SYRUP,ORAL,20220627,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE,1000; 4; 30,mg/30mL; mg/30mL; mg/30mL,"Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8206,HUMAN OTC DRUG,Theraflu Flu Relief Max Strength,Daytime Nighttime Value Pack,"Acetaminophen, Dextromethorphan HBr, and Acetaminophen, Chlorpheniramine maleate, Dextromethorphan HBr",KIT,,20220627,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8211,HUMAN OTC DRUG,Theraflu,Severe Cold Relief Daytime with Honey Ginger Flavor,"ACETAMINOPHEN, DEXTROMETHORPHAN HBr, PHENYLEPHRINE HCl","POWDER, FOR SOLUTION",ORAL,20230501,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 20; 10,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0067-8212,HUMAN OTC DRUG,Theraflu,Severe Cold Relief Nighttime with Honey Elderberry Flavor,"ACETAMINOPHEN, DIPHENHYDRAMINE HCl, PHENYLEPHRINE HCl","POWDER, FOR SOLUTION",ORAL,20230501,,OTC MONOGRAPH DRUG,M012,Haleon US Holdings LLC,ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE,650; 25; 10,mg/1; mg/1; mg/1,"Adrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0068-0597,HUMAN PRESCRIPTION DRUG,Rifadin IV,,rifampin,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,19890525,20260930,NDA,NDA050627,Sanofi-Aventis U.S. LLC,RIFAMPIN,600,mg/10mL,"Rifamycin Antibacterial [EPC], Rifamycins [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0068-0599,HUMAN PRESCRIPTION DRUG,Rifadin IV NOVAPLUS,,rifampin,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20170201,20251031,NDA,NDA050627,Sanofi-Aventis U.S. LLC,RIFAMPIN,600,mg/10mL,"Rifamycin Antibacterial [EPC], Rifamycins [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0043,HUMAN PRESCRIPTION DRUG,Heparin Sodium,,Heparin Sodium,INJECTION,INTRAVENOUS; SUBCUTANEOUS,20110721,,NDA,NDA201370,Pfizer Laboratories Div Pfizer Inc,HEPARIN SODIUM,1000,[USP'U]/mL,"Anti-coagulant [EPC], Heparin [CS], Unfractionated Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0058,HUMAN PRESCRIPTION DRUG,Heparin Sodium,,Heparin Sodium,INJECTION,INTRAVENOUS; SUBCUTANEOUS,20110721,,NDA,NDA201370,Pfizer Laboratories Div Pfizer Inc,HEPARIN SODIUM,1000,[USP'U]/mL,"Anti-coagulant [EPC], Heparin [CS], Unfractionated Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0059,HUMAN PRESCRIPTION DRUG,Heparin Sodium,,Heparin Sodium,INJECTION,INTRAVENOUS; SUBCUTANEOUS,20110721,,NDA,NDA201370,Pfizer Laboratories Div Pfizer Inc,HEPARIN SODIUM,5000,[USP'U]/mL,"Anti-coagulant [EPC], Heparin [CS], Unfractionated Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0106,HUMAN PRESCRIPTION DRUG,ELELYSO,,Taliglucerase alfa,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20120501,,BLA,BLA022458,Pfizer Laboratories Div Pfizer Inc,TALIGLUCERASE ALFA,200,U/5mL,"Glucosylceramidase [CS], Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0135,HUMAN PRESCRIPTION DRUG,BOSULIF,,Bosutinib,"TABLET, FILM COATED",ORAL,20120904,,NDA,NDA203341,Pfizer Laboratories Div Pfizer Inc,BOSUTINIB MONOHYDRATE,100,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0136,HUMAN PRESCRIPTION DRUG,BOSULIF,,Bosutinib,"TABLET, FILM COATED",ORAL,20120904,,NDA,NDA203341,Pfizer Laboratories Div Pfizer Inc,BOSUTINIB MONOHYDRATE,500,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0137,HUMAN PRESCRIPTION DRUG,Heparin Sodium,,Heparin Sodium,INJECTION,INTRAVENOUS; SUBCUTANEOUS,20130311,,NDA,NDA201370,Pfizer Laboratories Div Pfizer Inc,HEPARIN SODIUM,1000,[USP'U]/mL,"Anti-coagulant [EPC], Heparin [CS], Unfractionated Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0145,HUMAN PRESCRIPTION DRUG,INLYTA,,axitinib,"TABLET, FILM COATED",ORAL,20120127,,NDA,NDA202324,Pfizer Laboratories Div Pfizer Inc,AXITINIB,1,mg/1,"Kinase Inhibitor [EPC], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0151,HUMAN PRESCRIPTION DRUG,INLYTA,,axitinib,"TABLET, FILM COATED",ORAL,20120127,,NDA,NDA202324,Pfizer Laboratories Div Pfizer Inc,AXITINIB,5,mg/1,"Kinase Inhibitor [EPC], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0187,HUMAN PRESCRIPTION DRUG,Ibrance,,palbociclib,CAPSULE,ORAL,20150203,,NDA,NDA207103,Pfizer Laboratories Div Pfizer Inc,PALBOCICLIB,75,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0188,HUMAN PRESCRIPTION DRUG,Ibrance,,palbociclib,CAPSULE,ORAL,20150203,,NDA,NDA207103,Pfizer Laboratories Div Pfizer Inc,PALBOCICLIB,100,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0189,HUMAN PRESCRIPTION DRUG,Ibrance,,palbociclib,CAPSULE,ORAL,20150203,,NDA,NDA207103,Pfizer Laboratories Div Pfizer Inc,PALBOCICLIB,125,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0193,HUMAN PRESCRIPTION DRUG,BOSULIF,,Bosutinib,"TABLET, FILM COATED",ORAL,20171218,,NDA,NDA203341,Pfizer Laboratories Div Pfizer Inc,BOSUTINIB MONOHYDRATE,400,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0195,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,2500,[iU]/.2mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0196,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,5000,[iU]/.2mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0197,HUMAN PRESCRIPTION DRUG,Vizimpro,,dacomitinib,"TABLET, FILM COATED",ORAL,20181004,,NDA,NDA211288,Pfizer Laboratories Div Pfizer Inc,DACOMITINIB,15,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0206,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,7500,[iU]/.3mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0209,HUMAN PRESCRIPTION DRUG,Propofol,,Propofol,"INJECTION, EMULSION",INTRAVENOUS,20201005,,ANDA,ANDA205576,Pfizer Laboratories Div Pfizer Inc,PROPOFOL,10,mg/mL,"General Anesthesia [PE], General Anesthetic [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0217,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,10000,[iU]/mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0220,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,12500,[iU]/.5mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0223,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,15000,[iU]/.6mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0227,HUMAN PRESCRIPTION DRUG,Lorbrena,,lorlatinib,"TABLET, FILM COATED",ORAL,20181119,,NDA,NDA210868,Pfizer Laboratories Div Pfizer Inc,LORLATINIB,25,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Cation Transporter 1 Inhibitors [MoA], P-Glycoprotein Inducers [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0228,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,18000,[iU]/.72mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0231,HUMAN PRESCRIPTION DRUG,Lorbrena,,lorlatinib,"TABLET, FILM COATED",ORAL,20181119,,NDA,NDA210868,Pfizer Laboratories Div Pfizer Inc,LORLATINIB,100,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Cation Transporter 1 Inhibitors [MoA], P-Glycoprotein Inducers [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0232,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20150401,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,25000,[iU]/mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0234,HUMAN PRESCRIPTION DRUG,Propofol,,Propofol,"INJECTION, EMULSION",INTRAVENOUS,20201005,,ANDA,ANDA205576,Pfizer Laboratories Div Pfizer Inc,PROPOFOL,10,mg/mL,"General Anesthesia [PE], General Anesthetic [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0235,HUMAN PRESCRIPTION DRUG,Cibinqo,,abrocitinib,"TABLET, FILM COATED",ORAL,20220224,,NDA,NDA213871,Pfizer Laboratories Div Pfizer Inc,ABROCITINIB,50,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0238,HUMAN PRESCRIPTION DRUG,Ruxience,,rituximab-pvvr,"INJECTION, SOLUTION",INTRAVENOUS,20200123,,BLA,BLA761103,Pfizer Laboratories Div Pfizer Inc,RITUXIMAB,100,mg/10mL,"CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0242,HUMAN PRESCRIPTION DRUG,Toviaz,,fesoterodine fumarate,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20081031,,NDA,NDA022030,Pfizer Laboratories Div Pfizer Inc,FESOTERODINE FUMARATE,4,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0244,HUMAN PRESCRIPTION DRUG,Toviaz,,fesoterodine fumarate,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20081031,,NDA,NDA022030,Pfizer Laboratories Div Pfizer Inc,FESOTERODINE FUMARATE,8,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0248,HUMAN PRESCRIPTION DRUG,Propofol,,Propofol,"INJECTION, EMULSION",INTRAVENOUS,20201005,,ANDA,ANDA205576,Pfizer Laboratories Div Pfizer Inc,PROPOFOL,10,mg/mL,"General Anesthesia [PE], General Anesthetic [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0249,HUMAN PRESCRIPTION DRUG,Ruxience,,rituximab-pvvr,"INJECTION, SOLUTION",INTRAVENOUS,20200123,,BLA,BLA761103,Pfizer Laboratories Div Pfizer Inc,RITUXIMAB,500,mg/50mL,"CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0251,HUMAN PRESCRIPTION DRUG,Xalkori,,CRIZOTINIB,"CAPSULE, COATED PELLETS",ORAL,20231120,,NDA,NDA217581,Pfizer Laboratories Div Pfizer Inc,CRIZOTINIB,20,mg/1,"Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Organic Cation Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0252,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,"CAPSULE, LIQUID FILLED",ORAL,20240417,,NDA,NDA217439,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.1,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0253,HUMAN PRESCRIPTION DRUG,Fragmin,,Dalteparin Sodium,INJECTION,SUBCUTANEOUS,20221017,,NDA,NDA020287,Pfizer Laboratories Div Pfizer Inc,DALTEPARIN SODIUM,2500,[iU]/mL,"Anti-coagulant [EPC], Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0255,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20241014,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0274,HUMAN PRESCRIPTION DRUG,Velsipity,,etrasimod,"TABLET, FILM COATED",ORAL,20231019,,NDA,NDA216956,Pfizer Laboratories Div Pfizer Inc,ETRASIMOD ARGININE,2,mg/1,"Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0277,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20240819,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0284,HUMAN PRESCRIPTION DRUG,Ibrance,,palbociclib,"TABLET, FILM COATED",ORAL,20200330,,NDA,NDA212436,Pfizer Laboratories Div Pfizer Inc,PALBOCICLIB,75,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0291,HUMAN PRESCRIPTION DRUG,Nivestym,,filgrastim-aafi,"INJECTION, SOLUTION",SUBCUTANEOUS,20180924,,BLA,BLA761080,Pfizer Laboratories Div Pfizer Inc,FILGRASTIM,300,ug/.5mL,"Granulocyte Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0292,HUMAN PRESCRIPTION DRUG,Nivestym,,filgrastim-aafi,"INJECTION, SOLUTION",SUBCUTANEOUS,20180924,,BLA,BLA761080,Pfizer Laboratories Div Pfizer Inc,FILGRASTIM,480,ug/.8mL,"Granulocyte Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0293,HUMAN PRESCRIPTION DRUG,Nivestym,,filgrastim-aafi,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20190311,,BLA,BLA761080,Pfizer Laboratories Div Pfizer Inc,FILGRASTIM,300,ug/mL,"Granulocyte Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0294,HUMAN PRESCRIPTION DRUG,Nivestym,,filgrastim-aafi,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20190311,,BLA,BLA761080,Pfizer Laboratories Div Pfizer Inc,FILGRASTIM,480,ug/1.6mL,"Granulocyte Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0296,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,CAPSULE,ORAL,20181026,20270131,NDA,NDA211651,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.25,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0297,VACCINE,TicoVac,,Tick-Borne Encephalitis Vaccine,INJECTION,INTRAMUSCULAR,20220627,,BLA,BLA125740,Pfizer Laboratories Div Pfizer Inc,TICK-BORNE ENCEPHALITIS PURIFIED ANTIGEN (FORMALDEHYDE INACTIVATED),1.2,ug/.25mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0298,HUMAN PRESCRIPTION DRUG,Daurismo,,glasdegib,"TABLET, FILM COATED",ORAL,20181210,,NDA,NDA210656,Pfizer Laboratories Div Pfizer Inc,GLASDEGIB,25,mg/1,"Hedgehog Pathway Inhibitor [EPC], Smoothened Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0305,HUMAN PRESCRIPTION DRUG,Trazimera,,trastuzumab-qyyp,KIT,,20200224,,BLA,BLA761081,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0308,HUMAN PRESCRIPTION DRUG,Trazimera,,trastuzumab-qyyp,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20210310,,BLA,BLA761081,Pfizer Laboratories Div Pfizer Inc,TRASTUZUMAB,150,mg/7.15mL,"HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0315,HUMAN PRESCRIPTION DRUG,Zirabev,,bevacizumab-bvzr,"INJECTION, SOLUTION",INTRAVENOUS,20200113,,BLA,BLA761099,Pfizer Laboratories Div Pfizer Inc,BEVACIZUMAB,100,mg/4mL,"Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0324,HUMAN PRESCRIPTION DRUG,NYVEPRIA,,pegfilgrastim-apgf,"INJECTION, SOLUTION",SUBCUTANEOUS,20201215,,BLA,BLA761111,Pfizer Laboratories Div Pfizer Inc,PEGFILGRASTIM,6,mg/.6mL,"Granulocyte Colony-Stimulating Factor [CS], Granulocyte-Macrophage Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0325,HUMAN PRESCRIPTION DRUG,ABRILADA,,adalimumab-afzb,KIT,,20231018,,BLA,BLA761118,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0328,HUMAN PRESCRIPTION DRUG,ABRILADA,,adalimumab-afzb,KIT,,20231018,,BLA,BLA761118,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0333,HUMAN PRESCRIPTION DRUG,ABRILADA,,adalimumab-afzb,KIT,,20231018,,BLA,BLA761118,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0334,HUMAN PRESCRIPTION DRUG,Litfulo,,ritlecitinib,CAPSULE,ORAL,20230706,,NDA,NDA215830,Pfizer Laboratories Div Pfizer Inc,RITLECITINIB TOSYLATE,50,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Janus Kinase 3 Inhibitors [MoA], Kinase Inhibitor [EPC], Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0335,HUMAN PRESCRIPTION DRUG,Cibinqo,,abrocitinib,"TABLET, FILM COATED",ORAL,20220224,,NDA,NDA213871,Pfizer Laboratories Div Pfizer Inc,ABROCITINIB,100,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0336,HUMAN PRESCRIPTION DRUG,Revatio,,sildenafil citrate,"POWDER, FOR SUSPENSION",ORAL,20140602,20250630,NDA,NDA203109,PFIZER LABORATORIES DIV PFIZER INC,SILDENAFIL CITRATE,10,mg/mL,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0338,HUMAN PRESCRIPTION DRUG,Revatio,,sildenafil citrate,"INJECTION, SOLUTION",INTRAVENOUS,20091118,20260331,NDA,NDA022473,PFIZER LABORATORIES DIV PFIZER INC,SILDENAFIL CITRATE,0.8,mg/mL,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0342,HUMAN PRESCRIPTION DRUG,Zirabev,,bevacizumab-bvzr,"INJECTION, SOLUTION",INTRAVENOUS,20200113,,BLA,BLA761099,Pfizer Laboratories Div Pfizer Inc,BEVACIZUMAB,400,mg/16mL,"Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0343,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20241111,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0344,VACCINE,Abrysvo,,Respiratory Syncytial Virus Vaccine,KIT,,20230712,,BLA,BLA125769,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0353,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,"CAPSULE, LIQUID FILLED",ORAL,20240417,,NDA,NDA217439,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.25,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0358,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20240819,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0400,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20140307,,NDA,NDA050733,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,500,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0411,VACCINE,TicoVac,,Tick-Borne Encephalitis Vaccine,INJECTION,INTRAMUSCULAR,20211025,,BLA,BLA125740,Pfizer Laboratories Div Pfizer Inc,TICK-BORNE ENCEPHALITIS PURIFIED ANTIGEN (FORMALDEHYDE INACTIVATED),2.4,ug/.5mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0435,HUMAN PRESCRIPTION DRUG,Cibinqo,,abrocitinib,"TABLET, FILM COATED",ORAL,20220224,,NDA,NDA213871,Pfizer Laboratories Div Pfizer Inc,ABROCITINIB,200,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0454,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,"CAPSULE, LIQUID FILLED",ORAL,20240417,,NDA,NDA217439,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.35,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0468,HUMAN PRESCRIPTION DRUG,CHANTIX,,varenicline tartrate,"TABLET, FILM COATED",ORAL,20060510,,NDA,NDA021928,Pfizer Laboratories Div Pfizer Inc,VARENICLINE TARTRATE,0.5,mg/1,"Cholinergic Agonists [MoA], Cholinergic Receptor Agonist [EPC], Partial Cholinergic Nicotinic Agonist [EPC], Partial Cholinergic Nicotinic Agonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0469,HUMAN PRESCRIPTION DRUG,CHANTIX,,varenicline tartrate,"TABLET, FILM COATED",ORAL,20060510,,NDA,NDA021928,Pfizer Laboratories Div Pfizer Inc,VARENICLINE TARTRATE,1,mg/1,"Cholinergic Agonists [MoA], Cholinergic Receptor Agonist [EPC], Partial Cholinergic Nicotinic Agonist [EPC], Partial Cholinergic Nicotinic Agonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0471,HUMAN PRESCRIPTION DRUG,CHANTIX,,varenicline tartrate,KIT,,20060510,,NDA,NDA021928,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0486,HUMAN PRESCRIPTION DRUG,Ibrance,,palbociclib,"TABLET, FILM COATED",ORAL,20200330,,NDA,NDA212436,Pfizer Laboratories Div Pfizer Inc,PALBOCICLIB,100,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0501,HUMAN PRESCRIPTION DRUG,XELJANZ,XR,tofacitinib,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20160307,,NDA,NDA208246,Pfizer Laboratories Div Pfizer Inc,TOFACITINIB CITRATE,11,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0502,HUMAN PRESCRIPTION DRUG,XELJANZ,XR,tofacitinib,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20200121,,NDA,NDA208246,Pfizer Laboratories Div Pfizer Inc,TOFACITINIB CITRATE,22,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0504,HUMAN PRESCRIPTION DRUG,BOSULIF,,Bosutinib,CAPSULE,ORAL,20240102,,NDA,NDA217729,Pfizer Laboratories Div Pfizer Inc,BOSUTINIB MONOHYDRATE,50,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0505,HUMAN PRESCRIPTION DRUG,Ngenla,,somatrogon-ghla,"INJECTION, SOLUTION",SUBCUTANEOUS,20230731,,BLA,BLA761184,Pfizer Laboratories Div Pfizer Inc,SOMATROGON,24,mg/1.2mL,"11-beta Hydroxysteroid Dehydrogenase Type 1 Inhibitors [MoA], Human Growth Hormone [CS], Recombinant Human Growth Hormone [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0507,HUMAN PRESCRIPTION DRUG,Xalkori,,CRIZOTINIB,"CAPSULE, COATED PELLETS",ORAL,20231120,,NDA,NDA217581,Pfizer Laboratories Div Pfizer Inc,CRIZOTINIB,50,mg/1,"Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Organic Cation Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0520,HUMAN PRESCRIPTION DRUG,Ngenla,,somatrogon-ghla,"INJECTION, SOLUTION",SUBCUTANEOUS,20230731,,BLA,BLA761184,Pfizer Laboratories Div Pfizer Inc,SOMATROGON,60,mg/1.2mL,"11-beta Hydroxysteroid Dehydrogenase Type 1 Inhibitors [MoA], Human Growth Hormone [CS], Recombinant Human Growth Hormone [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0521,HUMAN PRESCRIPTION DRUG,Paxlovid,,nirmatrelvir and ritonavir,KIT,,20250415,,NDA,NDA217188,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0546,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,"CAPSULE, LIQUID FILLED",ORAL,20240417,,NDA,NDA217439,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.5,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0550,HUMAN PRESCRIPTION DRUG,SUTENT,,Sunitinib malate,CAPSULE,ORAL,20060126,,NDA,NDA021938,Pfizer Laboratories Div Pfizer Inc,SUNITINIB MALATE,12.5,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0600,VACCINE,PENBRAYA,,"meningococcal groups a, b, c, w, and y vaccine",KIT,,20231127,,BLA,BLA125770,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0655,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,"CAPSULE, LIQUID FILLED",ORAL,20240417,,NDA,NDA217439,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.75,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0688,HUMAN PRESCRIPTION DRUG,Ibrance,,palbociclib,"TABLET, FILM COATED",ORAL,20200330,,NDA,NDA212436,Pfizer Laboratories Div Pfizer Inc,PALBOCICLIB,125,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0757,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,"CAPSULE, LIQUID FILLED",ORAL,20240417,,NDA,NDA217439,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,1,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0770,HUMAN PRESCRIPTION DRUG,SUTENT,,Sunitinib malate,CAPSULE,ORAL,20060126,,NDA,NDA021938,Pfizer Laboratories Div Pfizer Inc,SUNITINIB MALATE,25,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0809,HUMAN PRESCRIPTION DRUG,INFLECTRA,,infliximab-dyyb,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20161121,,BLA,BLA125544,Pfizer Laboratories Div Pfizer Inc,INFLIXIMAB,100,mg/10mL,"Tumor Necrosis Factor Blocker [EPC], Tumor Necrosis Factor Receptor Blocking Activity [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0830,HUMAN PRESCRIPTION DRUG,SUTENT,,Sunitinib malate,CAPSULE,ORAL,20140712,,NDA,NDA021938,Pfizer Laboratories Div Pfizer Inc,SUNITINIB MALATE,37.5,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-0980,HUMAN PRESCRIPTION DRUG,SUTENT,,Sunitinib malate,CAPSULE,ORAL,20060126,,NDA,NDA021938,Pfizer Laboratories Div Pfizer Inc,SUNITINIB MALATE,50,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1001,HUMAN PRESCRIPTION DRUG,XELJANZ,,tofacitinib,"TABLET, FILM COATED",ORAL,20121109,,NDA,NDA203214,Pfizer Laboratories Div Pfizer Inc,TOFACITINIB CITRATE,5,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1002,HUMAN PRESCRIPTION DRUG,XELJANZ,,tofacitinib,"TABLET, FILM COATED",ORAL,20180702,,NDA,NDA203214,Pfizer Laboratories Div Pfizer Inc,TOFACITINIB CITRATE,10,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1011,PLASMA DERIVATIVE,Panzyga,,immune globulin intravenous (human),SOLUTION,INTRAVENOUS,20190809,,BLA,BLA125587,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1014,HUMAN PRESCRIPTION DRUG,BOSULIF,,Bosutinib,CAPSULE,ORAL,20240102,,NDA,NDA217729,Pfizer Laboratories Div Pfizer Inc,BOSUTINIB MONOHYDRATE,100,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1029,HUMAN PRESCRIPTION DRUG,XELJANZ,,tofacitinib,SOLUTION,ORAL,20210208,,NDA,NDA213082,Pfizer Laboratories Div Pfizer Inc,TOFACITINIB CITRATE,1,mg/mL,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1031,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,CAPSULE,ORAL,20230621,20251231,NDA,NDA211651,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.1,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1061,PLASMA DERIVATIVE,Cutaquig,,immunoglobulin G,SOLUTION,SUBCUTANEOUS,20190913,,BLA,BLA125668,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,165,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1109,PLASMA DERIVATIVE,Panzyga,,immune globulin intravenous (human),SOLUTION,INTRAVENOUS,20190809,,BLA,BLA125587,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1195,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,CAPSULE,ORAL,20181026,20270831,NDA,NDA211651,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,1,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1198,HUMAN PRESCRIPTION DRUG,Vizimpro,,dacomitinib,"TABLET, FILM COATED",ORAL,20181004,,NDA,NDA211288,Pfizer Laboratories Div Pfizer Inc,DACOMITINIB,30,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1224,PLASMA DERIVATIVE,Panzyga,,immune globulin intravenous (human),SOLUTION,INTRAVENOUS,20190809,,BLA,BLA125587,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1235,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,CAPSULE,ORAL,20230621,20251031,NDA,NDA211651,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.35,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1305,HUMAN PRESCRIPTION DRUG,RETACRIT,,epoetin alfa-epbx,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20180618,,BLA,BLA125545,Pfizer Laboratories Div Pfizer Inc,EPOETIN,2000,[iU]/mL,"Erythropoiesis-stimulating Agent [EPC], Erythropoietin [CS], Increased Erythroid Cell Production [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1306,HUMAN PRESCRIPTION DRUG,RETACRIT,,epoetin alfa-epbx,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20180618,,BLA,BLA125545,Pfizer Laboratories Div Pfizer Inc,EPOETIN,3000,[iU]/mL,"Erythropoiesis-stimulating Agent [EPC], Erythropoietin [CS], Increased Erythroid Cell Production [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1307,HUMAN PRESCRIPTION DRUG,RETACRIT,,epoetin alfa-epbx,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20180618,,BLA,BLA125545,Pfizer Laboratories Div Pfizer Inc,EPOETIN,4000,[iU]/mL,"Erythropoiesis-stimulating Agent [EPC], Erythropoietin [CS], Increased Erythroid Cell Production [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1308,HUMAN PRESCRIPTION DRUG,RETACRIT,,epoetin alfa-epbx,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20180618,,BLA,BLA125545,Pfizer Laboratories Div Pfizer Inc,EPOETIN,10000,[iU]/mL,"Erythropoiesis-stimulating Agent [EPC], Erythropoietin [CS], Increased Erythroid Cell Production [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1309,HUMAN PRESCRIPTION DRUG,RETACRIT,,epoetin alfa-epbx,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20180618,,BLA,BLA125545,Pfizer Laboratories Div Pfizer Inc,EPOETIN,40000,[iU]/mL,"Erythropoiesis-stimulating Agent [EPC], Erythropoietin [CS], Increased Erythroid Cell Production [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1311,HUMAN PRESCRIPTION DRUG,RETACRIT,,epoetin alfa-epbx,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20201109,,BLA,BLA125545,Pfizer Laboratories Div Pfizer Inc,EPOETIN,20000,[iU]/mL,"Erythropoiesis-stimulating Agent [EPC], Erythropoietin [CS], Increased Erythroid Cell Production [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1312,PLASMA DERIVATIVE,Panzyga,,immune globulin intravenous (human),SOLUTION,INTRAVENOUS,20190809,,BLA,BLA125587,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1318,HUMAN PRESCRIPTION DRUG,RETACRIT,,epoetin alfa-epbx,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20201109,,BLA,BLA125545,Pfizer Laboratories Div Pfizer Inc,EPOETIN,10000,[iU]/mL,"Erythropoiesis-stimulating Agent [EPC], Erythropoietin [CS], Increased Erythroid Cell Production [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1415,PLASMA DERIVATIVE,Panzyga,,immune globulin intravenous (human),SOLUTION,INTRAVENOUS,20190809,,BLA,BLA125587,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1442,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20241014,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1476,PLASMA DERIVATIVE,Cutaquig,,immunoglobulin G,SOLUTION,SUBCUTANEOUS,20190913,,BLA,BLA125668,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,165,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1500,HUMAN PRESCRIPTION DRUG,Xalkori,,CRIZOTINIB,"CAPSULE, COATED PELLETS",ORAL,20231120,,NDA,NDA217581,Pfizer Laboratories Div Pfizer Inc,CRIZOTINIB,150,mg/1,"Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Organic Cation Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1501,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,CAPSULE,ORAL,20220131,20270331,NDA,NDA211651,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.5,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1509,PLASMA DERIVATIVE,Cutaquig,,immunoglobulin G,SOLUTION,SUBCUTANEOUS,20190913,,BLA,BLA125668,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,165,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1520,HUMAN PRESCRIPTION DRUG,Norvasc,,amlodipine besylate,TABLET,ORAL,19920731,20271031,NDA,NDA019787,PFIZER LABORATORIES DIV PFIZER INC,AMLODIPINE BESYLATE,2.5,mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1530,HUMAN PRESCRIPTION DRUG,Norvasc,,amlodipine besylate,TABLET,ORAL,19920731,20270731,NDA,NDA019787,PFIZER LABORATORIES DIV PFIZER INC,AMLODIPINE BESYLATE,5,mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1531,HUMAN PRESCRIPTION DRUG,Daurismo,,glasdegib,"TABLET, FILM COATED",ORAL,20181210,,NDA,NDA210656,Pfizer Laboratories Div Pfizer Inc,GLASDEGIB,100,mg/1,"Hedgehog Pathway Inhibitor [EPC], Smoothened Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1540,HUMAN PRESCRIPTION DRUG,Norvasc,,amlodipine besylate,TABLET,ORAL,19920731,20271031,NDA,NDA019787,PFIZER LABORATORIES DIV PFIZER INC,AMLODIPINE BESYLATE,10,mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1542,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20240722,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1558,PLASMA DERIVATIVE,Panzyga,,immune globulin intravenous (human),SOLUTION,INTRAVENOUS,20190809,,BLA,BLA125587,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1751,HUMAN PRESCRIPTION DRUG,Talzenna,,talazoparib,CAPSULE,ORAL,20220131,20251130,NDA,NDA211651,Pfizer Laboratories Div Pfizer Inc,TALAZOPARIB TOSYLATE,0.75,mg/1,"Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1802,PLASMA DERIVATIVE,Cutaquig,,immunoglobulin G,SOLUTION,SUBCUTANEOUS,20190913,,BLA,BLA125668,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,165,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1960,PLASMA DERIVATIVE,Cutaquig,,immunoglobulin G,SOLUTION,SUBCUTANEOUS,20190913,,BLA,BLA125668,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,165,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1965,PLASMA DERIVATIVE,Cutaquig,,immunoglobulin G,SOLUTION,SUBCUTANEOUS,20190913,,BLA,BLA125668,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,165,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-1975,HUMAN PRESCRIPTION DRUG,Vyndaqel,,tafamidis meglumine,"CAPSULE, LIQUID FILLED",ORAL,20190516,,NDA,NDA211996,Pfizer Laboratories Div Pfizer Inc,TAFAMIDIS MEGLUMINE,20,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2151,HUMAN PRESCRIPTION DRUG,HYMPAVZI,,marstacimab-hncq,"INJECTION, SOLUTION",SUBCUTANEOUS,20241105,,BLA,BLA761369,Pfizer Laboratories Div Pfizer Inc,MARSTACIMAB,150,mg/mL,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2260,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine besylate and atorvastatin calcium,"TABLET, FILM COATED",ORAL,20040130,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,5; 80,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-2299,HUMAN PRESCRIPTION DRUG,Vizimpro,,dacomitinib,"TABLET, FILM COATED",ORAL,20181004,,NDA,NDA211288,Pfizer Laboratories Div Pfizer Inc,DACOMITINIB,45,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2432,VACCINE,Comirnaty,,"COVID-19 Vaccine, mRNA","INJECTION, SUSPENSION",INTRAMUSCULAR,20240822,,BLA,BLA125742,Pfizer Laboratories Div Pfizer Inc,BNT162B2 OMICRON (KP.2),0.042,mg/.418mL,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2465,VACCINE,Abrysvo,,Respiratory Syncytial Virus Vaccine,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAMUSCULAR,20240730,,BLA,BLA125769,Pfizer Laboratories Div Pfizer Inc,RECOMBINANT STABILIZED RSV A PREFUSION F ANTIGEN; RECOMBINANT STABILIZED RSV B PREFUSION F ANTIGEN,.06; .06,mg/.5mL; mg/.5mL,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2522,HUMAN PRESCRIPTION DRUG,Elrexfio,,elranatamab-bcmm,"INJECTION, SOLUTION",SUBCUTANEOUS,20230815,,BLA,BLA761345,Pfizer Laboratories Div Pfizer Inc,ELRANATAMAB,44,mg/1.1mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2650,HUMAN PRESCRIPTION DRUG,Procardia,XL,nifedipine,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,19890906,,NDA,NDA019684,Pfizer Laboratories Div Pfizer Inc,NIFEDIPINE,30,mg/1,"Calcium Channel Antagonists [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2660,HUMAN PRESCRIPTION DRUG,Procardia,XL,nifedipine,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,19890906,,NDA,NDA019684,Pfizer Laboratories Div Pfizer Inc,NIFEDIPINE,60,mg/1,"Calcium Channel Antagonists [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-2670,HUMAN PRESCRIPTION DRUG,Procardia,XL,nifedipine,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,19890906,,NDA,NDA019684,Pfizer Laboratories Div Pfizer Inc,NIFEDIPINE,90,mg/1,"Calcium Channel Antagonists [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3030,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,19871223,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3031,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,19871223,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3032,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,19871223,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3034,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,19871223,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3051,HUMAN PRESCRIPTION DRUG,ZITHROMAX,,AZITHROMYCIN DIHYDRATE,"POWDER, FOR SUSPENSION",ORAL,19940928,,NDA,NDA050693,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,1,g/1,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3060,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"TABLET, FILM COATED",ORAL,19960718,,NDA,NDA050711,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,250,mg/1,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3070,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"TABLET, FILM COATED",ORAL,20020524,,NDA,NDA050784,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,500,mg/1,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3110,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"POWDER, FOR SUSPENSION",ORAL,19951019,,NDA,NDA050710,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,100,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3120,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"POWDER, FOR SUSPENSION",ORAL,19951019,,NDA,NDA050710,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,200,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3130,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"POWDER, FOR SUSPENSION",ORAL,19951019,,NDA,NDA050710,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,200,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3140,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"POWDER, FOR SUSPENSION",ORAL,19951019,,NDA,NDA050710,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,200,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3150,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,19970130,,NDA,NDA050733,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,500,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3358,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20241111,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-3500,HUMAN PRESCRIPTION DRUG,ZAVZPRET,,zavegepant,SPRAY,NASAL,20230601,,NDA,NDA216386,Pfizer Laboratories Div Pfizer Inc,ZAVEGEPANT HYDROCHLORIDE,10,mg/.1mL,"Calcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4004,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20130317,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4015,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20140317,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4026,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20140317,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4031,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20250331,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4037,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20140317,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4061,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"TABLET, FILM COATED",ORAL,20190517,,NDA,NDA050711,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,250,mg/1,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4190,HUMAN PRESCRIPTION DRUG,Revatio,,sildenafil citrate,"TABLET, FILM COATED",ORAL,20050603,,NDA,NDA021845,PFIZER LABORATORIES DIV PFIZER INC,SILDENAFIL CITRATE,20,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4200,HUMAN PRESCRIPTION DRUG,Viagra,,sildenafil citrate,"TABLET, FILM COATED",ORAL,19980327,,NDA,NDA020895,PFIZER LABORATORIES DIV PFIZER INC,SILDENAFIL CITRATE,25,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4205,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20241111,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4210,HUMAN PRESCRIPTION DRUG,Viagra,,sildenafil citrate,"TABLET, FILM COATED",ORAL,19980327,,NDA,NDA020895,PFIZER LABORATORIES DIV PFIZER INC,SILDENAFIL CITRATE,50,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4220,HUMAN PRESCRIPTION DRUG,Viagra,,sildenafil citrate,"TABLET, FILM COATED",ORAL,19980327,,NDA,NDA020895,PFIZER LABORATORIES DIV PFIZER INC,SILDENAFIL CITRATE,100,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-4494,HUMAN PRESCRIPTION DRUG,Elrexfio,,elranatamab-bcmm,"INJECTION, SOLUTION",SUBCUTANEOUS,20230815,,BLA,BLA761345,Pfizer Laboratories Div Pfizer Inc,ELRANATAMAB,76,mg/1.9mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5317,HUMAN PRESCRIPTION DRUG,Paxlovid,,nirmatrelvir and ritonavir,KIT,,20231018,,NDA,NDA217188,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5321,HUMAN PRESCRIPTION DRUG,Paxlovid,,nirmatrelvir and ritonavir,KIT,,20231018,,NDA,NDA217188,Pfizer Laboratories Div Pfizer Inc,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5410,HUMAN PRESCRIPTION DRUG,Vistaril,,hydroxyzine pamoate,CAPSULE,ORAL,19941128,20260131,NDA,NDA011459,Pfizer Laboratories Div Pfizer Inc,HYDROXYZINE PAMOATE,25,mg/1,"Antihistamine [EPC], Histamine Receptor Antagonists [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5471,HUMAN PRESCRIPTION DRUG,CEREBYX,,Fosphenytoin Sodium,"INJECTION, SOLUTION",INTRAMUSCULAR; INTRAVENOUS,20131028,,NDA,NDA020450,Pfizer Laboratories Div Pfizer Inc,FOSPHENYTOIN SODIUM,50,mg/mL,"Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5474,HUMAN PRESCRIPTION DRUG,CEREBYX,,Fosphenytoin Sodium,"INJECTION, SOLUTION",INTRAMUSCULAR; INTRAVENOUS,20131028,,NDA,NDA020450,Pfizer Laboratories Div Pfizer Inc,FOSPHENYTOIN SODIUM,50,mg/mL,"Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5629,HUMAN PRESCRIPTION DRUG,Doxorubicin Hydrochloride,,Doxorubicin Hydrochloride,"INJECTION, SOLUTION",INTRAVENOUS,20250331,,NDA,NDA050629,Pfizer Laboratories Div Pfizer Inc,DOXORUBICIN HYDROCHLORIDE,2,mg/mL,"Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5800,HUMAN PRESCRIPTION DRUG,Tikosyn,,dofetilide,CAPSULE,ORAL,19991001,,NDA,NDA020931,Pfizer Laboratories Div Pfizer Inc,DOFETILIDE,0.125,mg/1,Antiarrhythmic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5810,HUMAN PRESCRIPTION DRUG,Tikosyn,,dofetilide,CAPSULE,ORAL,19991001,,NDA,NDA020931,Pfizer Laboratories Div Pfizer Inc,DOFETILIDE,0.25,mg/1,Antiarrhythmic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-5820,HUMAN PRESCRIPTION DRUG,Tikosyn,,dofetilide,CAPSULE,ORAL,19991001,,NDA,NDA020931,Pfizer Laboratories Div Pfizer Inc,DOFETILIDE,0.5,mg/1,Antiarrhythmic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-6001,HUMAN PRESCRIPTION DRUG,CEREBYX,,Fosphenytoin Sodium,"INJECTION, SOLUTION",INTRAMUSCULAR; INTRAVENOUS,20131028,,NDA,NDA020450,Pfizer Laboratories Div Pfizer Inc,FOSPHENYTOIN SODIUM,50,mg/mL,"Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-6002,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-6111,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-6180,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220831,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,5; 10,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-6237,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-6323,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220831,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,5; 20,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-6339,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-6550,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,100,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-6565,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220831,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,5; 40,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-6747,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220831,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,5; 80,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-7232,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220831,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,10; 20,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-7476,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220831,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,10; 80,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-7654,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220831,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,10; 40,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-7810,HUMAN PRESCRIPTION DRUG,Caduet,,amlodipine and atorvastatin,"TABLET, FILM COATED",ORAL,20220606,,NDA,NDA021540,Pfizer Laboratories Div Pfizer Inc,AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE,10; 10,mg/1; mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0069-8140,HUMAN PRESCRIPTION DRUG,Xalkori,,CRIZOTINIB,CAPSULE,ORAL,20110826,,NDA,NDA202570,Pfizer Laboratories Div Pfizer Inc,CRIZOTINIB,250,mg/1,"Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Organic Cation Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-8141,HUMAN PRESCRIPTION DRUG,Xalkori,,CRIZOTINIB,CAPSULE,ORAL,20110826,,NDA,NDA202570,Pfizer Laboratories Div Pfizer Inc,CRIZOTINIB,200,mg/1,"Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Organic Cation Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-8400,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,50,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-8425,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,50,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-8451,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,50,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-8476,PLASMA DERIVATIVE,Octagam Immune Globulin (Human),,Immune Globulin,SOLUTION,INTRAVENOUS,20231113,,BLA,BLA125062,Pfizer Laboratories Div Pfizer Inc,HUMAN IMMUNOGLOBULIN G,50,mg/mL,"Antigen Neutralization [MoA], Human Immunoglobulin G [EPC], Immunoglobulins [CS], Passively Acquired Immunity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-8730,HUMAN PRESCRIPTION DRUG,Vyndamax,,tafamidis,"CAPSULE, LIQUID FILLED",ORAL,20190827,,NDA,NDA212161,Pfizer Laboratories Div Pfizer Inc,TAFAMIDIS,61,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0069-9500,HUMAN PRESCRIPTION DRUG,Zithromax,,azithromycin dihydrate,"TABLET, FILM COATED",ORAL,20200430,,UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE,,Pfizer Laboratories Div Pfizer Inc,AZITHROMYCIN DIHYDRATE,250,mg/1,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0007,HUMAN PRESCRIPTION DRUG,Dilantin Infatabs,,Phenytoin,"TABLET, CHEWABLE",ORAL,19790226,,ANDA,ANDA084427,Parke-Davis Div of Pfizer Inc,PHENYTOIN,50,mg/1,"Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0156,HUMAN PRESCRIPTION DRUG,Lipitor,,atorvastatin calcium,"TABLET, FILM COATED",ORAL,19961217,20250930,NDA,NDA020702,Parke-Davis Div of Pfizer Inc,ATORVASTATIN CALCIUM TRIHYDRATE,20,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0071-0157,HUMAN PRESCRIPTION DRUG,Lipitor,,atorvastatin calcium,"TABLET, FILM COATED",ORAL,19961217,20260331,NDA,NDA020702,Parke-Davis Div of Pfizer Inc,ATORVASTATIN CALCIUM TRIHYDRATE,40,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0071-0158,HUMAN PRESCRIPTION DRUG,Lipitor,,atorvastatin calcium,"TABLET, FILM COATED",ORAL,20000407,20250930,NDA,NDA020702,Parke-Davis Div of Pfizer Inc,ATORVASTATIN CALCIUM TRIHYDRATE,80,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0071-0237,HUMAN PRESCRIPTION DRUG,Zarontin,,Ethosuximide,CAPSULE,ORAL,20000922,,NDA,NDA012380,Parke-Davis Div of Pfizer Inc,ETHOSUXIMIDE,250,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0350,HUMAN PRESCRIPTION DRUG,Nardil,,Phenelzine Sulfate,"TABLET, FILM COATED",ORAL,19610609,,NDA,NDA011909,Parke-Davis Div of Pfizer Inc,PHENELZINE SULFATE,15,mg/1,"Monoamine Oxidase Inhibitor [EPC], Monoamine Oxidase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0369,HUMAN PRESCRIPTION DRUG,Dilantin,,Extended Phenytoin Sodium,CAPSULE,ORAL,19760827,20260131,ANDA,ANDA084349,Parke-Davis Div of Pfizer Inc,PHENYTOIN SODIUM,100,mg/1,"Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0401,HUMAN PRESCRIPTION DRUG,Neurontin,,gabapentin,"TABLET, FILM COATED",ORAL,19981009,,NDA,NDA020882,Parke-Davis Div of Pfizer Inc,GABAPENTIN,800,mg/1,Decreased Central Nervous System Disorganized Electrical Activity [PE],,N,20251231,G89.3,"[{""icd10_code"":""G89.3"",""description"":""Neoplasm related pain (acute)(chronic)"",""confidence"":0.3,""context"":""neuropathic pain""},{""icd10_code"":""G40.909"",""description"":""Epilepsy, unspecified, not intractable, without status epilepticus"",""confidence"":0.25,""context"":""seizure disorder""},{""icd10_code"":""M79.2"",""description"":""Neuralgia and neuritis, unspecified"",""confidence"":0.2,""context"":""nerve pain""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""off-label anxiety""},{""icd10_code"":""G25.3"",""description"":""Myoclonus"",""confidence"":0.1,""context"":""movement disorders""}]",0.30
0071-0417,HUMAN PRESCRIPTION DRUG,Nitrostat,,nitroglycerin,TABLET,SUBLINGUAL,20000501,20260228,NDA,NDA021134,Parke-Davis Div of Pfizer Inc,NITROGLYCERIN,0.3,mg/1,"Nitrate Vasodilator [EPC], Nitrates [CS], Vasodilation [PE]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0513,HUMAN PRESCRIPTION DRUG,Neurontin,,gabapentin,"TABLET, FILM COATED",ORAL,19981009,,NDA,NDA020882,Parke-Davis Div of Pfizer Inc,GABAPENTIN,600,mg/1,Decreased Central Nervous System Disorganized Electrical Activity [PE],,N,20251231,G89.3,"[{""icd10_code"":""G89.3"",""description"":""Neoplasm related pain (acute)(chronic)"",""confidence"":0.3,""context"":""neuropathic pain""},{""icd10_code"":""G40.909"",""description"":""Epilepsy, unspecified, not intractable, without status epilepticus"",""confidence"":0.25,""context"":""seizure disorder""},{""icd10_code"":""M79.2"",""description"":""Neuralgia and neuritis, unspecified"",""confidence"":0.2,""context"":""nerve pain""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""off-label anxiety""},{""icd10_code"":""G25.3"",""description"":""Myoclonus"",""confidence"":0.1,""context"":""movement disorders""}]",0.30
0071-0525,HUMAN PRESCRIPTION DRUG,Celontin,,methsuximide,CAPSULE,ORAL,19570208,,NDA,NDA010596,Parke-Davis Div of Pfizer Inc,METHSUXIMIDE,300,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0527,HUMAN PRESCRIPTION DRUG,Accupril,,quinapril hydrochloride,"TABLET, FILM COATED",ORAL,19911119,,NDA,NDA019885,Parke-Davis Div of Pfizer Inc,QUINAPRIL HYDROCHLORIDE,5,mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0530,HUMAN PRESCRIPTION DRUG,Accupril,,quinapril hydrochloride,"TABLET, FILM COATED",ORAL,19911119,,NDA,NDA019885,Parke-Davis Div of Pfizer Inc,QUINAPRIL HYDROCHLORIDE,10,mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0532,HUMAN PRESCRIPTION DRUG,Accupril,,quinapril hydrochloride,"TABLET, FILM COATED",ORAL,19911119,,NDA,NDA019885,Parke-Davis Div of Pfizer Inc,QUINAPRIL HYDROCHLORIDE,20,mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0535,HUMAN PRESCRIPTION DRUG,Accupril,,quinapril hydrochloride,"TABLET, FILM COATED",ORAL,19911119,,NDA,NDA019885,Parke-Davis Div of Pfizer Inc,QUINAPRIL HYDROCHLORIDE,40,mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0737,HUMAN PRESCRIPTION DRUG,Lopid,,gemfibrozil,"TABLET, FILM COATED",ORAL,20040330,,NDA,NDA018422,Parke-Davis Div of Pfizer Inc,GEMFIBROZIL,600,mg/1,"PPAR alpha [CS], Peroxisome Proliferator Receptor alpha Agonist [EPC], Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-0803,HUMAN PRESCRIPTION DRUG,Neurontin,,gabapentin,CAPSULE,ORAL,19931230,,NDA,NDA020235,Parke-Davis Div of Pfizer Inc,GABAPENTIN,100,mg/1,Decreased Central Nervous System Disorganized Electrical Activity [PE],,N,20251231,G89.3,"[{""icd10_code"":""G89.3"",""description"":""Neoplasm related pain (acute)(chronic)"",""confidence"":0.3,""context"":""neuropathic pain""},{""icd10_code"":""G40.909"",""description"":""Epilepsy, unspecified, not intractable, without status epilepticus"",""confidence"":0.25,""context"":""seizure disorder""},{""icd10_code"":""M79.2"",""description"":""Neuralgia and neuritis, unspecified"",""confidence"":0.2,""context"":""nerve pain""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""off-label anxiety""},{""icd10_code"":""G25.3"",""description"":""Myoclonus"",""confidence"":0.1,""context"":""movement disorders""}]",0.30
0071-0805,HUMAN PRESCRIPTION DRUG,Neurontin,,gabapentin,CAPSULE,ORAL,19931230,,NDA,NDA020235,Parke-Davis Div of Pfizer Inc,GABAPENTIN,300,mg/1,Decreased Central Nervous System Disorganized Electrical Activity [PE],,N,20251231,G89.3,"[{""icd10_code"":""G89.3"",""description"":""Neoplasm related pain (acute)(chronic)"",""confidence"":0.3,""context"":""neuropathic pain""},{""icd10_code"":""G40.909"",""description"":""Epilepsy, unspecified, not intractable, without status epilepticus"",""confidence"":0.25,""context"":""seizure disorder""},{""icd10_code"":""M79.2"",""description"":""Neuralgia and neuritis, unspecified"",""confidence"":0.2,""context"":""nerve pain""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""off-label anxiety""},{""icd10_code"":""G25.3"",""description"":""Myoclonus"",""confidence"":0.1,""context"":""movement disorders""}]",0.30
0071-0806,HUMAN PRESCRIPTION DRUG,Neurontin,,gabapentin,CAPSULE,ORAL,19931230,,NDA,NDA020235,Parke-Davis Div of Pfizer Inc,GABAPENTIN,400,mg/1,Decreased Central Nervous System Disorganized Electrical Activity [PE],,N,20251231,G89.3,"[{""icd10_code"":""G89.3"",""description"":""Neoplasm related pain (acute)(chronic)"",""confidence"":0.3,""context"":""neuropathic pain""},{""icd10_code"":""G40.909"",""description"":""Epilepsy, unspecified, not intractable, without status epilepticus"",""confidence"":0.25,""context"":""seizure disorder""},{""icd10_code"":""M79.2"",""description"":""Neuralgia and neuritis, unspecified"",""confidence"":0.2,""context"":""nerve pain""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""off-label anxiety""},{""icd10_code"":""G25.3"",""description"":""Myoclonus"",""confidence"":0.1,""context"":""movement disorders""}]",0.30
0071-1012,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,20251130,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,25,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1013,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,20251130,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,50,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1014,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,75,mg/1,,CV,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1015,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,20260331,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,100,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1016,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,20251130,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,150,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1017,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,20260731,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,200,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1018,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,300,mg/1,,CV,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1019,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,CAPSULE,ORAL,20041230,20260531,NDA,NDA021446,Parke-Davis Div of Pfizer Inc,PREGABALIN,225,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1020,HUMAN PRESCRIPTION DRUG,Lyrica,,PREGABALIN,SOLUTION,ORAL,20100104,20250930,NDA,NDA022488,Parke-Davis Div of Pfizer Inc,PREGABALIN,20,mg/mL,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1026,HUMAN PRESCRIPTION DRUG,Lyrica CR,,PREGABALIN,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20180101,20251130,NDA,NDA209501,Parke-Davis Div of Pfizer Inc,PREGABALIN,82.5,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-1027,HUMAN PRESCRIPTION DRUG,Lyrica CR,,PREGABALIN,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20180101,20251130,NDA,NDA209501,Parke-Davis Div of Pfizer Inc,PREGABALIN,165,mg/1,,CV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-2012,HUMAN PRESCRIPTION DRUG,Neurontin,,gabapentin,SOLUTION,ORAL,20000302,,NDA,NDA021129,Parke-Davis Div of Pfizer Inc,GABAPENTIN,250,mg/5mL,Decreased Central Nervous System Disorganized Electrical Activity [PE],,N,20251231,G89.3,"[{""icd10_code"":""G89.3"",""description"":""Neoplasm related pain (acute)(chronic)"",""confidence"":0.3,""context"":""neuropathic pain""},{""icd10_code"":""G40.909"",""description"":""Epilepsy, unspecified, not intractable, without status epilepticus"",""confidence"":0.25,""context"":""seizure disorder""},{""icd10_code"":""M79.2"",""description"":""Neuralgia and neuritis, unspecified"",""confidence"":0.2,""context"":""nerve pain""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""off-label anxiety""},{""icd10_code"":""G25.3"",""description"":""Myoclonus"",""confidence"":0.1,""context"":""movement disorders""}]",0.30
0071-2418,HUMAN PRESCRIPTION DRUG,Zarontin,,Ethosuximide,SOLUTION,ORAL,20200310,,ANDA,ANDA080258,Parke-Davis Div of Pfizer Inc,ETHOSUXIMIDE,250,mg/5mL,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-3112,HUMAN PRESCRIPTION DRUG,ACCURETIC,,quinapril and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20211129,,NDA,NDA020125,Parke-Davis Div of Pfizer Inc,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE,12.5; 10,mg/1; mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-3740,HUMAN PRESCRIPTION DRUG,Dilantin,,Extended Phenytoin Sodium,CAPSULE,ORAL,19760827,20260131,ANDA,ANDA084349,Parke-Davis Div of Pfizer Inc,PHENYTOIN SODIUM,30,mg/1,"Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0071-5212,HUMAN PRESCRIPTION DRUG,ACCURETIC,,quinapril and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20211206,,NDA,NDA020125,Parke-Davis Div of Pfizer Inc,HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE,12.5; 20,mg/1; mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0038,HUMAN PRESCRIPTION DRUG,Orilissa,,Elagolix,"TABLET, FILM COATED",ORAL,20180723,,NDA,NDA210450,AbbVie Inc.,ELAGOLIX SODIUM,150,mg/1,"Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Decreased GnRH Secretion [PE], Gonadotropin Releasing Hormone Receptor Antagonist [EPC], Gonadotropin Releasing Hormone Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0039,HUMAN PRESCRIPTION DRUG,Orilissa,,Elagolix,"TABLET, FILM COATED",ORAL,20180723,,NDA,NDA210450,AbbVie Inc.,ELAGOLIX SODIUM,200,mg/1,"Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Decreased GnRH Secretion [PE], Gonadotropin Releasing Hormone Receptor Antagonist [EPC], Gonadotropin Releasing Hormone Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0124,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20170421,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0243,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20151123,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0501,HUMAN PRESCRIPTION DRUG,Vyalev,,foscarbidopa/foslevodopa,INJECTION,SUBCUTANEOUS,20220412,,NDA,NDA216962,AbbVie Inc.,FOSCARBIDOPA; FOSLEVODOPA,12; 240,mg/mL; mg/mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0522,HUMAN PRESCRIPTION DRUG,Kaletra,,Lopinavir and Ritonavir,"TABLET, FILM COATED",ORAL,20100618,,NDA,NDA021906,AbbVie Inc.,LOPINAVIR; RITONAVIR,100; 25,mg/1; mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], HIV Protease Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0554,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20160309,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0561,HUMAN PRESCRIPTION DRUG,Venclexta,,Venetoclax,"TABLET, FILM COATED",ORAL,20160411,,NDA,NDA208573,AbbVie Inc.,VENETOCLAX,10,mg/1,"BCL-2 Inhibitor [EPC], Increased Cellular Death [PE], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0566,HUMAN PRESCRIPTION DRUG,Venclexta,,Venetoclax,"TABLET, FILM COATED",ORAL,20160411,,NDA,NDA208573,AbbVie Inc.,VENETOCLAX,50,mg/1,"BCL-2 Inhibitor [EPC], Increased Cellular Death [PE], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0576,HUMAN PRESCRIPTION DRUG,Venclexta,,Venetoclax,"TABLET, FILM COATED",ORAL,20160411,,NDA,NDA208573,AbbVie Inc.,VENETOCLAX,100,mg/1,"BCL-2 Inhibitor [EPC], Increased Cellular Death [PE], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0579,HUMAN PRESCRIPTION DRUG,Venclexta,,Venetoclax,KIT,,20160411,,NDA,NDA208573,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0616,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20170428,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-0817,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20170428,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1017,HUMAN PRESCRIPTION DRUG,Oriahnn,,Elagolix and Estradiol and Norethisterone,KIT,,20200529,,NDA,NDA213388,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1040,HUMAN PRESCRIPTION DRUG,Survanta,,Beractant,SUSPENSION,ENDOTRACHEAL,19910701,,BLA,BLA020032,AbbVie Inc.,BERACTANT,25,mg/mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1043,HUMAN PRESCRIPTION DRUG,Rinvoq,,Upadacitinib,"TABLET, EXTENDED RELEASE",ORAL,20190816,,NDA,NDA211675,AbbVie Inc.,UPADACITINIB,45,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1044,HUMAN PRESCRIPTION DRUG,Telisotuzumab Vedotin,,Telisotuzumab Vedotin,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20250514,,BLA,BLA761384,AbbVie Inc.,TELISOTUZUMAB VEDOTIN,20,mg/mL,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1050,HUMAN PRESCRIPTION DRUG,Skyrizi,,risankizumab-rzaa,INJECTION,SUBCUTANEOUS,20210426,,BLA,BLA761105,AbbVie Inc.,RISANKIZUMAB,150,mg/mL,"Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1055,HUMAN PRESCRIPTION DRUG,Telisotuzumab Vedotin,,Telisotuzumab Vedotin,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20250514,,BLA,BLA761384,AbbVie Inc.,TELISOTUZUMAB VEDOTIN,100,mg/mL,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1065,HUMAN PRESCRIPTION DRUG,Skyrizi,,Risankizumab-rzaa,KIT,INTRAVENOUS,20220923,,BLA,BLA761105,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1070,HUMAN PRESCRIPTION DRUG,Skyrizi,,Risankizumab-rzaa,KIT,INTRAVENOUS,20220616,,BLA,BLA761105,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1539,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20170421,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-1658,HUMAN PRESCRIPTION DRUG,Zemplar,,Paricalcitol,"INJECTION, SOLUTION",INTRAVENOUS,19980417,,NDA,NDA020819,AbbVie Inc.,PARICALCITOL,5,ug/mL,"Ergocalciferols [CS], Vitamin D Analog [EPC], Vitamin D2 Analog [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2100,HUMAN PRESCRIPTION DRUG,Skyrizi,,risankizumab-rzaa,INJECTION,SUBCUTANEOUS,20210426,,BLA,BLA761105,AbbVie Inc.,RISANKIZUMAB,150,mg/mL,"Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2108,HUMAN PRESCRIPTION DRUG,Lupron Depot-PED,,leuprolide acetate,KIT,,19930416,,NDA,NDA020263,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2282,HUMAN PRESCRIPTION DRUG,Lupron Depot-PED,,leuprolide acetate,KIT,,19930416,,NDA,NDA020263,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2306,HUMAN PRESCRIPTION DRUG,Rinvoq,,Upadacitinib,"TABLET, EXTENDED RELEASE",ORAL,20190816,,NDA,NDA211675,AbbVie Inc.,UPADACITINIB,15,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2310,HUMAN PRESCRIPTION DRUG,Rinvoq,,Upadacitinib,"TABLET, EXTENDED RELEASE",ORAL,20190816,,NDA,NDA211675,AbbVie Inc.,UPADACITINIB,30,mg/1,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2320,HUMAN PRESCRIPTION DRUG,Rinvoq,,Upadacitinib,SOLUTION,ORAL,20240426,,NDA,NDA218347,AbbVie Inc.,UPADACITINIB,1,mg/mL,"Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2340,HUMAN PRESCRIPTION DRUG,Norvir,,Ritonavir,"TABLET, FILM COATED",ORAL,20220816,,NDA,NDA022417,AbbVie Inc.,RITONAVIR,100,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2440,HUMAN PRESCRIPTION DRUG,Lupron Depot-PED,,leuprolide acetate,KIT,,19930416,,NDA,NDA020263,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2540,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20161017,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2600,HUMAN PRESCRIPTION DRUG,Mavyret,,Glecaprevir and Pibrentasvir,PELLET,ORAL,20210610,,NDA,NDA215110,AbbVie Inc.,GLECAPREVIR; PIBRENTASVIR,50; 20,mg/1; mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HCV NS3/4A Protease Inhibitors [MoA], Hepatitis C Virus NS3/4A Protease Inhibitor [EPC], Hepatitis C Virus NS5A Inhibitor [EPC], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-2625,HUMAN PRESCRIPTION DRUG,Mavyret,,Glecaprevir and Pibrentasvir,"TABLET, FILM COATED",ORAL,20170803,,NDA,NDA209394,AbbVie Inc.,GLECAPREVIR; PIBRENTASVIR,100; 40,mg/1; mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HCV NS3/4A Protease Inhibitors [MoA], Hepatitis C Virus NS3/4A Protease Inhibitor [EPC], Hepatitis C Virus NS5A Inhibitor [EPC], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3008,HUMAN PRESCRIPTION DRUG,Kaletra,,Lopinavir and Ritonavir,"TABLET, FILM COATED",ORAL,20200408,,NDA,NDA021906,AbbVie Inc.,LOPINAVIR; RITONAVIR,100; 25,mg/1; mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], HIV Protease Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3012,HUMAN PRESCRIPTION DRUG,Duopa,,Carbidopa and Levodopa,SUSPENSION,ENTERAL,20150115,,NDA,NDA203952,AbbVie Inc.,CARBIDOPA; LEVODOPA,4.63; 20,mg/mL; mg/mL,"Amino Acids, Aromatic [CS], Aromatic Amino Acid [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3108,HUMAN PRESCRIPTION DRUG,Gengraf,,Cyclosporine,CAPSULE,ORAL,20151101,,ANDA,ANDA065003,AbbVie Inc.,CYCLOSPORINE,25,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3109,HUMAN PRESCRIPTION DRUG,Gengraf,,Cyclosporine,CAPSULE,ORAL,20151101,,ANDA,ANDA065003,AbbVie Inc.,CYCLOSPORINE,100,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3173,HUMAN PRESCRIPTION DRUG,Tricor,,Fenofibrate,TABLET,ORAL,20160205,20251130,NDA,NDA021656,AbbVie Inc.,FENOFIBRATE,48,mg/1,Peroxisome Proliferator Receptor alpha Agonist [EPC],,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3189,HUMAN PRESCRIPTION DRUG,Tricor,,Fenofibrate,TABLET,ORAL,20160205,20260330,NDA,NDA021656,AbbVie Inc.,FENOFIBRATE,145,mg/1,Peroxisome Proliferator Receptor alpha Agonist [EPC],,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3346,HUMAN PRESCRIPTION DRUG,Lupron Depot,,leuprolide acetate,KIT,,19951222,,NDA,NDA020517,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3399,HUMAN PRESCRIPTION DRUG,Norvir,,Ritonavir,POWDER,ORAL,20170607,,NDA,NDA209512,AbbVie Inc.,RITONAVIR,100,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3473,HUMAN PRESCRIPTION DRUG,Lupron Depot,,leuprolide acetate,KIT,,19951222,,NDA,NDA020517,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3575,HUMAN PRESCRIPTION DRUG,Lupron Depot-PED,,leuprolide acetate,KIT,,20230414,,NDA,NDA020263,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3641,HUMAN PRESCRIPTION DRUG,Lupron Depot,,leuprolide acetate,KIT,,19901022,,NDA,NDA020011,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3642,HUMAN PRESCRIPTION DRUG,Lupron Depot,,leuprolide acetate,KIT,,19890126,,NDA,NDA019732,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3663,HUMAN PRESCRIPTION DRUG,Lupron Depot,,leuprolide acetate,KIT,,20101108,,NDA,NDA020708,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3683,HUMAN PRESCRIPTION DRUG,Lupron Depot,,leuprolide acetate,KIT,,19951222,,NDA,NDA020517,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3727,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,137,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-3779,HUMAN PRESCRIPTION DRUG,Lupron Depot-PED,,leuprolide acetate,KIT,,19930416,,NDA,NDA020263,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3799,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20021231,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3878,HUMAN PRESCRIPTION DRUG,EMBLAVEO,,aztreonam and avibactam,"POWDER, FOR SOLUTION",INTRAVENOUS,20250207,,NDA,NDA217906,AbbVie Inc.,AVIBACTAM; AZTREONAM,42.3; 127,mg/mL; mg/mL,"Monobactam Antibacterial [EPC], Monobactams [CS], beta Lactamase Inhibitor [EPC], beta Lactamase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-3956,HUMAN PRESCRIPTION DRUG,Kaletra,,Lopinavir and Ritonavir,SOLUTION,ORAL,20100618,,NDA,NDA021251,AbbVie Inc.,LOPINAVIR; RITONAVIR,80; 20,mg/mL; mg/mL,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], HIV Protease Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-4014,HUMAN PRESCRIPTION DRUG,Kaletra,,Lopinavir and Ritonavir,"TABLET, FILM COATED",ORAL,20200408,,NDA,NDA021906,AbbVie Inc.,LOPINAVIR; RITONAVIR,200; 50,mg/1; mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], HIV Protease Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-4339,HUMAN PRESCRIPTION DRUG,Humira,,Adalimumab,KIT,,20060623,,BLA,BLA125057,AbbVie Inc.,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-4341,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,25,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-4456,HUMAN PRESCRIPTION DRUG,Ultane,,Sevoflurane,LIQUID,RESPIRATORY (INHALATION),19950607,,NDA,NDA020478,AbbVie Inc.,SEVOFLURANE,250,mL/250mL,"General Anesthesia [PE], General Anesthetic [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-4456,HUMAN PRESCRIPTION DRUG,Ultane,,Sevoflurane,LIQUID,RESPIRATORY (INHALATION),19950607,,NDA,NDA020478,AbbVie Inc.,SEVOFLURANE,250,mL/250mL,"General Anesthesia [PE], General Anesthetic [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-4552,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,50,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-4637,HUMAN PRESCRIPTION DRUG,Zemplar,,Paricalcitol,"INJECTION, SOLUTION",INTRAVENOUS,19980417,,NDA,NDA020819,AbbVie Inc.,PARICALCITOL,2,ug/mL,"Ergocalciferols [CS], Vitamin D Analog [EPC], Vitamin D2 Analog [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-5015,HUMAN PRESCRIPTION DRUG,Skyrizi,,risankizumab-rzaa,INJECTION,INTRAVENOUS,20220616,,BLA,BLA761262,AbbVie Inc.,RISANKIZUMAB,600,mg/10mL,"Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-5182,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,75,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-6114,HUMAN PRESCRIPTION DRUG,Depakote,Sprinkles,Divalproex Sodium,CAPSULE,ORAL,19890912,,NDA,NDA019680,AbbVie Inc.,DIVALPROEX SODIUM,125,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-6594,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,88,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-6624,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,100,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-6799,HUMAN PRESCRIPTION DRUG,Kaletra,,Lopinavir and Ritonavir,"TABLET, FILM COATED",ORAL,20100618,,NDA,NDA021906,AbbVie Inc.,LOPINAVIR; RITONAVIR,200; 50,mg/1; mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], HIV Protease Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Protease Inhibitor [EPC], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inducers [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7040,HUMAN PRESCRIPTION DRUG,Skyrizi,,Risankizumab-rzaa,KIT,,20240304,,BLA,BLA761105,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7042,HUMAN PRESCRIPTION DRUG,Skyrizi,,Risankizumab-rzaa,KIT,,20240304,,BLA,BLA761105,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7068,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,125,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-7069,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,150,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-7070,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,175,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-7094,HUMAN PRESCRIPTION DRUG,Qulipta,,Atogepant,TABLET,ORAL,20210930,,NDA,NDA215206,AbbVie Inc.,ATOGEPANT,60,mg/1,"Calcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7095,HUMAN PRESCRIPTION DRUG,Qulipta,,Atogepant,TABLET,ORAL,20210930,,NDA,NDA215206,AbbVie Inc.,ATOGEPANT,10,mg/1,"Calcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7096,HUMAN PRESCRIPTION DRUG,Qulipta,,Atogepant,TABLET,ORAL,20210930,,NDA,NDA215206,AbbVie Inc.,ATOGEPANT,30,mg/1,"Calcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7098,HUMAN PRESCRIPTION DRUG,VUITY,,Pilocarpine Hydrochloride,SOLUTION/ DROPS,OPHTHALMIC,20211028,,NDA,NDA214028,AbbVie Inc.,PILOCARPINE HYDROCHLORIDE,12.5,mg/mL,"Cholinergic Agonists [MoA], Cholinergic Muscarinic Agonists [MoA], Cholinergic Receptor Agonist [EPC]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0074-7148,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020224,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,200,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-7149,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,300,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-7269,HUMAN PRESCRIPTION DRUG,Gengraf,,Cyclosporine,SOLUTION,ORAL,20100525,20260228,ANDA,ANDA065025,AbbVie Inc.,CYCLOSPORINE,100,mg/mL,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7325,HUMAN PRESCRIPTION DRUG,Depakote,,Divalproex Sodium,"TABLET, DELAYED RELEASE",ORAL,19830310,,NDA,NDA018723,AbbVie Inc.,DIVALPROEX SODIUM,125,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7326,HUMAN PRESCRIPTION DRUG,Depakote,,Divalproex Sodium,"TABLET, DELAYED RELEASE",ORAL,20230630,,NDA,NDA018723,AbbVie Inc.,DIVALPROEX SODIUM,250,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7327,HUMAN PRESCRIPTION DRUG,Depakote,,Divalproex Sodium,"TABLET, DELAYED RELEASE",ORAL,19830310,,NDA,NDA018723,AbbVie Inc.,DIVALPROEX SODIUM,500,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7401,HUMAN PRESCRIPTION DRUG,Depakote,ER,Divalproex Sodium,"TABLET, EXTENDED RELEASE",ORAL,20000804,,NDA,NDA021168,AbbVie Inc.,DIVALPROEX SODIUM,250,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-7402,HUMAN PRESCRIPTION DRUG,Depakote,ER,Divalproex Sodium,"TABLET, EXTENDED RELEASE",ORAL,20000804,,NDA,NDA021168,AbbVie Inc.,DIVALPROEX SODIUM,500,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-9036,HUMAN PRESCRIPTION DRUG,Zemplar,,Paricalcitol,"CAPSULE, LIQUID FILLED",ORAL,20180420,,NDA,NDA021606,AbbVie Inc.,PARICALCITOL,1,ug/1,"Ergocalciferols [CS], Vitamin D Analog [EPC], Vitamin D2 Analog [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-9037,HUMAN PRESCRIPTION DRUG,Zemplar,,Paricalcitol,"CAPSULE, LIQUID FILLED",ORAL,20180420,,NDA,NDA021606,AbbVie Inc.,PARICALCITOL,2,ug/1,"Ergocalciferols [CS], Vitamin D Analog [EPC], Vitamin D2 Analog [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0074-9296,HUMAN PRESCRIPTION DRUG,Synthroid,,Levothyroxine Sodium,TABLET,ORAL,20020724,,NDA,NDA021402,AbbVie Inc.,LEVOTHYROXINE SODIUM,112,ug/1,"Thyroxine [CS], l-Thyroxine [EPC]",,N,20251231,E03.9,"[{""icd10_code"":""E03.9"",""description"":""Hypothyroidism, unspecified"",""confidence"":0.8,""context"":""hypothyroidism""},{""icd10_code"":""E89.0"",""description"":""Postprocedural hypothyroidism"",""confidence"":0.15,""context"":""post-thyroidectomy""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.05,""context"":""hormone replacement""}]",0.80
0074-9694,HUMAN PRESCRIPTION DRUG,Lupron Depot-PED,,leuprolide acetate,KIT,,19930416,,NDA,NDA020263,AbbVie Inc.,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-0620,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,40,mg/.4mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-0621,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,60,mg/.6mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-0622,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,80,mg/.8mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-0623,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,100,mg/mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-0624,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,30,mg/.3mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-0626,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,INTRAVENOUS; SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,300,mg/3mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-2912,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,120,mg/.8mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-2915,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,150,mg/mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8013,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,30,mg/.3mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8014,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,40,mg/.4mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8016,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,60,mg/.6mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8018,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,80,mg/.8mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8020,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,100,mg/mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8022,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,120,mg/.8mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8025,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,150,mg/mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0075-8030,HUMAN PRESCRIPTION DRUG,Lovenox,,enoxaparin sodium,INJECTION,INTRAVENOUS; SUBCUTANEOUS,19930329,,NDA,NDA020164,Sanofi-Aventis U.S. LLC,ENOXAPARIN SODIUM,300,mg/3mL,"Heparin, Low-Molecular-Weight [CS], Low Molecular Weight Heparin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0109,HUMAN PRESCRIPTION DRUG,Sandimmune,,cyclosporine,INJECTION,INTRAVENOUS,19831114,,NDA,NDA050573,Novartis Pharmaceuticals Corporation,CYCLOSPORINE,50,mg/mL,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0110,HUMAN PRESCRIPTION DRUG,Sandimmune,,cyclosporine,SOLUTION,ORAL,19831114,20251231,NDA,NDA050574,Novartis Pharmaceuticals Corporation,CYCLOSPORINE,100,mg/mL,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0180,HUMAN PRESCRIPTION DRUG,Sandostatin,,octreotide acetate,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,19881021,,NDA,NDA019667,Novartis Pharmaceuticals Corporation,OCTREOTIDE ACETATE,50,ug/mL,"Somatostatin Analog [EPC], Somatostatin Receptor Agonists [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0078-0181,HUMAN PRESCRIPTION DRUG,Sandostatin,,octreotide acetate,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,19881021,,NDA,NDA019667,Novartis Pharmaceuticals Corporation,OCTREOTIDE ACETATE,100,ug/mL,"Somatostatin Analog [EPC], Somatostatin Receptor Agonists [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0078-0182,HUMAN PRESCRIPTION DRUG,Sandostatin,,octreotide acetate,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,19881021,,NDA,NDA019667,Novartis Pharmaceuticals Corporation,OCTREOTIDE ACETATE,500,ug/mL,"Somatostatin Analog [EPC], Somatostatin Receptor Agonists [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0078-0240,HUMAN PRESCRIPTION DRUG,Sandimmune,,cyclosporine,"CAPSULE, LIQUID FILLED",ORAL,19900302,,NDA,NDA050625,Novartis Pharmaceuticals Corporation,CYCLOSPORINE,25,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0241,HUMAN PRESCRIPTION DRUG,Sandimmune,,cyclosporine,"CAPSULE, LIQUID FILLED",ORAL,19900302,,NDA,NDA050625,Novartis Pharmaceuticals Corporation,CYCLOSPORINE,100,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0246,HUMAN PRESCRIPTION DRUG,Neoral,,cyclosporine,"CAPSULE, LIQUID FILLED",ORAL,19950714,,NDA,NDA050715,Novartis Pharmaceuticals Corporation,CYCLOSPORINE,25,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0248,HUMAN PRESCRIPTION DRUG,Neoral,,cyclosporine,"CAPSULE, LIQUID FILLED",ORAL,19950714,,NDA,NDA050715,Novartis Pharmaceuticals Corporation,CYCLOSPORINE,100,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0249,HUMAN PRESCRIPTION DRUG,Femara,,letrozole,"TABLET, FILM COATED",ORAL,19970731,,NDA,NDA020726,Novartis Pharmaceuticals Corporation,LETROZOLE,2.5,mg/1,"Aromatase Inhibitor [EPC], Aromatase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0274,HUMAN PRESCRIPTION DRUG,Neoral,,cyclosporine,SOLUTION,ORAL,19950714,,NDA,NDA050716,Novartis Pharmaceuticals Corporation,CYCLOSPORINE,100,mg/mL,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0314,HUMAN PRESCRIPTION DRUG,Diovan HCT,,valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,19980306,,NDA,NDA020818,Novartis Pharmaceuticals Corporation,HYDROCHLOROTHIAZIDE; VALSARTAN,12.5; 80,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0315,HUMAN PRESCRIPTION DRUG,Diovan HCT,,valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,19980306,,NDA,NDA020818,Novartis Pharmaceuticals Corporation,HYDROCHLOROTHIAZIDE; VALSARTAN,12.5; 160,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0331,HUMAN PRESCRIPTION DRUG,Simulect,,basiliximab,"INJECTION, POWDER, FOR SOLUTION",INTRAVENOUS,19980512,,BLA,BLA103764,Novartis Pharmaceuticals Corporation,BASILIXIMAB,20,mg/5mL,"Interleukin 2 Receptor Antagonists [MoA], Interleukin 2 Receptor-directed Antibody Interactions [MoA], Interleukin-2 Receptor Blocking Antibody [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0337,HUMAN PRESCRIPTION DRUG,Trileptal,,oxcarbazepine,"TABLET, FILM COATED",ORAL,20000130,,NDA,NDA021014,Novartis Pharmaceuticals Corporation,OXCARBAZEPINE,300,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0343,HUMAN PRESCRIPTION DRUG,Vivelle-Dot,,estradiol,"PATCH, EXTENDED RELEASE",TRANSDERMAL,19990108,,NDA,NDA020538,Novartis Pharmaceuticals Corporation,ESTRADIOL,0.0375,mg/d,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0344,HUMAN PRESCRIPTION DRUG,Vivelle-Dot,,estradiol,"PATCH, EXTENDED RELEASE",TRANSDERMAL,19990108,,NDA,NDA020538,Novartis Pharmaceuticals Corporation,ESTRADIOL,0.05,mg/d,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0345,HUMAN PRESCRIPTION DRUG,Vivelle-Dot,,estradiol,"PATCH, EXTENDED RELEASE",TRANSDERMAL,19990108,,NDA,NDA020538,Novartis Pharmaceuticals Corporation,ESTRADIOL,0.075,mg/d,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0346,HUMAN PRESCRIPTION DRUG,Vivelle-Dot,,estradiol,"PATCH, EXTENDED RELEASE",TRANSDERMAL,19990108,,NDA,NDA020538,Novartis Pharmaceuticals Corporation,ESTRADIOL,0.1,mg/d,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0354,HUMAN PRESCRIPTION DRUG,Lescol,XL,fluvastatin sodium,"TABLET, EXTENDED RELEASE",ORAL,20001006,,NDA,NDA021192,Novartis Pharmaceuticals Corporation,FLUVASTATIN SODIUM,80,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0078-0357,HUMAN PRESCRIPTION DRUG,Trileptal,,oxcarbazepine,SUSPENSION,ORAL,20010530,,NDA,NDA021285,Novartis Pharmaceuticals Corporation,OXCARBAZEPINE,60,mg/mL,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0358,HUMAN PRESCRIPTION DRUG,Diovan,,valsartan,TABLET,ORAL,20010701,,NDA,NDA021283,Novartis Pharmaceuticals Corporation,VALSARTAN,80,mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0359,HUMAN PRESCRIPTION DRUG,Diovan,,valsartan,TABLET,ORAL,20010701,,NDA,NDA021283,Novartis Pharmaceuticals Corporation,VALSARTAN,160,mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0360,HUMAN PRESCRIPTION DRUG,Diovan,,valsartan,TABLET,ORAL,20010701,,NDA,NDA021283,Novartis Pharmaceuticals Corporation,VALSARTAN,320,mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0364,HUMAN PRESCRIPTION DRUG,Lotrel,,amlodipine besylate and benazepril hydrochloride,CAPSULE,ORAL,19950303,20260930,NDA,NDA020364,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE,10; 20,mg/1; mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Decreased Blood Pressure [PE], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0365,HUMAN PRESCRIPTION DRUG,Vivelle-Dot,,estradiol,"PATCH, EXTENDED RELEASE",TRANSDERMAL,19990108,,NDA,NDA020538,Novartis Pharmaceuticals Corporation,ESTRADIOL,0.025,mg/d,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0370,HUMAN PRESCRIPTION DRUG,Ritalin,LA,methylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20020605,,NDA,NDA021284,Novartis Pharmaceuticals Corporation,METHYLPHENIDATE HYDROCHLORIDE,20,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0371,HUMAN PRESCRIPTION DRUG,Ritalin,LA,methylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20020605,,NDA,NDA021284,Novartis Pharmaceuticals Corporation,METHYLPHENIDATE HYDROCHLORIDE,30,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0372,HUMAN PRESCRIPTION DRUG,Ritalin,LA,methylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20020605,,NDA,NDA021284,Novartis Pharmaceuticals Corporation,METHYLPHENIDATE HYDROCHLORIDE,40,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0379,HUMAN PRESCRIPTION DRUG,Lotrel,,amlodipine besylate and benazepril hydrochloride,CAPSULE,ORAL,19950303,20260930,NDA,NDA020364,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE,10; 40,mg/1; mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Decreased Blood Pressure [PE], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0380,HUMAN PRESCRIPTION DRUG,Focalin,,dexmethylphenidate hydrochloride,TABLET,ORAL,20011130,,NDA,NDA021278,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,2.5,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0381,HUMAN PRESCRIPTION DRUG,Focalin,,dexmethylphenidate hydrochloride,TABLET,ORAL,20011130,,NDA,NDA021278,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,5,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0382,HUMAN PRESCRIPTION DRUG,Focalin,,dexmethylphenidate hydrochloride,TABLET,ORAL,20011130,,NDA,NDA021278,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,10,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0383,HUMAN PRESCRIPTION DRUG,Diovan HCT,,valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,19980306,,NDA,NDA020818,Novartis Pharmaceuticals Corporation,HYDROCHLOROTHIAZIDE; VALSARTAN,25; 160,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0385,HUMAN PRESCRIPTION DRUG,Myfortic,,mycophenolic acid,"TABLET, DELAYED RELEASE",ORAL,20040227,,NDA,NDA050791,Novartis Pharmaceuticals Corporation,MYCOPHENOLATE SODIUM,180,mg/1,Antimetabolite Immunosuppressant [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0386,HUMAN PRESCRIPTION DRUG,Myfortic,,mycophenolic acid,"TABLET, DELAYED RELEASE",ORAL,20040227,,NDA,NDA050791,Novartis Pharmaceuticals Corporation,MYCOPHENOLATE SODIUM,360,mg/1,Antimetabolite Immunosuppressant [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0393,HUMAN PRESCRIPTION DRUG,Simulect,,basiliximab,"INJECTION, POWDER, FOR SOLUTION",INTRAVENOUS,19980512,,BLA,BLA103764,Novartis Pharmaceuticals Corporation,BASILIXIMAB,10,mg/2.5mL,"Interleukin 2 Receptor Antagonists [MoA], Interleukin 2 Receptor-directed Antibody Interactions [MoA], Interleukin-2 Receptor Blocking Antibody [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0401,HUMAN PRESCRIPTION DRUG,Gleevec,,imatinib mesylate,TABLET,ORAL,20010515,,NDA,NDA021588,Novartis Pharmaceuticals Corporation,IMATINIB MESYLATE,100,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0405,HUMAN PRESCRIPTION DRUG,Lotrel,,amlodipine besylate and benazepril hydrochloride,CAPSULE,ORAL,19950303,20260930,NDA,NDA020364,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE,5; 10,mg/1; mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Decreased Blood Pressure [PE], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0406,HUMAN PRESCRIPTION DRUG,Lotrel,,amlodipine besylate and benazepril hydrochloride,CAPSULE,ORAL,19950303,20260930,NDA,NDA020364,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE,5; 20,mg/1; mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Decreased Blood Pressure [PE], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0414,HUMAN PRESCRIPTION DRUG,Zortress,,everolimus,TABLET,ORAL,20100422,,NDA,NDA021560,Novartis Pharmaceuticals Corporation,EVEROLIMUS,0.5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0415,HUMAN PRESCRIPTION DRUG,Zortress,,everolimus,TABLET,ORAL,20100422,,NDA,NDA021560,Novartis Pharmaceuticals Corporation,EVEROLIMUS,0.75,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0417,HUMAN PRESCRIPTION DRUG,Zortress,,everolimus,TABLET,ORAL,20100422,,NDA,NDA021560,Novartis Pharmaceuticals Corporation,EVEROLIMUS,0.25,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0422,HUMAN PRESCRIPTION DRUG,Zortress,,everolimus,TABLET,ORAL,20100422,,NDA,NDA021560,Novartis Pharmaceuticals Corporation,EVEROLIMUS,1,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0423,HUMAN PRESCRIPTION DRUG,Diovan,,valsartan,TABLET,ORAL,20010701,,NDA,NDA021283,Novartis Pharmaceuticals Corporation,VALSARTAN,40,mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0424,HUMAN PRESCRIPTION DRUG,Ritalin,LA,methylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20020605,,NDA,NDA021284,Novartis Pharmaceuticals Corporation,METHYLPHENIDATE HYDROCHLORIDE,10,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0430,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,5,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0431,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,10,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0432,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,20,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0433,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,30,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0434,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,40,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0435,HUMAN PRESCRIPTION DRUG,Reclast,,zoledronic acid,"INJECTION, SOLUTION",INTRAVENOUS,20070401,,NDA,NDA021817,Novartis Pharmaceuticals Corporation,ZOLEDRONIC ACID,5,mg/100mL,"Bisphosphonate [EPC], Diphosphonates [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0439,HUMAN PRESCRIPTION DRUG,Ritalin,,methylphenidate hydrochloride,TABLET,ORAL,19551231,20260831,NDA,NDA010187,Novartis Pharmaceuticals Corporation,METHYLPHENIDATE HYDROCHLORIDE,5,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0440,HUMAN PRESCRIPTION DRUG,Ritalin,,methylphenidate hydrochloride,TABLET,ORAL,19551231,20260831,NDA,NDA010187,Novartis Pharmaceuticals Corporation,METHYLPHENIDATE HYDROCHLORIDE,10,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0441,HUMAN PRESCRIPTION DRUG,Ritalin,,methylphenidate hydrochloride,TABLET,ORAL,19551231,20260831,NDA,NDA010187,Novartis Pharmaceuticals Corporation,METHYLPHENIDATE HYDROCHLORIDE,20,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0456,HUMAN PRESCRIPTION DRUG,Trileptal,,oxcarbazepine,"TABLET, FILM COATED",ORAL,20000130,,NDA,NDA021014,Novartis Pharmaceuticals Corporation,OXCARBAZEPINE,150,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0457,HUMAN PRESCRIPTION DRUG,Trileptal,,oxcarbazepine,"TABLET, FILM COATED",ORAL,20000130,,NDA,NDA021014,Novartis Pharmaceuticals Corporation,OXCARBAZEPINE,600,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0467,HUMAN PRESCRIPTION DRUG,Desferal,,deferoxamine mesylate,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS,19680402,,NDA,NDA016267,Novartis Pharmaceuticals Corporation,DEFEROXAMINE MESYLATE,500,mg/1,"Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0468,HUMAN PRESCRIPTION DRUG,Exjade,,deferasirox,"TABLET, FOR SUSPENSION",ORAL,20051130,,NDA,NDA021882,Novartis Pharmaceuticals Corporation,DEFERASIROX,125,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0469,HUMAN PRESCRIPTION DRUG,Exjade,,deferasirox,"TABLET, FOR SUSPENSION",ORAL,20051130,,NDA,NDA021882,Novartis Pharmaceuticals Corporation,DEFERASIROX,250,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0470,HUMAN PRESCRIPTION DRUG,Exjade,,deferasirox,"TABLET, FOR SUSPENSION",ORAL,20051130,,NDA,NDA021882,Novartis Pharmaceuticals Corporation,DEFERASIROX,500,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0471,HUMAN PRESCRIPTION DRUG,Diovan HCT,,valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20060428,,NDA,NDA020818,Novartis Pharmaceuticals Corporation,HYDROCHLOROTHIAZIDE; VALSARTAN,12.5; 320,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0472,HUMAN PRESCRIPTION DRUG,Diovan HCT,,valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20060428,,NDA,NDA020818,Novartis Pharmaceuticals Corporation,HYDROCHLOROTHIAZIDE; VALSARTAN,25; 320,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0488,HUMAN PRESCRIPTION DRUG,Exforge,,amlodipine besylate and valsartan,"TABLET, FILM COATED",ORAL,20070620,,NDA,NDA021990,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; VALSARTAN,5; 160,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0489,HUMAN PRESCRIPTION DRUG,Exforge,,amlodipine besylate and valsartan,"TABLET, FILM COATED",ORAL,20070620,,NDA,NDA021990,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; VALSARTAN,10; 160,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0490,HUMAN PRESCRIPTION DRUG,Exforge,,amlodipine besylate and valsartan,"TABLET, FILM COATED",ORAL,20070620,,NDA,NDA021990,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; VALSARTAN,5; 320,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0491,HUMAN PRESCRIPTION DRUG,Exforge,,amlodipine besylate and valsartan,"TABLET, FILM COATED",ORAL,20070620,,NDA,NDA021990,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; VALSARTAN,10; 320,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0493,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,15,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0501,HUMAN PRESCRIPTION DRUG,Exelon,,rivastigmine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20070706,,NDA,NDA022083,Novartis Pharmaceuticals Corporation,RIVASTIGMINE,4.6,mg/24h,"Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0502,HUMAN PRESCRIPTION DRUG,Exelon,,rivastigmine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20070706,,NDA,NDA022083,Novartis Pharmaceuticals Corporation,RIVASTIGMINE,9.5,mg/24h,"Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0503,HUMAN PRESCRIPTION DRUG,Exelon,,rivastigmine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20070706,,NDA,NDA022083,Novartis Pharmaceuticals Corporation,RIVASTIGMINE,13.3,mg/24h,"Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0508,HUMAN PRESCRIPTION DRUG,Tegretol,,carbamazepine,SUSPENSION,ORAL,19871218,,NDA,NDA018927,Novartis Pharmaceuticals Corporation,CARBAMAZEPINE,100,mg/5mL,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0509,HUMAN PRESCRIPTION DRUG,Tegretol,,carbamazepine,TABLET,ORAL,19680311,,NDA,NDA016608,Novartis Pharmaceuticals Corporation,CARBAMAZEPINE,200,mg/1,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0510,HUMAN PRESCRIPTION DRUG,Tegretol,XR,carbamazepine,"TABLET, EXTENDED RELEASE",ORAL,19960325,,NDA,NDA020234,Novartis Pharmaceuticals Corporation,CARBAMAZEPINE,100,mg/1,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0511,HUMAN PRESCRIPTION DRUG,Tegretol,XR,carbamazepine,"TABLET, EXTENDED RELEASE",ORAL,19960325,,NDA,NDA020234,Novartis Pharmaceuticals Corporation,CARBAMAZEPINE,200,mg/1,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0512,HUMAN PRESCRIPTION DRUG,Tegretol,XR,carbamazepine,"TABLET, EXTENDED RELEASE",ORAL,19960325,,NDA,NDA020234,Novartis Pharmaceuticals Corporation,CARBAMAZEPINE,400,mg/1,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0526,HUMAN PRESCRIPTION DRUG,Tasigna,,nilotinib,CAPSULE,ORAL,20071029,,NDA,NDA022068,Novartis Pharmaceuticals Corporation,NILOTINIB HYDROCHLORIDE MONOHYDRATE,200,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0559,HUMAN PRESCRIPTION DRUG,Exforge HCT,,amlodipine valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20090404,,NDA,NDA022314,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN,5; 12.5; 160,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0560,HUMAN PRESCRIPTION DRUG,Exforge HCT,,amlodipine valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20090404,,NDA,NDA022314,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN,5; 25; 160,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0561,HUMAN PRESCRIPTION DRUG,Exforge HCT,,amlodipine valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20090404,,NDA,NDA022314,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN,10; 12.5; 160,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0562,HUMAN PRESCRIPTION DRUG,Exforge HCT,,amlodipine valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20090404,,NDA,NDA022314,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN,10; 25; 160,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0563,HUMAN PRESCRIPTION DRUG,Exforge HCT,,amlodipine valsartan and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20090404,,NDA,NDA022314,Novartis Pharmaceuticals Corporation,AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN,10; 25; 320,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0566,HUMAN PRESCRIPTION DRUG,Afinitor,,everolimus,TABLET,ORAL,20090331,,NDA,NDA022334,Novartis Pharmaceuticals Corporation,EVEROLIMUS,5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0567,HUMAN PRESCRIPTION DRUG,Afinitor,,everolimus,TABLET,ORAL,20090331,,NDA,NDA022334,Novartis Pharmaceuticals Corporation,EVEROLIMUS,10,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0568,HUMAN PRESCRIPTION DRUG,COARTEM,,artemether and lumefantrine,TABLET,ORAL,20090407,,NDA,NDA022268,Novartis Pharmaceuticals Corporation,ARTEMETHER; LUMEFANTRINE,20; 120,mg/1; mg/1,"Antimalarial [EPC], Antimalarial [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0592,HUMAN PRESCRIPTION DRUG,Tasigna,,nilotinib,CAPSULE,ORAL,20071029,,NDA,NDA022068,Novartis Pharmaceuticals Corporation,NILOTINIB HYDROCHLORIDE MONOHYDRATE,150,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0594,HUMAN PRESCRIPTION DRUG,Afinitor,,everolimus,TABLET,ORAL,20100709,,NDA,NDA022334,Novartis Pharmaceuticals Corporation,EVEROLIMUS,2.5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0607,HUMAN PRESCRIPTION DRUG,Gilenya,,Fingolimod hcl,CAPSULE,ORAL,20100921,,NDA,NDA022527,Novartis Pharmaceuticals Corporation,FINGOLIMOD HYDROCHLORIDE,0.5,mg/1,"Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0608,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,25,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0609,HUMAN PRESCRIPTION DRUG,Focalin,XR,dexmethylphenidate hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20050531,,NDA,NDA021802,Novartis Pharmaceuticals Corporation,DEXMETHYLPHENIDATE HYDROCHLORIDE,35,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0620,HUMAN PRESCRIPTION DRUG,Afinitor,,everolimus,TABLET,ORAL,20110729,,NDA,NDA022334,Novartis Pharmaceuticals Corporation,EVEROLIMUS,7.5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0626,HUMAN PRESCRIPTION DRUG,Afinitor,Disperz,everolimus,"TABLET, FOR SUSPENSION",ORAL,20120829,,NDA,NDA203985,Novartis Pharmaceuticals Corporation,EVEROLIMUS,2,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0627,HUMAN PRESCRIPTION DRUG,Afinitor,Disperz,everolimus,"TABLET, FOR SUSPENSION",ORAL,20120829,,NDA,NDA203985,Novartis Pharmaceuticals Corporation,EVEROLIMUS,3,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0628,HUMAN PRESCRIPTION DRUG,Afinitor,Disperz,everolimus,"TABLET, FOR SUSPENSION",ORAL,20120829,,NDA,NDA203985,Novartis Pharmaceuticals Corporation,EVEROLIMUS,5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0639,HUMAN PRESCRIPTION DRUG,COSENTYX,,secukinumab,INJECTION,SUBCUTANEOUS,20150121,,BLA,BLA125504,Novartis Pharmaceuticals Corporation,SECUKINUMAB,150,mg/mL,"Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0649,HUMAN PRESCRIPTION DRUG,Gleevec,,imatinib mesylate,TABLET,ORAL,20141223,,NDA,NDA021588,Novartis Pharmaceuticals Corporation,IMATINIB MESYLATE,400,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0654,HUMAN PRESCRIPTION DRUG,Jadenu,,deferasirox,"TABLET, FILM COATED",ORAL,20150330,,NDA,NDA206910,Novartis Pharmaceuticals Corporation,DEFERASIROX,90,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0655,HUMAN PRESCRIPTION DRUG,Jadenu,,deferasirox,"TABLET, FILM COATED",ORAL,20150330,,NDA,NDA206910,Novartis Pharmaceuticals Corporation,DEFERASIROX,180,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0656,HUMAN PRESCRIPTION DRUG,Jadenu,,deferasirox,"TABLET, FILM COATED",ORAL,20150330,,NDA,NDA206910,Novartis Pharmaceuticals Corporation,DEFERASIROX,360,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0659,HUMAN PRESCRIPTION DRUG,ENTRESTO,,Sacubitril and Valsartan,"TABLET, FILM COATED",ORAL,20150707,,NDA,NDA207620,Novartis Pharmaceuticals Corporation,SACUBITRIL; VALSARTAN,24; 26,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0669,HUMAN PRESCRIPTION DRUG,ARZERRA,,ofatumumab,"INJECTION, SOLUTION",INTRAVENOUS,20160201,,BLA,BLA125326,Novartis Pharmaceuticals Corporation,OFATUMUMAB,20,mg/mL,"CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0671,HUMAN PRESCRIPTION DRUG,TYKERB,,lapatinib,TABLET,ORAL,20160803,,NDA,NDA022059,Novartis Pharmaceuticals Corporation,LAPATINIB DITOSYLATE,250,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0672,HUMAN PRESCRIPTION DRUG,HYCAMTIN,,topotecan,CAPSULE,ORAL,20170707,,NDA,NDA020981,Novartis Pharmaceuticals Corporation,TOPOTECAN HYDROCHLORIDE,0.25,mg/1,"Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0673,HUMAN PRESCRIPTION DRUG,HYCAMTIN,,topotecan,CAPSULE,ORAL,20170224,,NDA,NDA020981,Novartis Pharmaceuticals Corporation,TOPOTECAN HYDROCHLORIDE,1,mg/1,"Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0674,HUMAN PRESCRIPTION DRUG,HYCAMTIN,,topotecan hydrochloride,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20161221,,NDA,NDA020671,Novartis Pharmaceuticals Corporation,TOPOTECAN HYDROCHLORIDE,4,mg/4mL,"Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0681,HUMAN PRESCRIPTION DRUG,Tafinlar,,dabrafenib,CAPSULE,ORAL,20160401,,NDA,NDA202806,Novartis Pharmaceuticals Corporation,DABRAFENIB MESYLATE,75,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Kinase Inhibitor [EPC], Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0682,HUMAN PRESCRIPTION DRUG,Tafinlar,,dabrafenib,CAPSULE,ORAL,20160412,,NDA,NDA202806,Novartis Pharmaceuticals Corporation,DABRAFENIB MESYLATE,50,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Kinase Inhibitor [EPC], Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0683,HUMAN PRESCRIPTION DRUG,Arranon,,nelarabine,INJECTION,INTRAVENOUS,20161005,20260930,NDA,NDA021877,Novartis Pharmaceuticals Corporation,NELARABINE,5,mg/mL,"Nucleic Acid Synthesis Inhibitors [MoA], Nucleoside Metabolic Inhibitor [EPC]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0684,HUMAN PRESCRIPTION DRUG,PROMACTA,,eltrombopag olamine,"TABLET, FILM COATED",ORAL,20160822,,NDA,NDA022291,Novartis Pharmaceuticals Corporation,ELTROMBOPAG OLAMINE,12.5,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist [EPC], Thrombopoietin Receptor Agonists [MoA], UGT1A1 Inhibitors [MoA], UGT1A3 Inhibitors [MoA], UGT1A4 Inhibitors [MoA], UGT1A6 Inhibitors [MoA], UGT1A9 Inhibitors [MoA], UGT2B15 Inhibitors [MoA], UGT2B7 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0685,HUMAN PRESCRIPTION DRUG,PROMACTA,,eltrombopag olamine,"TABLET, FILM COATED",ORAL,20160524,,NDA,NDA022291,Novartis Pharmaceuticals Corporation,ELTROMBOPAG OLAMINE,25,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist [EPC], Thrombopoietin Receptor Agonists [MoA], UGT1A1 Inhibitors [MoA], UGT1A3 Inhibitors [MoA], UGT1A4 Inhibitors [MoA], UGT1A6 Inhibitors [MoA], UGT1A9 Inhibitors [MoA], UGT2B15 Inhibitors [MoA], UGT2B7 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0686,HUMAN PRESCRIPTION DRUG,PROMACTA,,eltrombopag olamine,"TABLET, FILM COATED",ORAL,20160407,,NDA,NDA022291,Novartis Pharmaceuticals Corporation,ELTROMBOPAG OLAMINE,50,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist [EPC], Thrombopoietin Receptor Agonists [MoA], UGT1A1 Inhibitors [MoA], UGT1A3 Inhibitors [MoA], UGT1A4 Inhibitors [MoA], UGT1A6 Inhibitors [MoA], UGT1A9 Inhibitors [MoA], UGT2B15 Inhibitors [MoA], UGT2B7 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0687,HUMAN PRESCRIPTION DRUG,PROMACTA,,eltrombopag olamine,"TABLET, FILM COATED",ORAL,20160401,,NDA,NDA022291,Novartis Pharmaceuticals Corporation,ELTROMBOPAG OLAMINE,75,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist [EPC], Thrombopoietin Receptor Agonists [MoA], UGT1A1 Inhibitors [MoA], UGT1A3 Inhibitors [MoA], UGT1A4 Inhibitors [MoA], UGT1A6 Inhibitors [MoA], UGT1A9 Inhibitors [MoA], UGT2B15 Inhibitors [MoA], UGT2B7 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0690,HUMAN PRESCRIPTION DRUG,ARZERRA,,ofatumumab,"INJECTION, SOLUTION",INTRAVENOUS,20160201,,BLA,BLA125326,Novartis Pharmaceuticals Corporation,OFATUMUMAB,20,mg/mL,"CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0694,HUMAN PRESCRIPTION DRUG,ZYKADIA,,ceritinib,"TABLET, FILM COATED",ORAL,20190318,,NDA,NDA211225,Novartis Pharmaceuticals Corporation,CERITINIB,150,mg/1,"Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Tyrosine Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0696,HUMAN PRESCRIPTION DRUG,ENTRESTO,,Sacubitril and Valsartan,"TABLET, FILM COATED",ORAL,20150707,,NDA,NDA207620,Novartis Pharmaceuticals Corporation,SACUBITRIL; VALSARTAN,97; 103,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0697,HUMAN PRESCRIPTION DRUG,PROMACTA,,eltrombopag olamine,"POWDER, FOR SUSPENSION",ORAL,20180927,,NDA,NDA207027,Novartis Pharmaceuticals Corporation,ELTROMBOPAG OLAMINE,25,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist [EPC], Thrombopoietin Receptor Agonists [MoA], UGT1A1 Inhibitors [MoA], UGT1A3 Inhibitors [MoA], UGT1A4 Inhibitors [MoA], UGT1A6 Inhibitors [MoA], UGT1A9 Inhibitors [MoA], UGT2B15 Inhibitors [MoA], UGT2B7 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0698,HUMAN PRESCRIPTION DRUG,RYDAPT,,RYDAPT,"CAPSULE, LIQUID FILLED",ORAL,20170428,,NDA,NDA207997,Novartis Pharmaceuticals Corporation,MIDOSTAURIN,25,mg/1,"Kinase Inhibitor [EPC], Receptor Tyrosine Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0701,HUMAN PRESCRIPTION DRUG,PIQRAY,,alpelisib,TABLET,ORAL,20190524,,NDA,NDA212526,Novartis Pharmaceuticals Corporation,ALPELISIB,200,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0708,HUMAN PRESCRIPTION DRUG,PIQRAY,,alpelisib,TABLET,ORAL,20190524,,NDA,NDA212526,Novartis Pharmaceuticals Corporation,ALPELISIB,150,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0709,HUMAN PRESCRIPTION DRUG,TABRECTA,,capmatinib,"TABLET, FILM COATED",ORAL,20200506,,NDA,NDA213591,Novartis Pharmaceuticals Corporation,CAPMATINIB HYDROCHLORIDE,150,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Kinase Inhibitor [EPC], Mesenchymal Epithelial Transition Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0713,HUMAN PRESCRIPTION DRUG,Jadenu,,deferasirox,GRANULE,ORAL,20170518,,NDA,NDA207968,Novartis Pharmaceuticals Corporation,DEFERASIROX,180,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0715,HUMAN PRESCRIPTION DRUG,PIQRAY,,alpelisib,KIT,,20190524,,NDA,NDA212526,Novartis Pharmaceuticals Corporation,,,,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0716,HUMAN PRESCRIPTION DRUG,TABRECTA,,capmatinib,"TABLET, FILM COATED",ORAL,20200506,,NDA,NDA213591,Novartis Pharmaceuticals Corporation,CAPMATINIB HYDROCHLORIDE,200,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Kinase Inhibitor [EPC], Mesenchymal Epithelial Transition Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0720,HUMAN PRESCRIPTION DRUG,Jadenu,,deferasirox,GRANULE,ORAL,20170518,,NDA,NDA207968,Novartis Pharmaceuticals Corporation,DEFERASIROX,360,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0722,HUMAN PRESCRIPTION DRUG,Azopt,,brinzolamide,SUSPENSION/ DROPS,OPHTHALMIC,19980430,,NDA,NDA020816,Novartis Pharmaceuticals Corporation,BRINZOLAMIDE,10,mg/mL,"Carbonic Anhydrase Inhibitor [EPC], Carbonic Anhydrase Inhibitors [MoA]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0727,HUMAN PRESCRIPTION DRUG,Jadenu,,deferasirox,GRANULE,ORAL,20170518,,NDA,NDA207968,Novartis Pharmaceuticals Corporation,DEFERASIROX,90,mg/1,"Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Iron Chelating Activity [MoA], Iron Chelator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0729,HUMAN PRESCRIPTION DRUG,Betoptic S,,betaxolol hydrochloride,SUSPENSION/ DROPS,OPHTHALMIC,19960115,20261130,NDA,NDA019845,Novartis Pharmaceuticals Corporation,BETAXOLOL HYDROCHLORIDE,2.8,mg/mL,"Adrenergic beta-Antagonists [MoA], beta-Adrenergic Blocker [EPC]",,N,,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0734,HUMAN PRESCRIPTION DRUG,Ilaris,,canakinumab,"INJECTION, SOLUTION",SUBCUTANEOUS,20161222,,BLA,BLA125319,Novartis Pharmaceuticals Corporation,CANAKINUMAB,150,mg/mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0771,HUMAN PRESCRIPTION DRUG,MAXITROL,,"neomycin sulfate, polymyxin b sulfate and dexamethasone",OINTMENT,OPHTHALMIC,19720117,,NDA,NDA050065,Novartis Pharmaceuticals Corporation,DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE,1; 3.5; 10000,mg/g; mg/g; [USP'U]/g,"Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Polymyxin-class Antibacterial [EPC], Polymyxins [CS]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0777,HUMAN PRESCRIPTION DRUG,ENTRESTO,,Sacubitril and Valsartan,"TABLET, FILM COATED",ORAL,20150707,,NDA,NDA207620,Novartis Pharmaceuticals Corporation,SACUBITRIL; VALSARTAN,49; 51,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0799,HUMAN PRESCRIPTION DRUG,CIPRODEX,,ciprofloxacin and dexamethasone,SUSPENSION/ DROPS,AURICULAR (OTIC),20030804,,NDA,NDA021537,Novartis Pharmaceuticals Corporation,CIPROFLOXACIN HYDROCHLORIDE; DEXAMETHASONE,3; 1,mg/mL; mg/mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Cytochrome P450 1A2 Inhibitors [MoA], Fluoroquinolone Antibacterial [EPC], Fluoroquinolones [CS]",,N,20251231,H60.9,"[{""icd10_code"":""H60.9"",""description"":""Unspecified otitis externa"",""confidence"":0.5,""context"":""ear infection""},{""icd10_code"":""H61.20"",""description"":""Impacted cerumen, unspecified ear"",""confidence"":0.3,""context"":""ear wax""},{""icd10_code"":""H92.09"",""description"":""Otalgia, unspecified ear"",""confidence"":0.2,""context"":""ear pain""}]",0.50
0078-0811,HUMAN PRESCRIPTION DRUG,Sandostatin LAR Depot,,octreotide acetate,KIT,,20160722,,NDA,NDA021008,Novartis Pharmaceuticals Corporation,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0813,HUMAN PRESCRIPTION DRUG,TOBREX,,tobramycin,OINTMENT,OPHTHALMIC,19810628,,NDA,NDA050555,Novartis Pharmaceuticals Corporation,TOBRAMYCIN,3,mg/g,"Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS]",,N,20261231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0818,HUMAN PRESCRIPTION DRUG,Sandostatin LAR Depot,,octreotide acetate,KIT,,20160722,,NDA,NDA021008,Novartis Pharmaceuticals Corporation,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0825,HUMAN PRESCRIPTION DRUG,Sandostatin LAR Depot,,octreotide acetate,KIT,,20160722,,NDA,NDA021008,Novartis Pharmaceuticals Corporation,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0827,HUMAN PRESCRIPTION DRUG,BEOVU,,brolucizumab,"INJECTION, SOLUTION",INTRAVITREAL,20191007,,BLA,BLA761125,Novartis Pharmaceuticals Corporation,BROLUCIZUMAB,6,mg/.05mL,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0841,HUMAN PRESCRIPTION DRUG,CILOXAN,,ciprofloxacin hydrochloride,OINTMENT,OPHTHALMIC,19980602,,NDA,NDA020369,Novartis Pharmaceuticals Corporation,CIPROFLOXACIN HYDROCHLORIDE,3,mg/g,"Cytochrome P450 1A2 Inhibitors [MoA], Fluoroquinolone Antibacterial [EPC], Fluoroquinolones [CS]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0846,CELLULAR THERAPY,KYMRIAH,,tisagenlecleucel,"INJECTION, SUSPENSION",INTRAVENOUS,20170830,,BLA,BLA125646,Novartis Pharmaceuticals Corporation,TISAGENLECLEUCEL,2000000,1-Jan,"CD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes, Cultured, Autologous, Genetically-modified [EXT]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0855,HUMAN PRESCRIPTION DRUG,CIPRO,HC,ciprofloxacin hydrochloride and hydrocortisone,SUSPENSION/ DROPS,AURICULAR (OTIC),19990315,,NDA,NDA020805,Novartis Pharmaceuticals Corporation,CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE,2; 10,mg/mL; mg/mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Cytochrome P450 1A2 Inhibitors [MoA], Fluoroquinolone Antibacterial [EPC], Fluoroquinolones [CS]",,N,20251231,H60.9,"[{""icd10_code"":""H60.9"",""description"":""Unspecified otitis externa"",""confidence"":0.5,""context"":""ear infection""},{""icd10_code"":""H61.20"",""description"":""Impacted cerumen, unspecified ear"",""confidence"":0.3,""context"":""ear wax""},{""icd10_code"":""H92.09"",""description"":""Otalgia, unspecified ear"",""confidence"":0.2,""context"":""ear pain""}]",0.50
0078-0860,HUMAN PRESCRIPTION DRUG,KISQALI,,ribociclib,"TABLET, FILM COATED",ORAL,20170313,,NDA,NDA209092,Novartis Pharmaceuticals Corporation,RIBOCICLIB SUCCINATE,200,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0862,HUMAN PRESCRIPTION DRUG,DUREZOL,,difluprednate,EMULSION,OPHTHALMIC,20110125,,NDA,NDA022212,Novartis Pharmaceuticals Corporation,DIFLUPREDNATE,0.5,mg/mL,,,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0867,HUMAN PRESCRIPTION DRUG,KISQALI,,ribociclib,"TABLET, FILM COATED",ORAL,20170313,,NDA,NDA209092,Novartis Pharmaceuticals Corporation,RIBOCICLIB SUCCINATE,200,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0874,HUMAN PRESCRIPTION DRUG,KISQALI,,ribociclib,"TABLET, FILM COATED",ORAL,20170313,,NDA,NDA209092,Novartis Pharmaceuticals Corporation,RIBOCICLIB SUCCINATE,200,mg/1,"Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0876,HUMAN PRESCRIPTION DRUG,TobraDex,,tobramycin and dexamethasone,OINTMENT,OPHTHALMIC,19881015,,NDA,NDA050616,Novartis Pharmaceuticals Corporation,DEXAMETHASONE; TOBRAMYCIN,1; 3,mg/g; mg/g,"Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20261231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0883,HUMAN PRESCRIPTION DRUG,ADAKVEO,,crizanlizumab,INJECTION,INTRAVENOUS,20191115,,BLA,BLA761128,Novartis Pharmaceuticals Corporation,CRIZANLIZUMAB,10,mg/mL,"P-Selectin Blockers [MoA], Selectin Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0897,HUMAN PRESCRIPTION DRUG,TRIESENCE,,triamcinolone acetonide,"INJECTION, SUSPENSION",OPHTHALMIC,20241001,,NDA,NDA022048,Novartis Pharmaceuticals Corporation,TRIAMCINOLONE ACETONIDE,40,mg/mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0909,HUMAN PRESCRIPTION DRUG,KISQALI FEMARA CO-PACK,,letrozole and ribociclib,KIT,,20170504,20260831,NDA,NDA209935,Novartis Pharmaceuticals Corporation,,,,,,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0911,HUMAN PRESCRIPTION DRUG,Xiidra,,Lifitegrast,SOLUTION/ DROPS,OPHTHALMIC,20160711,,NDA,NDA208073,Novartis Pharmaceuticals Corporation,LIFITEGRAST,50,mg/mL,"Lymphocyte Function-Associated Antigen-1 Antagonist [EPC], Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0916,HUMAN PRESCRIPTION DRUG,KISQALI FEMARA CO-PACK,,letrozole and ribociclib,KIT,,20170504,20260831,NDA,NDA209935,Novartis Pharmaceuticals Corporation,,,,,,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0923,HUMAN PRESCRIPTION DRUG,KISQALI FEMARA CO-PACK,,letrozole and ribociclib,KIT,,20170504,20260831,NDA,NDA209935,Novartis Pharmaceuticals Corporation,,,,,,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0925,HUMAN PRESCRIPTION DRUG,Maxidex,,dexamethasone,SUSPENSION/ DROPS,OPHTHALMIC,19660515,20250930,NDA,NDA013422,Novartis Pharmaceuticals Corporation,DEXAMETHASONE,1,mg/mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0937,HUMAN PRESCRIPTION DRUG,EGATEN,,triclabendazole,TABLET,ORAL,20190213,,NDA,NDA208711,Novartis Pharmaceuticals Corporation,TRICLABENDAZOLE,250,mg/1,"Anthelmintic [EPC], Anthelmintics [CS], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2A6 Inhibitors [MoA], Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0946,HUMAN PRESCRIPTION DRUG,Travatan Z,,travoprost,SOLUTION/ DROPS,OPHTHALMIC,20061020,,NDA,NDA021994,Novartis Pharmaceuticals Corporation,TRAVOPROST,0.04,mg/mL,"Prostaglandin Analog [EPC], Prostaglandins [CS]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0951,HUMAN PRESCRIPTION DRUG,Tasigna,,nilotinib,CAPSULE,ORAL,20071029,,NDA,NDA022068,Novartis Pharmaceuticals Corporation,NILOTINIB HYDROCHLORIDE MONOHYDRATE,50,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0953,HUMAN PRESCRIPTION DRUG,TobraDex,,tobramycin and dexamethasone,SUSPENSION/ DROPS,OPHTHALMIC,19880915,,NDA,NDA050592,Novartis Pharmaceuticals Corporation,DEXAMETHASONE; TOBRAMYCIN,1; 3,mg/mL; mg/mL,"Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,H10.9,"[{""icd10_code"":""H10.9"",""description"":""Unspecified conjunctivitis"",""confidence"":0.4,""context"":""eye infection""},{""icd10_code"":""H40.9"",""description"":""Unspecified glaucoma"",""confidence"":0.3,""context"":""glaucoma""},{""icd10_code"":""H16.9"",""description"":""Unspecified keratitis"",""confidence"":0.3,""context"":""corneal condition""}]",0.40
0078-0958,CELLULAR THERAPY,KYMRIAH,,tisagenlecleucel,"INJECTION, SUSPENSION",INTRAVENOUS,20180501,,BLA,BLA125646,Novartis Pharmaceuticals Corporation,TISAGENLECLEUCEL,60000000,1-Jan,"CD19 Receptor Interactions [MoA], CD19-directed Chimeric Antigen Receptor [EPC], CD19-specific Chimeric Antigen Receptor [CS], Genetically-modified Autologous T Cells [EPC], Increased T Lymphocyte Activation [PE], T Lymphocytes, Cultured, Autologous, Genetically-modified [EXT]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0965,HUMAN PRESCRIPTION DRUG,Gilenya,,Fingolimod hcl,CAPSULE,ORAL,20100921,,NDA,NDA022527,Novartis Pharmaceuticals Corporation,FINGOLIMOD HYDROCHLORIDE,0.25,mg/1,"Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0972,HUMAN PRESCRIPTION DRUG,PROMACTA,,eltrombopag olamine,"POWDER, FOR SUSPENSION",ORAL,20180927,,NDA,NDA207027,Novartis Pharmaceuticals Corporation,ELTROMBOPAG OLAMINE,12.5,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist [EPC], Thrombopoietin Receptor Agonists [MoA], UGT1A1 Inhibitors [MoA], UGT1A3 Inhibitors [MoA], UGT1A4 Inhibitors [MoA], UGT1A6 Inhibitors [MoA], UGT1A9 Inhibitors [MoA], UGT2B15 Inhibitors [MoA], UGT2B7 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0979,HUMAN PRESCRIPTION DRUG,MAYZENT,,siponimod,"TABLET, FILM COATED",ORAL,20190326,,NDA,NDA209884,Novartis Pharmaceuticals Corporation,SIPONIMOD,0.25,mg/1,"Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-0986,HUMAN PRESCRIPTION DRUG,MAYZENT,,siponimod,"TABLET, FILM COATED",ORAL,20190326,,NDA,NDA209884,Novartis Pharmaceuticals Corporation,SIPONIMOD,2,mg/1,"Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1000,HUMAN PRESCRIPTION DRUG,LEQVIO,,inclisiran,"INJECTION, SOLUTION",SUBCUTANEOUS,20211222,,NDA,NDA214012,Novartis Pharmaceuticals Corporation,INCLISIRAN SODIUM,284,mg/1.5mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1007,HUMAN PRESCRIPTION DRUG,KESIMPTA,,ofatumumab,"INJECTION, SOLUTION",SUBCUTANEOUS,20091026,,BLA,BLA125326,Novartis Pharmaceuticals Corporation,OFATUMUMAB,20,mg/.4mL,"CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1014,HUMAN PRESCRIPTION DRUG,MAYZENT,,siponimod,"TABLET, FILM COATED",ORAL,20190326,,NDA,NDA209884,Novartis Pharmaceuticals Corporation,SIPONIMOD,1,mg/1,"Sphingosine 1-Phosphate Receptor Modulators [MoA], Sphingosine 1-phosphate Receptor Modulator [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1021,HUMAN PRESCRIPTION DRUG,VIJOICE,,alpelisib,TABLET,ORAL,20220405,,NDA,NDA215039,Novartis Pharmaceuticals Corporation,ALPELISIB,50,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1028,HUMAN PRESCRIPTION DRUG,VIJOICE,,alpelisib,TABLET,ORAL,20220405,,NDA,NDA215039,Novartis Pharmaceuticals Corporation,ALPELISIB,125,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1035,HUMAN PRESCRIPTION DRUG,VIJOICE,,alpelisib,KIT,,20220405,,NDA,NDA215039,Novartis Pharmaceuticals Corporation,,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1056,HUMAN PRESCRIPTION DRUG,COSENTYX,,secukinumab,INJECTION,SUBCUTANEOUS,20150121,,BLA,BLA125504,Novartis Pharmaceuticals Corporation,SECUKINUMAB,75,mg/.5mL,"Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1070,HUMAN PRESCRIPTION DRUG,COSENTYX,,secukinumab,INJECTION,SUBCUTANEOUS,20150121,,BLA,BLA125504,Novartis Pharmaceuticals Corporation,SECUKINUMAB,300,mg/2mL,"Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1077,HUMAN PRESCRIPTION DRUG,VOTRIENT,,pazopanib hydrochloride,"TABLET, FILM COATED",ORAL,20160712,,NDA,NDA022465,Novartis Pharmaceuticals Corporation,PAZOPANIB HYDROCHLORIDE,200,mg/1,"Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1091,HUMAN PRESCRIPTION DRUG,SCEMBLIX,,asciminib,"TABLET, FILM COATED",ORAL,20211029,,NDA,NDA215358,Novartis Pharmaceuticals Corporation,ASCIMINIB HYDROCHLORIDE,20,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1098,HUMAN PRESCRIPTION DRUG,SCEMBLIX,,asciminib,"TABLET, FILM COATED",ORAL,20211029,,NDA,NDA215358,Novartis Pharmaceuticals Corporation,ASCIMINIB HYDROCHLORIDE,40,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1105,HUMAN PRESCRIPTION DRUG,Mekinist,,trametinib,"TABLET, FILM COATED",ORAL,20160317,,NDA,NDA204114,Novartis Pharmaceuticals Corporation,TRAMETINIB DIMETHYL SULFOXIDE,0.5,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1112,HUMAN PRESCRIPTION DRUG,Mekinist,,trametinib,"TABLET, FILM COATED",ORAL,20160317,,NDA,NDA204114,Novartis Pharmaceuticals Corporation,TRAMETINIB DIMETHYL SULFOXIDE,2,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1154,HUMAN PRESCRIPTION DRUG,Tafinlar,,dabrafenib,"TABLET, FOR SUSPENSION",ORAL,20230316,,NDA,NDA217514,Novartis Pharmaceuticals Corporation,DABRAFENIB MESYLATE,10,mg/1,"Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Kinase Inhibitor [EPC], Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1161,HUMAN PRESCRIPTION DRUG,Mekinist,,trametinib,"POWDER, FOR SOLUTION",ORAL,20230316,,NDA,NDA217513,Novartis Pharmaceuticals Corporation,TRAMETINIB DIMETHYL SULFOXIDE,0.05,mg/mL,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1168,HUMAN PRESCRIPTION DRUG,COSENTYX,,secukinumab,"INJECTION, SOLUTION, CONCENTRATE",INTRAVENOUS,20231006,,BLA,BLA761349,Novartis Pharmaceuticals Corporation,SECUKINUMAB,25,mg/mL,"Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1175,HUMAN PRESCRIPTION DRUG,VIJOICE,,alpelisib,GRANULE,ORAL,20240424,,NDA,NDA218466,Novartis Pharmaceuticals Corporation,ALPELISIB,50,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1189,HUMAN PRESCRIPTION DRUG,FABHALTA,,iptacopan,CAPSULE,ORAL,20231205,,NDA,NDA218276,Novartis Pharmaceuticals Corporation,IPTACOPAN HYDROCHLORIDE,200,mg/1,"Complement Factor B Inhibitor [EPC], Complement Factor B Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1196,HUMAN PRESCRIPTION DRUG,SCEMBLIX,,asciminib,"TABLET, FILM COATED",ORAL,20211029,,NDA,NDA215358,Novartis Pharmaceuticals Corporation,ASCIMINIB HYDROCHLORIDE,100,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1231,HUMAN PRESCRIPTION DRUG,ENTRESTO,,Sacubitril and Valsartan,PELLET,ORAL,20240412,,NDA,NDA218591,Novartis Pharmaceuticals Corporation,SACUBITRIL; VALSARTAN,6; 6,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1238,HUMAN PRESCRIPTION DRUG,ENTRESTO,,Sacubitril and Valsartan,PELLET,ORAL,20240412,,NDA,NDA218591,Novartis Pharmaceuticals Corporation,SACUBITRIL; VALSARTAN,15; 16,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-1420,HUMAN PRESCRIPTION DRUG,VANRAFIA,,atrasentan,"TABLET, FILM COATED",ORAL,20250402,,NDA,NDA219208,Novartis Pharmaceuticals Corporation,ATRASENTAN HYDROCHLORIDE,0.75,mg/1,,,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-9659,HUMAN PRESCRIPTION DRUG,ENTRESTO,,Sacubitril and Valsartan,"TABLET, FILM COATED",ORAL,20150707,,NDA,NDA207620,Novartis Pharmaceuticals Corporation,SACUBITRIL; VALSARTAN,24; 26,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0078-9777,HUMAN PRESCRIPTION DRUG,ENTRESTO,,Sacubitril and Valsartan,"TABLET, FILM COATED",ORAL,20150707,,NDA,NDA207620,Novartis Pharmaceuticals Corporation,SACUBITRIL; VALSARTAN,49; 51,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-1328,HUMAN PRESCRIPTION DRUG,NOXAFIL,,posaconazole,SUSPENSION,ORAL,20060915,,NDA,NDA022003,Merck Sharp & Dohme LLC,POSACONAZOLE,40,mg/mL,"Azole Antifungal [EPC], Azoles [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-1366,HUMAN PRESCRIPTION DRUG,TEMODAR,,Temozolomide,CAPSULE,ORAL,19990811,,NDA,NDA021029,Merck Sharp & Dohme LLC,TEMOZOLOMIDE,100,mg/1,"Alkylating Activity [MoA], Alkylating Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-1381,HUMAN PRESCRIPTION DRUG,TEMODAR,,Temozolomide,"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",INTRAVENOUS,20090227,,NDA,NDA022277,Merck Sharp & Dohme LLC,TEMOZOLOMIDE,2.5,mg/mL,"Alkylating Activity [MoA], Alkylating Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-1417,HUMAN PRESCRIPTION DRUG,TEMODAR,,Temozolomide,CAPSULE,ORAL,19990811,,NDA,NDA021029,Merck Sharp & Dohme LLC,TEMOZOLOMIDE,250,mg/1,"Alkylating Activity [MoA], Alkylating Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-1425,HUMAN PRESCRIPTION DRUG,TEMODAR,,Temozolomide,CAPSULE,ORAL,19990811,,NDA,NDA021029,Merck Sharp & Dohme LLC,TEMOZOLOMIDE,140,mg/1,"Alkylating Activity [MoA], Alkylating Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-1430,HUMAN PRESCRIPTION DRUG,TEMODAR,,Temozolomide,CAPSULE,ORAL,19990811,,NDA,NDA021029,Merck Sharp & Dohme LLC,TEMOZOLOMIDE,180,mg/1,"Alkylating Activity [MoA], Alkylating Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-1519,HUMAN PRESCRIPTION DRUG,TEMODAR,,Temozolomide,CAPSULE,ORAL,19990811,,NDA,NDA021029,Merck Sharp & Dohme LLC,TEMOZOLOMIDE,20,mg/1,"Alkylating Activity [MoA], Alkylating Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-2224,HUMAN PRESCRIPTION DRUG,NOXAFIL,,posaconazole,"POWDER, FOR SUSPENSION",ORAL,20210608,,NDA,NDA214770,Merck Sharp & Dohme LLC,POSACONAZOLE,300,mg/1,"Azole Antifungal [EPC], Azoles [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-3004,HUMAN PRESCRIPTION DRUG,TEMODAR,,Temozolomide,CAPSULE,ORAL,19990811,,NDA,NDA021029,Merck Sharp & Dohme LLC,TEMOZOLOMIDE,5,mg/1,"Alkylating Activity [MoA], Alkylating Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-4324,HUMAN PRESCRIPTION DRUG,NOXAFIL,,posaconazole,"TABLET, COATED",ORAL,20131125,,NDA,NDA205053,Merck Sharp & Dohme LLC,POSACONAZOLE,100,mg/1,"Azole Antifungal [EPC], Azoles [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0085-4331,HUMAN PRESCRIPTION DRUG,NOXAFIL,,posaconazole,SOLUTION,INTRAVENOUS,20140313,,NDA,NDA205596,Merck Sharp & Dohme LLC,POSACONAZOLE,18,mg/mL,"Azole Antifungal [EPC], Azoles [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0088-2102,HUMAN PRESCRIPTION DRUG,Priftin,,rifapentine,"TABLET, FILM COATED",ORAL,20170208,,NDA,NDA021024,sanofi-aventis U.S. LLC,RIFAPENTINE,150,mg/1,"Rifamycin Antimycobacterial [EPC], Rifamycins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0088-2160,HUMAN PRESCRIPTION DRUG,Arava,,leflunomide,"TABLET, FILM COATED",ORAL,19980910,,NDA,NDA020905,sanofi-aventis U.S. LLC,LEFLUNOMIDE,10,mg/1,Antirheumatic Agent [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0088-2161,HUMAN PRESCRIPTION DRUG,Arava,,leflunomide,"TABLET, FILM COATED",ORAL,19980910,,NDA,NDA020905,sanofi-aventis U.S. LLC,LEFLUNOMIDE,20,mg/1,Antirheumatic Agent [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0088-2162,HUMAN PRESCRIPTION DRUG,Arava,,leflunomide,"TABLET, FILM COATED",ORAL,19980910,,NDA,NDA020905,sanofi-aventis U.S. LLC,LEFLUNOMIDE,100,mg/1,Antirheumatic Agent [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0088-2219,HUMAN PRESCRIPTION DRUG,Lantus Solostar,,insulin glargine,"INJECTION, SOLUTION",SUBCUTANEOUS,20090923,,BLA,BLA021081,sanofi-aventis U.S. LLC,INSULIN GLARGINE,100,[iU]/mL,"Insulin Analog [EPC], Insulin [CS]",,N,20251231,E11.9,"[{""icd10_code"":""E10.9"",""description"":""Type 1 diabetes mellitus without complications"",""confidence"":0.3,""context"":""insulin-dependent""},{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.6,""context"":""most common""},{""icd10_code"":""E13.9"",""description"":""Other specified diabetes mellitus without complications"",""confidence"":0.1,""context"":""secondary diabetes""}]",0.60
0088-2220,HUMAN PRESCRIPTION DRUG,Lantus,,insulin glargine,"INJECTION, SOLUTION",SUBCUTANEOUS,20090923,,BLA,BLA021081,sanofi-aventis U.S. LLC,INSULIN GLARGINE,100,[iU]/mL,"Insulin Analog [EPC], Insulin [CS]",,N,20251231,E11.9,"[{""icd10_code"":""E10.9"",""description"":""Type 1 diabetes mellitus without complications"",""confidence"":0.3,""context"":""insulin-dependent""},{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.6,""context"":""most common""},{""icd10_code"":""E13.9"",""description"":""Other specified diabetes mellitus without complications"",""confidence"":0.1,""context"":""secondary diabetes""}]",0.60
0088-2500,HUMAN PRESCRIPTION DRUG,Apidra,,insulin glulisine,"INJECTION, SOLUTION",INTRAVENOUS; SUBCUTANEOUS,20090224,,BLA,BLA021629,sanofi-aventis U.S. LLC,INSULIN GLULISINE,100,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20251231,E11.9,"[{""icd10_code"":""E10.9"",""description"":""Type 1 diabetes mellitus without complications"",""confidence"":0.3,""context"":""insulin-dependent""},{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.6,""context"":""most common""},{""icd10_code"":""E13.9"",""description"":""Other specified diabetes mellitus without complications"",""confidence"":0.1,""context"":""secondary diabetes""}]",0.60
0088-2502,HUMAN PRESCRIPTION DRUG,Apidra SoloStar,,insulin glulisine,"INJECTION, SOLUTION",SUBCUTANEOUS,20090224,,BLA,BLA021629,sanofi-aventis U.S. LLC,INSULIN GLULISINE,100,[iU]/mL,"Insulin Analog [EPC], Insulin [Chemical/Ingredient]",,N,20251231,E11.9,"[{""icd10_code"":""E10.9"",""description"":""Type 1 diabetes mellitus without complications"",""confidence"":0.3,""context"":""insulin-dependent""},{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.6,""context"":""most common""},{""icd10_code"":""E13.9"",""description"":""Other specified diabetes mellitus without complications"",""confidence"":0.1,""context"":""secondary diabetes""}]",0.60
0088-5020,HUMAN PRESCRIPTION DRUG,Lantus Solostar,,insulin glargine,"INJECTION, SOLUTION",SUBCUTANEOUS,20170604,,BLA,BLA021081,sanofi-aventis U.S. LLC,INSULIN GLARGINE,100,[iU]/mL,"Insulin Analog [EPC], Insulin [CS]",,N,20251231,E11.9,"[{""icd10_code"":""E10.9"",""description"":""Type 1 diabetes mellitus without complications"",""confidence"":0.3,""context"":""insulin-dependent""},{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.6,""context"":""most common""},{""icd10_code"":""E13.9"",""description"":""Other specified diabetes mellitus without complications"",""confidence"":0.1,""context"":""secondary diabetes""}]",0.60
0088-5021,HUMAN PRESCRIPTION DRUG,Lantus,,insulin glargine,"INJECTION, SOLUTION",SUBCUTANEOUS,20170604,,BLA,BLA021081,sanofi-aventis U.S. LLC,INSULIN GLARGINE,100,[iU]/mL,"Insulin Analog [EPC], Insulin [CS]",,N,20251231,E11.9,"[{""icd10_code"":""E10.9"",""description"":""Type 1 diabetes mellitus without complications"",""confidence"":0.3,""context"":""insulin-dependent""},{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.6,""context"":""most common""},{""icd10_code"":""E13.9"",""description"":""Other specified diabetes mellitus without complications"",""confidence"":0.1,""context"":""secondary diabetes""}]",0.60
0093-0010,HUMAN PRESCRIPTION DRUG,Tolterodine Tartrate,,Tolterodine Tartrate,"TABLET, FILM COATED",ORAL,20151101,,ANDA,ANDA077006,"Teva Pharmaceuticals USA, Inc.",TOLTERODINE TARTRATE,1,mg/1,"Cholinergic Muscarinic Antagonist [EPC], Cholinergic Muscarinic Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0017,HUMAN PRESCRIPTION DRUG,Moexipril Hydrochloride,,Moexipril Hydrochloride,"TABLET, FILM COATED",ORAL,20030508,,ANDA,ANDA076204,"Teva Pharmaceuticals USA, Inc.",MOEXIPRIL HYDROCHLORIDE,7.5,mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0018,HUMAN PRESCRIPTION DRUG,Tolterodine Tartrate,,Tolterodine Tartrate,"TABLET, FILM COATED",ORAL,20151101,,ANDA,ANDA077006,"Teva Pharmaceuticals USA, Inc.",TOLTERODINE TARTRATE,2,mg/1,"Cholinergic Muscarinic Antagonist [EPC], Cholinergic Muscarinic Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0051,HUMAN PRESCRIPTION DRUG,Carvedilol,,Carvedilol,"TABLET, FILM COATED",ORAL,20070906,,ANDA,ANDA076373,"Teva Pharmaceuticals USA, Inc.",CARVEDILOL,3.125,mg/1,"Adrenergic alpha-Antagonists [MoA], Adrenergic beta1-Antagonists [MoA], Adrenergic beta2-Antagonists [MoA], alpha-Adrenergic Blocker [EPC], beta-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0053,HUMAN PRESCRIPTION DRUG,Buspirone Hydrochloride,,Buspirone Hydrochloride,TABLET,ORAL,20020228,,ANDA,ANDA075022,"Teva Pharmaceuticals USA, Inc.",BUSPIRONE HYDROCHLORIDE,5,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0054,HUMAN PRESCRIPTION DRUG,Buspirone Hydrochloride,,Buspirone Hydrochloride,TABLET,ORAL,20020228,,ANDA,ANDA075022,"Teva Pharmaceuticals USA, Inc.",BUSPIRONE HYDROCHLORIDE,10,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0058,HUMAN PRESCRIPTION DRUG,Tramadol Hydrochloride,,Tramadol Hydrochloride,"TABLET, FILM COATED",ORAL,20020620,20260228,ANDA,ANDA075977,"Teva Pharmaceuticals USA, Inc.",TRAMADOL HYDROCHLORIDE,50,mg/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CIV,N,,M79.3,"[{""icd10_code"":""M79.3"",""description"":""Panniculitis, unspecified"",""confidence"":0.4,""context"":""moderate pain""},{""icd10_code"":""G89.29"",""description"":""Other chronic pain"",""confidence"":0.3,""context"":""chronic pain""},{""icd10_code"":""M25.50"",""description"":""Pain in unspecified joint"",""confidence"":0.2,""context"":""joint pain""},{""icd10_code"":""G89.18"",""description"":""Other acute pain"",""confidence"":0.1,""context"":""acute pain""}]",0.40
0093-0073,HUMAN PRESCRIPTION DRUG,Zolpidem Tartrate,,Zolpidem Tartrate,"TABLET, FILM COATED",ORAL,20070423,,ANDA,ANDA076410,"Teva Pharmaceuticals USA, Inc.",ZOLPIDEM TARTRATE,5,mg/1,"Central Nervous System Depression [PE], GABA A Receptor Positive Modulators [MoA], gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]",CIV,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0074,HUMAN PRESCRIPTION DRUG,Zolpidem Tartrate,,Zolpidem Tartrate,"TABLET, FILM COATED",ORAL,20070423,,ANDA,ANDA076410,"Teva Pharmaceuticals USA, Inc.",ZOLPIDEM TARTRATE,10,mg/1,"Central Nervous System Depression [PE], GABA A Receptor Positive Modulators [MoA], gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]",CIV,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0090,HUMAN PRESCRIPTION DRUG,Epitol,,Carbamazepine,TABLET,ORAL,19900930,,ANDA,ANDA070541,"Teva Pharmaceuticals USA, Inc.",CARBAMAZEPINE,200,mg/1,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0109,HUMAN PRESCRIPTION DRUG,Carbamazepine,,Carbamazepine,TABLET,ORAL,19900930,,ANDA,ANDA070541,"Teva Pharmaceuticals USA, Inc.",CARBAMAZEPINE,200,mg/1,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0135,HUMAN PRESCRIPTION DRUG,Carvedilol,,Carvedilol,"TABLET, FILM COATED",ORAL,20070906,,ANDA,ANDA076373,"Teva Pharmaceuticals USA, Inc.",CARVEDILOL,6.25,mg/1,"Adrenergic alpha-Antagonists [MoA], Adrenergic beta1-Antagonists [MoA], Adrenergic beta2-Antagonists [MoA], alpha-Adrenergic Blocker [EPC], beta-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0262,HUMAN PRESCRIPTION DRUG,Fluocinonide,,Fluocinonide,CREAM,TOPICAL,19900930,,ANDA,ANDA072488,"Teva Pharmaceuticals USA, Inc.",FLUOCINONIDE,0.5,mg/g,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-0263,HUMAN PRESCRIPTION DRUG,Fluocinonide,,Fluocinonide,CREAM,TOPICAL,19900930,,ANDA,ANDA072490,"Teva Pharmaceuticals USA, Inc.",FLUOCINONIDE,0.5,mg/g,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-0264,HUMAN PRESCRIPTION DRUG,Fluocinonide,,Fluocinonide,OINTMENT,TOPICAL,19920501,,ANDA,ANDA073481,"Teva Pharmaceuticals USA, Inc.",FLUOCINONIDE,0.5,mg/g,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-0308,HUMAN PRESCRIPTION DRUG,Clemastine Fumarate,,Clemastine Fumarate,TABLET,ORAL,19920401,20260331,ANDA,ANDA073283,"Teva Pharmaceuticals USA, Inc.",CLEMASTINE FUMARATE,2.68,mg/1,,,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0311,HUMAN PRESCRIPTION DRUG,Loperamide Hydrochloride,,Loperamide Hydrochloride,CAPSULE,ORAL,19930501,,ANDA,ANDA073192,"Teva Pharmaceuticals USA, Inc.",LOPERAMIDE HYDROCHLORIDE,2,mg/1,"Opioid Agonist [EPC], Opioid Agonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0314,HUMAN PRESCRIPTION DRUG,Ketorolac Tromethamine,,Ketorolac Tromethamine,"TABLET, FILM COATED",ORAL,19980617,,ANDA,ANDA074754,"Teva Pharmaceuticals USA, Inc.",KETOROLAC TROMETHAMINE,10,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitor [EPC], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0318,HUMAN PRESCRIPTION DRUG,Diltiazem Hydrochloride,,Diltiazem Hydrochloride,"TABLET, FILM COATED",ORAL,19951222,,ANDA,ANDA074185,"Teva Pharmaceuticals USA, Inc.",DILTIAZEM HYDROCHLORIDE,30,mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0319,HUMAN PRESCRIPTION DRUG,Diltiazem Hydrochloride,,Diltiazem Hydrochloride,"TABLET, FILM COATED",ORAL,19951222,,ANDA,ANDA074185,"Teva Pharmaceuticals USA, Inc.",DILTIAZEM HYDROCHLORIDE,60,mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0320,HUMAN PRESCRIPTION DRUG,Diltiazem Hydrochloride,,Diltiazem Hydrochloride,"TABLET, FILM COATED",ORAL,19951222,,ANDA,ANDA074185,"Teva Pharmaceuticals USA, Inc.",DILTIAZEM HYDROCHLORIDE,90,mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0321,HUMAN PRESCRIPTION DRUG,Diltiazem Hydrochloride,,Diltiazem Hydrochloride,"TABLET, FILM COATED",ORAL,19951226,,ANDA,ANDA074185,"Teva Pharmaceuticals USA, Inc.",DILTIAZEM HYDROCHLORIDE,120,mg/1,"Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0576,HUMAN PRESCRIPTION DRUG,Lovastatin,,Lovastatin,TABLET,ORAL,20011217,,ANDA,ANDA075551,"Teva Pharmaceuticals USA, Inc.",LOVASTATIN,20,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-0711,HUMAN PRESCRIPTION DRUG,Flurbiprofen,,Flurbiprofen,"TABLET, FILM COATED",ORAL,19950602,20260131,ANDA,ANDA074431,"Teva Pharmaceuticals USA, Inc.",FLURBIPROFEN,100,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0752,HUMAN PRESCRIPTION DRUG,Atenolol,,Atenolol,TABLET,ORAL,19950222,,ANDA,ANDA074056,"Teva Pharmaceuticals USA, Inc.",ATENOLOL,50,mg/1,"Adrenergic beta-Antagonists [MoA], beta-Adrenergic Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0753,HUMAN PRESCRIPTION DRUG,Atenolol,,Atenolol,TABLET,ORAL,19950217,,ANDA,ANDA074056,"Teva Pharmaceuticals USA, Inc.",ATENOLOL,100,mg/1,"Adrenergic beta-Antagonists [MoA], beta-Adrenergic Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0756,HUMAN PRESCRIPTION DRUG,Piroxicam,,Piroxicam,CAPSULE,ORAL,19941019,,ANDA,ANDA074131,"Teva Pharmaceuticals USA, Inc.",PIROXICAM,10,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0757,HUMAN PRESCRIPTION DRUG,Piroxicam,,Piroxicam,CAPSULE,ORAL,19940126,,ANDA,ANDA074131,"Teva Pharmaceuticals USA, Inc.",PIROXICAM,20,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0771,HUMAN PRESCRIPTION DRUG,Pravastatin Sodium,,Pravastatin Sodium,TABLET,ORAL,20060425,20260930,ANDA,ANDA076056,"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,10,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-0778,HUMAN PRESCRIPTION DRUG,Carbamazepine,,Carbamazepine,"TABLET, CHEWABLE",ORAL,19950918,20250630,ANDA,ANDA073524,"Teva Pharmaceuticals USA, Inc.",CARBAMAZEPINE,100,mg/1,"Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE], Mood Stabilizer [EPC]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0787,HUMAN PRESCRIPTION DRUG,Atenolol,,Atenolol,TABLET,ORAL,20041116,,ANDA,ANDA074056,"Teva Pharmaceuticals USA, Inc.",ATENOLOL,25,mg/1,"Adrenergic beta-Antagonists [MoA], beta-Adrenergic Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0810,HUMAN PRESCRIPTION DRUG,Nortriptyline Hydrochloride,,Nortriptyline Hydrochloride,CAPSULE,ORAL,19950405,,ANDA,ANDA074132,"Teva Pharmaceuticals USA, Inc.",NORTRIPTYLINE HYDROCHLORIDE,10,mg/1,Tricyclic Antidepressant [EPC],,N,20261231,F32.9,"[{""icd10_code"":""F32.9"",""description"":""Major depressive disorder, single episode, unspecified"",""confidence"":0.5,""context"":""depression""},{""icd10_code"":""F33.9"",""description"":""Major depressive disorder, recurrent, unspecified"",""confidence"":0.25,""context"":""recurrent depression""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""anxiety/panic""},{""icd10_code"":""F43.10"",""description"":""Post-traumatic stress disorder, unspecified"",""confidence"":0.05,""context"":""PTSD""},{""icd10_code"":""F50.00"",""description"":""Anorexia nervosa, unspecified"",""confidence"":0.05,""context"":""eating disorders""}]",0.50
0093-0811,HUMAN PRESCRIPTION DRUG,Nortriptyline Hydrochloride,,Nortriptyline Hydrochloride,CAPSULE,ORAL,19950406,,ANDA,ANDA074132,"Teva Pharmaceuticals USA, Inc.",NORTRIPTYLINE HYDROCHLORIDE,25,mg/1,Tricyclic Antidepressant [EPC],,N,20261231,F32.9,"[{""icd10_code"":""F32.9"",""description"":""Major depressive disorder, single episode, unspecified"",""confidence"":0.5,""context"":""depression""},{""icd10_code"":""F33.9"",""description"":""Major depressive disorder, recurrent, unspecified"",""confidence"":0.25,""context"":""recurrent depression""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""anxiety/panic""},{""icd10_code"":""F43.10"",""description"":""Post-traumatic stress disorder, unspecified"",""confidence"":0.05,""context"":""PTSD""},{""icd10_code"":""F50.00"",""description"":""Anorexia nervosa, unspecified"",""confidence"":0.05,""context"":""eating disorders""}]",0.50
0093-0812,HUMAN PRESCRIPTION DRUG,Nortriptyline Hydrochloride,,Nortriptyline Hydrochloride,CAPSULE,ORAL,19950405,,ANDA,ANDA074132,"Teva Pharmaceuticals USA, Inc.",NORTRIPTYLINE HYDROCHLORIDE,50,mg/1,Tricyclic Antidepressant [EPC],,N,20261231,F32.9,"[{""icd10_code"":""F32.9"",""description"":""Major depressive disorder, single episode, unspecified"",""confidence"":0.5,""context"":""depression""},{""icd10_code"":""F33.9"",""description"":""Major depressive disorder, recurrent, unspecified"",""confidence"":0.25,""context"":""recurrent depression""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""anxiety/panic""},{""icd10_code"":""F43.10"",""description"":""Post-traumatic stress disorder, unspecified"",""confidence"":0.05,""context"":""PTSD""},{""icd10_code"":""F50.00"",""description"":""Anorexia nervosa, unspecified"",""confidence"":0.05,""context"":""eating disorders""}]",0.50
0093-0813,HUMAN PRESCRIPTION DRUG,Nortriptyline Hydrochloride,,Nortriptyline Hydrochloride,CAPSULE,ORAL,19950405,,ANDA,ANDA074132,"Teva Pharmaceuticals USA, Inc.",NORTRIPTYLINE HYDROCHLORIDE,75,mg/1,Tricyclic Antidepressant [EPC],,N,20261231,F32.9,"[{""icd10_code"":""F32.9"",""description"":""Major depressive disorder, single episode, unspecified"",""confidence"":0.5,""context"":""depression""},{""icd10_code"":""F33.9"",""description"":""Major depressive disorder, recurrent, unspecified"",""confidence"":0.25,""context"":""recurrent depression""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""anxiety/panic""},{""icd10_code"":""F43.10"",""description"":""Post-traumatic stress disorder, unspecified"",""confidence"":0.05,""context"":""PTSD""},{""icd10_code"":""F50.00"",""description"":""Anorexia nervosa, unspecified"",""confidence"":0.05,""context"":""eating disorders""}]",0.50
0093-0832,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,TABLET,ORAL,19960918,,ANDA,ANDA074569,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,0.5,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0926,HUMAN PRESCRIPTION DRUG,Lovastatin,,Lovastatin,TABLET,ORAL,20011217,,ANDA,ANDA075551,"Teva Pharmaceuticals USA, Inc.",LOVASTATIN,10,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-0928,HUMAN PRESCRIPTION DRUG,Lovastatin,,Lovastatin,TABLET,ORAL,20011217,,ANDA,ANDA075551,"Teva Pharmaceuticals USA, Inc.",LOVASTATIN,40,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20261231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-0948,HUMAN PRESCRIPTION DRUG,Diclofenac Potassium,,Diclofenac Potassium,"TABLET, FILM COATED",ORAL,19980811,,ANDA,ANDA075219,"Teva Pharmaceuticals USA, Inc.",DICLOFENAC POTASSIUM,50,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Prostaglandin Production [PE], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-0983,HUMAN PRESCRIPTION DRUG,Nystatin,,Nystatin,"TABLET, FILM COATED",ORAL,19900930,,ANDA,ANDA062506,"Teva Pharmaceuticals USA, Inc.",NYSTATIN,500000,[USP'U]/1,"Polyene Antifungal [EPC], Polyenes [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1003,HUMAN PRESCRIPTION DRUG,Buspirone Hydrochloride,,Buspirone Hydrochloride,TABLET,ORAL,20020301,,ANDA,ANDA075022,"Teva Pharmaceuticals USA, Inc.",BUSPIRONE HYDROCHLORIDE,15,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1010,HUMAN PRESCRIPTION DRUG,Mupirocin,,Mupirocin,OINTMENT,TOPICAL,20031107,,ANDA,ANDA065085,"Teva Pharmaceuticals USA, Inc.",MUPIROCIN,20,mg/g,"RNA Synthetase Inhibitor Antibacterial [EPC], RNA Synthetase Inhibitors [MoA]",,N,20261231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-1024,HUMAN PRESCRIPTION DRUG,Nefazodone Hydrochloride,,Nefazodone Hydrochloride,TABLET,ORAL,20030916,,ANDA,ANDA076037,"Teva Pharmaceuticals USA, Inc.",NEFAZODONE HYDROCHLORIDE,100,mg/1,Serotonin Reuptake Inhibitor [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1025,HUMAN PRESCRIPTION DRUG,Nefazodone Hydrochloride,,Nefazodone Hydrochloride,TABLET,ORAL,20030916,,ANDA,ANDA076037,"Teva Pharmaceuticals USA, Inc.",NEFAZODONE HYDROCHLORIDE,200,mg/1,Serotonin Reuptake Inhibitor [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1026,HUMAN PRESCRIPTION DRUG,Nefazodone Hydrochloride,,Nefazodone Hydrochloride,TABLET,ORAL,20030916,,ANDA,ANDA076037,"Teva Pharmaceuticals USA, Inc.",NEFAZODONE HYDROCHLORIDE,250,mg/1,Serotonin Reuptake Inhibitor [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1060,HUMAN PRESCRIPTION DRUG,Sotalol Hydrochloride,,Sotalol Hydrochloride,TABLET,ORAL,20000505,,ANDA,ANDA075429,"Teva Pharmaceuticals USA, Inc.",SOTALOL HYDROCHLORIDE,120,mg/1,"Adrenergic beta-Antagonists [MoA], Antiarrhythmic [EPC], Cardiac Rhythm Alteration [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1061,HUMAN PRESCRIPTION DRUG,Sotalol Hydrochloride,,Sotalol Hydrochloride,TABLET,ORAL,20000504,,ANDA,ANDA075429,"Teva Pharmaceuticals USA, Inc.",SOTALOL HYDROCHLORIDE,80,mg/1,"Adrenergic beta-Antagonists [MoA], Antiarrhythmic [EPC], Cardiac Rhythm Alteration [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1062,HUMAN PRESCRIPTION DRUG,Sotalol Hydrochloride,,Sotalol Hydrochloride,TABLET,ORAL,20000505,,ANDA,ANDA075429,"Teva Pharmaceuticals USA, Inc.",SOTALOL HYDROCHLORIDE,160,mg/1,"Adrenergic beta-Antagonists [MoA], Antiarrhythmic [EPC], Cardiac Rhythm Alteration [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1063,HUMAN PRESCRIPTION DRUG,Sotalol Hydrochloride,,Sotalol Hydrochloride,TABLET,ORAL,20000505,,ANDA,ANDA075429,"Teva Pharmaceuticals USA, Inc.",SOTALOL HYDROCHLORIDE,240,mg/1,"Adrenergic beta-Antagonists [MoA], Antiarrhythmic [EPC], Cardiac Rhythm Alteration [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1077,HUMAN PRESCRIPTION DRUG,Cefprozil,,Cefprozil,"TABLET, FILM COATED",ORAL,20051223,,ANDA,ANDA065208,"Teva Pharmaceuticals USA, Inc.",CEFPROZIL,250,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1078,HUMAN PRESCRIPTION DRUG,Cefprozil,,Cefprozil,"TABLET, FILM COATED",ORAL,20051223,,ANDA,ANDA065208,"Teva Pharmaceuticals USA, Inc.",CEFPROZIL,500,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1087,HUMAN PRESCRIPTION DRUG,Cefaclor,,Cefaclor,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20020926,,ANDA,ANDA065058,"Teva Pharmaceuticals USA, Inc.",CEFACLOR,500,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1106,HUMAN PRESCRIPTION DRUG,Teriparatide,,Teriparatide,"INJECTION, SOLUTION",SUBCUTANEOUS,20231218,,ANDA,ANDA208569,"Teva Pharmaceuticals USA, Inc.",TERIPARATIDE ACETATE,250,ug/mL,"Parathyroid Hormone Analog [EPC], Parathyroid Hormone [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1118,HUMAN PRESCRIPTION DRUG,Etodolac,,Etodolac,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20000817,,ANDA,ANDA075665,"Teva Pharmaceuticals USA, Inc.",ETODOLAC,600,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1122,HUMAN PRESCRIPTION DRUG,Etodolac,,Etodolac,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20010209,,ANDA,ANDA075665,"Teva Pharmaceuticals USA, Inc.",ETODOLAC,400,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1135,HUMAN PRESCRIPTION DRUG,Acitretin,,Acitretin,CAPSULE,ORAL,20130719,,ANDA,ANDA091455,"Teva Pharmaceuticals USA, Inc.",ACITRETIN,10,mg/1,"Retinoid [EPC], Retinoids [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1136,HUMAN PRESCRIPTION DRUG,Acitretin,,Acitretin,CAPSULE,ORAL,20130719,,ANDA,ANDA091455,"Teva Pharmaceuticals USA, Inc.",ACITRETIN,25,mg/1,"Retinoid [EPC], Retinoids [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1138,HUMAN PRESCRIPTION DRUG,Acitretin,,Acitretin,CAPSULE,ORAL,20130719,,ANDA,ANDA202897,"Teva Pharmaceuticals USA, Inc.",ACITRETIN,17.5,mg/1,"Retinoid [EPC], Retinoids [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1172,HUMAN PRESCRIPTION DRUG,Penicillin V Potassium,,Penicillin V Potassium,TABLET,ORAL,19900930,,ANDA,ANDA060711,"Teva Pharmaceuticals USA, Inc.",PENICILLIN V POTASSIUM,250,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1174,HUMAN PRESCRIPTION DRUG,Penicillin V Potassium,,Penicillin V Potassium,TABLET,ORAL,19900930,,ANDA,ANDA060711,"Teva Pharmaceuticals USA, Inc.",PENICILLIN V POTASSIUM,500,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1177,HUMAN PRESCRIPTION DRUG,Neomycin Sulfate,,Neomycin Sulfate,TABLET,ORAL,19900930,,ANDA,ANDA060304,"Teva Pharmaceuticals USA, Inc.",NEOMYCIN SULFATE,500,mg/1,"Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1712,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20151019,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,1,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1713,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20150505,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,2,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1714,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20150407,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,2.5,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1715,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20150714,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,3,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1716,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20150609,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,4,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1718,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20150722,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,6,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1720,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20150512,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,10,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1721,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20150407,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,5,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1723,HUMAN PRESCRIPTION DRUG,Warfarin Sodium,,Warfarin Sodium,TABLET,ORAL,20180827,,ANDA,ANDA040616,"Teva Pharmaceuticals USA, Inc.",WARFARIN SODIUM,7.5,mg/1,"Vitamin K Antagonist [EPC], Vitamin K Inhibitors [MoA]",,N,20261231,I48.91,"[{""icd10_code"":""I48.91"",""description"":""Unspecified atrial fibrillation"",""confidence"":0.4,""context"":""AFib anticoagulation""},{""icd10_code"":""Z79.01"",""description"":""Long term use of anticoagulants"",""confidence"":0.3,""context"":""chronic anticoagulation""},{""icd10_code"":""I26.99"",""description"":""Other pulmonary embolism without acute cor pulmonale"",""confidence"":0.15,""context"":""PE treatment""},{""icd10_code"":""I82.90"",""description"":""Chronic embolism and thrombosis of unspecified vein"",""confidence"":0.1,""context"":""DVT treatment""},{""icd10_code"":""Z95.2"",""description"":""Presence of prosthetic heart valve"",""confidence"":0.05,""context"":""mechanical valve""}]",0.40
0093-1920,HUMAN PRESCRIPTION DRUG,Cyclobenzaprine Hydrochloride,,Cyclobenzaprine Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20190304,,NDA AUTHORIZED GENERIC,NDA021777,"Teva Pharmaceuticals USA, Inc.",CYCLOBENZAPRINE HYDROCHLORIDE,15,mg/1,"Centrally-mediated Muscle Relaxation [PE], Muscle Relaxant [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-1921,HUMAN PRESCRIPTION DRUG,Cyclobenzaprine Hydrochloride,,Cyclobenzaprine Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20190304,,NDA AUTHORIZED GENERIC,NDA021777,"Teva Pharmaceuticals USA, Inc.",CYCLOBENZAPRINE HYDROCHLORIDE,30,mg/1,"Centrally-mediated Muscle Relaxation [PE], Muscle Relaxant [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2026,HUMAN PRESCRIPTION DRUG,Azithromycin,,Azithromycin,"POWDER, FOR SUSPENSION",ORAL,20101217,,ANDA,ANDA065246,"Teva Pharmaceuticals USA, Inc.",AZITHROMYCIN MONOHYDRATE,200,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2027,HUMAN PRESCRIPTION DRUG,Azithromycin,,Azithromycin,"POWDER, FOR SUSPENSION",ORAL,20101228,,ANDA,ANDA065246,"Teva Pharmaceuticals USA, Inc.",AZITHROMYCIN MONOHYDRATE,100,mg/5mL,"Macrolide Antimicrobial [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2063,HUMAN PRESCRIPTION DRUG,Quetiapine,,Quetiapine,"TABLET, FILM COATED",ORAL,20140312,,ANDA,ANDA077745,"Teva Pharmaceuticals USA, Inc.",QUETIAPINE FUMARATE,25,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2064,HUMAN PRESCRIPTION DRUG,Cilostazol,,Cilostazol,TABLET,ORAL,20121024,,ANDA,ANDA077027,"Teva Pharmaceuticals USA, Inc.",CILOSTAZOL,100,mg/1,"Phosphodiesterase 3 Inhibitor [EPC], Phosphodiesterase 3 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2065,HUMAN PRESCRIPTION DRUG,Cilostazol,,Cilostazol,TABLET,ORAL,20120424,,ANDA,ANDA077027,"Teva Pharmaceuticals USA, Inc.",CILOSTAZOL,50,mg/1,"Phosphodiesterase 3 Inhibitor [EPC], Phosphodiesterase 3 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2067,HUMAN PRESCRIPTION DRUG,Doxazosin,,Doxazosin Mesylate,TABLET,ORAL,20141205,,ANDA,ANDA075536,"Teva Pharmaceuticals USA, Inc.",DOXAZOSIN MESYLATE,8,mg/1,"Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2068,HUMAN PRESCRIPTION DRUG,Doxazosin,,Doxazosin Mesylate,TABLET,ORAL,20140909,,ANDA,ANDA075536,"Teva Pharmaceuticals USA, Inc.",DOXAZOSIN MESYLATE,4,mg/1,"Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2069,HUMAN PRESCRIPTION DRUG,Doxazosin,,Doxazosin Mesylate,TABLET,ORAL,20140806,,ANDA,ANDA075536,"Teva Pharmaceuticals USA, Inc.",DOXAZOSIN MESYLATE,2,mg/1,"Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2070,HUMAN PRESCRIPTION DRUG,Doxazosin,,Doxazosin Mesylate,TABLET,ORAL,20140806,,ANDA,ANDA075536,"Teva Pharmaceuticals USA, Inc.",DOXAZOSIN MESYLATE,1,mg/1,"Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2140,HUMAN PRESCRIPTION DRUG,Tri-Lo-Sprintec,,Norgestimate and Ethinyl Estradiol,KIT,,20151230,,ANDA,ANDA076784,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2165,HUMAN PRESCRIPTION DRUG,Naloxone Hydrochloride,,Naloxone Hydrochloride,"SPRAY, METERED",NASAL,20211222,20260630,ANDA,ANDA209522,"Teva Pharmaceuticals USA, Inc.",NALOXONE HYDROCHLORIDE,4,mg/.1mL,"Opioid Antagonist [EPC], Opioid Antagonists [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2178,HUMAN PRESCRIPTION DRUG,Liothyronine Sodium,,Liothyronine Sodium,TABLET,ORAL,20210226,,ANDA,ANDA211510,"Teva Pharmaceuticals USA, Inc.",LIOTHYRONINE SODIUM,25,ug/1,"Triiodothyronine [CS], l-Triiodothyronine [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2179,HUMAN PRESCRIPTION DRUG,Liothyronine Sodium,,Liothyronine Sodium,TABLET,ORAL,20210226,,ANDA,ANDA211510,"Teva Pharmaceuticals USA, Inc.",LIOTHYRONINE SODIUM,5,ug/1,"Triiodothyronine [CS], l-Triiodothyronine [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2180,HUMAN PRESCRIPTION DRUG,Liothyronine Sodium,,Liothyronine Sodium,TABLET,ORAL,20210226,,ANDA,ANDA211510,"Teva Pharmaceuticals USA, Inc.",LIOTHYRONINE SODIUM,50,ug/1,"Triiodothyronine [CS], l-Triiodothyronine [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2203,HUMAN PRESCRIPTION DRUG,Metoclopramide,,Metoclopramide,TABLET,ORAL,19900930,,ANDA,ANDA070184,"Teva Pharmaceuticals USA, Inc.",METOCLOPRAMIDE HYDROCHLORIDE,10,mg/1,"Dopamine D2 Antagonists [MoA], Dopamine-2 Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2204,HUMAN PRESCRIPTION DRUG,Metoclopramide,,Metoclopramide,TABLET,ORAL,19930701,,ANDA,ANDA072801,"Teva Pharmaceuticals USA, Inc.",METOCLOPRAMIDE HYDROCHLORIDE,5,mg/1,"Dopamine D2 Antagonists [MoA], Dopamine-2 Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2210,HUMAN PRESCRIPTION DRUG,Sucralfate,,Sucralfate,TABLET,ORAL,19961111,,ANDA,ANDA070848,"Teva Pharmaceuticals USA, Inc.",SUCRALFATE,1,g/1,"Aluminum Complex [EPC], Organometallic Compounds [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2238,HUMAN PRESCRIPTION DRUG,Cephalexin,,Cephalexin,TABLET,ORAL,19900930,,ANDA,ANDA063023,"Teva Pharmaceuticals USA, Inc.",CEPHALEXIN,250,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2240,HUMAN PRESCRIPTION DRUG,Cephalexin,,Cephalexin,TABLET,ORAL,19900930,,ANDA,ANDA063024,"Teva Pharmaceuticals USA, Inc.",CEPHALEXIN,500,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2263,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,"TABLET, FILM COATED",ORAL,20001121,,ANDA,ANDA065056,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,500,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2264,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,"TABLET, FILM COATED",ORAL,20000926,,ANDA,ANDA065056,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,875,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2267,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,"TABLET, CHEWABLE",ORAL,19951001,,ANDA,ANDA064013,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,125,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2268,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,"TABLET, CHEWABLE",ORAL,19930101,,ANDA,ANDA064013,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,250,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2274,HUMAN PRESCRIPTION DRUG,Amoxicillin and Clavulanate Potassium,,Amoxicillin and Clavulanate Potassium,"TABLET, FILM COATED",ORAL,20021031,,ANDA,ANDA065101,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN; CLAVULANATE POTASSIUM,500; 125,mg/1; mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS], beta Lactamase Inhibitor [EPC], beta Lactamase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2275,HUMAN PRESCRIPTION DRUG,Amoxicillin and Clavulanate Potassium,,Amoxicillin and Clavulanate Potassium,"TABLET, FILM COATED",ORAL,20021031,,ANDA,ANDA065096,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN; CLAVULANATE POTASSIUM,875; 125,mg/1; mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS], beta Lactamase Inhibitor [EPC], beta Lactamase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2277,HUMAN PRESCRIPTION DRUG,Amoxicillin and Clavulanate Potassium,,Amoxicillin and Clavulanate Potassium,"POWDER, FOR SUSPENSION",ORAL,20050113,,ANDA,ANDA065089,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN; CLAVULANATE POTASSIUM,200; 28.5,mg/5mL; mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS], beta Lactamase Inhibitor [EPC], beta Lactamase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2279,HUMAN PRESCRIPTION DRUG,Amoxicillin and Clavulanate Potassium,,Amoxicillin and Clavulanate Potassium,"POWDER, FOR SUSPENSION",ORAL,20050113,,ANDA,ANDA065089,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN; CLAVULANATE POTASSIUM,400; 57,mg/5mL; mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS], beta Lactamase Inhibitor [EPC], beta Lactamase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-2401,HUMAN PRESCRIPTION DRUG,Hydroxychloroquine Sulfate,,Hydroxychloroquine Sulfate,"TABLET, FILM COATED",ORAL,20201008,,ANDA,ANDA040081,"Teva Pharmaceuticals USA, Inc.",HYDROXYCHLOROQUINE SULFATE,200,mg/1,"Antimalarial [EPC], Antirheumatic Agent [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3002,HUMAN PRESCRIPTION DRUG,Quinine Sulfate,,Quinine Sulfate,CAPSULE,ORAL,20120928,,ANDA,ANDA091661,"Teva Pharmaceuticals USA, Inc.",QUININE SULFATE,324,mg/1,Antimalarial [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3008,HUMAN PRESCRIPTION DRUG,Lansoprazole,,Lansoprazole,"TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE",ORAL,20180308,,ANDA,ANDA208784,"Teva Pharmaceuticals USA, Inc.",LANSOPRAZOLE,15,mg/1,"Inhibition Gastric Acid Secretion [PE], Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3009,HUMAN PRESCRIPTION DRUG,Lansoprazole,,Lansoprazole,"TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE",ORAL,20180308,,ANDA,ANDA208784,"Teva Pharmaceuticals USA, Inc.",LANSOPRAZOLE,30,mg/1,"Inhibition Gastric Acid Secretion [PE], Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3016,HUMAN PRESCRIPTION DRUG,Tadalafil,,Tadalafil,"TABLET, FILM COATED",ORAL,20180927,20250930,ANDA,ANDA090141,"Teva Pharmaceuticals USA, Inc.",TADALAFIL,2.5,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3017,HUMAN PRESCRIPTION DRUG,Tadalafil,,Tadalafil,"TABLET, FILM COATED",ORAL,20180927,20250930,ANDA,ANDA090141,"Teva Pharmaceuticals USA, Inc.",TADALAFIL,5,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3060,HUMAN PRESCRIPTION DRUG,Rasagiline,,Rasagiline,TABLET,ORAL,20170103,,NDA AUTHORIZED GENERIC,NDA021641,"Teva Pharmaceuticals USA, Inc.",RASAGILINE MESYLATE,0.5,mg/1,"Monoamine Oxidase Inhibitor [EPC], Monoamine Oxidase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3061,HUMAN PRESCRIPTION DRUG,Rasagiline,,Rasagiline,TABLET,ORAL,20170103,,NDA AUTHORIZED GENERIC,NDA021641,"Teva Pharmaceuticals USA, Inc.",RASAGILINE MESYLATE,1,mg/1,"Monoamine Oxidase Inhibitor [EPC], Monoamine Oxidase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3066,HUMAN PRESCRIPTION DRUG,Icatibant,,Icatibant,"INJECTION, SOLUTION",SUBCUTANEOUS,20190715,,ANDA,ANDA210118,"Teva Pharmaceuticals USA, Inc.",ICATIBANT ACETATE,10,mg/mL,"Bradykinin B2 Receptor Antagonist [EPC], Bradykinin B2 Receptor Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3090,HUMAN PRESCRIPTION DRUG,Armodafinil,,Armodafinil,TABLET,ORAL,20161129,20270930,NDA AUTHORIZED GENERIC,NDA021875,"Teva Pharmaceuticals USA, Inc.",ARMODAFINIL,50,mg/1,,CIV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3092,HUMAN PRESCRIPTION DRUG,Armodafinil,,Armodafinil,TABLET,ORAL,20161129,20270831,NDA AUTHORIZED GENERIC,NDA021875,"Teva Pharmaceuticals USA, Inc.",ARMODAFINIL,150,mg/1,,CIV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3093,HUMAN PRESCRIPTION DRUG,Armodafinil,,Armodafinil,TABLET,ORAL,20161129,20260630,NDA AUTHORIZED GENERIC,NDA021875,"Teva Pharmaceuticals USA, Inc.",ARMODAFINIL,200,mg/1,,CIV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3094,HUMAN PRESCRIPTION DRUG,Armodafinil,,Armodafinil,TABLET,ORAL,20161129,20280531,NDA AUTHORIZED GENERIC,NDA021875,"Teva Pharmaceuticals USA, Inc.",ARMODAFINIL,250,mg/1,,CIV,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3098,HUMAN PRESCRIPTION DRUG,Risedronate Sodium,,Risedronate Sodium,"TABLET, FILM COATED",ORAL,20150601,,ANDA,ANDA077132,"Teva Pharmaceuticals USA, Inc.",RISEDRONATE SODIUM MONOHYDRATE,35,mg/1,"Bisphosphonate [EPC], Diphosphonates [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3099,HUMAN PRESCRIPTION DRUG,Risedronate Sodium,,Risedronate Sodium,"TABLET, FILM COATED",ORAL,20150601,,ANDA,ANDA077132,"Teva Pharmaceuticals USA, Inc.",RISEDRONATE SODIUM MONOHYDRATE,5,mg/1,"Bisphosphonate [EPC], Diphosphonates [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3100,HUMAN PRESCRIPTION DRUG,Risedronate Sodium,,Risedronate Sodium,"TABLET, FILM COATED",ORAL,20150601,,ANDA,ANDA077132,"Teva Pharmaceuticals USA, Inc.",RISEDRONATE SODIUM MONOHYDRATE,30,mg/1,"Bisphosphonate [EPC], Diphosphonates [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3107,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,CAPSULE,ORAL,19900930,,ANDA,ANDA061926,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,250,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3109,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,CAPSULE,ORAL,19900930,,ANDA,ANDA061926,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,500,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3122,HUMAN PRESCRIPTION DRUG,Jinteli,,norethindrone acetate and ethinyl estradiol,TABLET,ORAL,20110217,,ANDA,ANDA076221,"Teva Pharmaceuticals USA, Inc.",ETHINYL ESTRADIOL; NORETHINDRONE ACETATE,5; 1,ug/1; mg/1,"Estrogen Receptor Agonists [MoA], Estrogen [EPC], Progesterone Congeners [CS], Progestin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3123,HUMAN PRESCRIPTION DRUG,Dicloxacillin Sodium,,Dicloxacillin Sodium,CAPSULE,ORAL,19900930,,ANDA,ANDA062286,"Teva Pharmaceuticals USA, Inc.",DICLOXACILLIN SODIUM,250,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3125,HUMAN PRESCRIPTION DRUG,Dicloxacillin Sodium,,Dicloxacillin Sodium,CAPSULE,ORAL,19900930,,ANDA,ANDA062286,"Teva Pharmaceuticals USA, Inc.",DICLOXACILLIN SODIUM,500,mg/1,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3127,HUMAN PRESCRIPTION DRUG,Disopyramide Phosphate,,Disopyramide Phosphate,CAPSULE,ORAL,19900930,,ANDA,ANDA070101,"Teva Pharmaceuticals USA, Inc.",DISOPYRAMIDE PHOSPHATE,100,mg/1,Antiarrhythmic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3129,HUMAN PRESCRIPTION DRUG,Disopyramide Phosphate,,Disopyramide Phosphate,CAPSULE,ORAL,19900930,,ANDA,ANDA070102,"Teva Pharmaceuticals USA, Inc.",DISOPYRAMIDE PHOSPHATE,150,mg/1,Antiarrhythmic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3133,HUMAN PRESCRIPTION DRUG,Imiquimod,,imiquimod,CREAM,TOPICAL,20200730,,NDA AUTHORIZED GENERIC,NDA022483,"Teva Pharmaceuticals USA, Inc.",IMIQUIMOD,37.5,mg/g,"Increased Cytokine Activity [PE], Increased Cytokine Production [PE], Interferon Inducers [MoA]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-3134,HUMAN PRESCRIPTION DRUG,Camrese,,Levonorgestrel / Ethinyl Estradiol and Ethinyl Estradiol,KIT,,20110728,,NDA AUTHORIZED GENERIC,NDA021840,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3145,HUMAN PRESCRIPTION DRUG,Cephalexin,,Cephalexin,CAPSULE,ORAL,19900930,,ANDA,ANDA062702,"Teva Pharmaceuticals USA, Inc.",CEPHALEXIN,250,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3147,HUMAN PRESCRIPTION DRUG,Cephalexin,,Cephalexin,CAPSULE,ORAL,19900930,,ANDA,ANDA062702,"Teva Pharmaceuticals USA, Inc.",CEPHALEXIN,500,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3160,HUMAN PRESCRIPTION DRUG,Cefdinir,,Cefdinir,CAPSULE,ORAL,20070509,,ANDA,ANDA065368,"Teva Pharmaceuticals USA, Inc.",CEFDINIR,300,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3174,HUMAN PRESCRIPTION DRUG,Albuterol Sulfate,HFA,Albuterol Sulfate,"AEROSOL, METERED",RESPIRATORY (INHALATION),20190116,,NDA AUTHORIZED GENERIC,NDA021457,"Teva Pharmaceuticals USA, Inc.",ALBUTEROL SULFATE,90,ug/1,"Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC]",,N,20251231,J45.9,"[{""icd10_code"":""J45.9"",""description"":""Asthma, unspecified"",""confidence"":0.7,""context"":""asthma rescue""},{""icd10_code"":""J44.1"",""description"":""Chronic obstructive pulmonary disease with acute exacerbation"",""confidence"":0.2,""context"":""COPD exacerbation""},{""icd10_code"":""J44.0"",""description"":""Chronic obstructive pulmonary disease with acute lower respiratory infection"",""confidence"":0.1,""context"":""COPD with infection""}]",0.70
0093-3186,HUMAN PRESCRIPTION DRUG,Penciclovir,,Penciclovir,CREAM,TOPICAL,20221114,,ANDA,ANDA212710,"Teva Pharmaceuticals USA, Inc.",PENCICLOVIR,10,mg/g,"DNA Polymerase Inhibitors [MoA], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-3196,HUMAN PRESCRIPTION DRUG,Cefadroxil,,Cefadroxil,CAPSULE,ORAL,20070131,,ANDA,ANDA065282,"Teva Pharmaceuticals USA, Inc.",CEFADROXIL,500,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3212,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,TABLET,ORAL,19960917,,ANDA,ANDA074569,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,1,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3213,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,TABLET,ORAL,19960918,,ANDA,ANDA074569,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,2,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3219,HUMAN PRESCRIPTION DRUG,Ketoconazole,,Ketoconazole,CREAM,TOPICAL,20190208,,ANDA,ANDA075581,"Teva Pharmaceuticals USA, Inc.",KETOCONAZOLE,20,mg/g,"Azole Antifungal [EPC], Azoles [CS], Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 3A5 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-3223,HUMAN PRESCRIPTION DRUG,Estradiol,,Estradiol,INSERT,VAGINAL,20170724,,ANDA,ANDA206388,"Teva Pharmaceuticals USA, Inc.",ESTRADIOL,10,ug/1,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3234,HUMAN PRESCRIPTION DRUG,Sulfasalazine,,Sulfasalazine,TABLET,ORAL,20221215,,ANDA,ANDA085828,"Teva Pharmaceuticals USA, Inc.",SULFASALAZINE,500,mg/1,"Aminosalicylate [EPC], Aminosalicylic Acids [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3239,HUMAN PRESCRIPTION DRUG,Buprenorphine,,Buprenorphine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20211227,,ANDA,ANDA204937,"Teva Pharmaceuticals USA, Inc.",BUPRENORPHINE,7.5,ug/h,"Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]",CIII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3241,HUMAN PRESCRIPTION DRUG,bisoprolol fumarate and hydrochlorothiazide,,bisoprolol fumarate and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20190807,,NDA AUTHORIZED GENERIC,NDA020186,"Teva Pharmaceuticals USA, Inc.",BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE,2.5; 6.25,mg/1; mg/1,"Adrenergic beta-Antagonists [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS], beta-Adrenergic Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3242,HUMAN PRESCRIPTION DRUG,bisoprolol fumarate and hydrochlorothiazide,,bisoprolol fumarate and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20190807,,NDA AUTHORIZED GENERIC,NDA020186,"Teva Pharmaceuticals USA, Inc.",BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE,5; 6.25,mg/1; mg/1,"Adrenergic beta-Antagonists [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS], beta-Adrenergic Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3243,HUMAN PRESCRIPTION DRUG,bisoprolol fumarate and hydrochlorothiazide,,bisoprolol fumarate and hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20190807,,NDA AUTHORIZED GENERIC,NDA020186,"Teva Pharmaceuticals USA, Inc.",BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE,10; 6.25,mg/1; mg/1,"Adrenergic beta-Antagonists [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS], beta-Adrenergic Blocker [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3301,HUMAN PRESCRIPTION DRUG,Tramadol Hydrochloride,,Tramadol Hydrochloride,"TABLET, FILM COATED",ORAL,20240912,,ANDA,ANDA075977,"Teva Pharmaceuticals USA, Inc.",TRAMADOL HYDROCHLORIDE,50,mg/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CIV,N,20251231,M79.3,"[{""icd10_code"":""M79.3"",""description"":""Panniculitis, unspecified"",""confidence"":0.4,""context"":""moderate pain""},{""icd10_code"":""G89.29"",""description"":""Other chronic pain"",""confidence"":0.3,""context"":""chronic pain""},{""icd10_code"":""M25.50"",""description"":""Pain in unspecified joint"",""confidence"":0.2,""context"":""joint pain""},{""icd10_code"":""G89.18"",""description"":""Other acute pain"",""confidence"":0.1,""context"":""acute pain""}]",0.40
0093-3304,HUMAN PRESCRIPTION DRUG,Reclipsen,28 Day,Desogestrel and Ethinyl Estradiol,KIT,,20170101,,ANDA,ANDA075256,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3420,HUMAN PRESCRIPTION DRUG,Cyclobenzaprine Hydrochloride,,Cyclobenzaprine Hydrochloride,"TABLET, FILM COATED",ORAL,20210720,,ANDA,ANDA071611,"Teva Pharmaceuticals USA, Inc.",CYCLOBENZAPRINE HYDROCHLORIDE,5,mg/1,"Centrally-mediated Muscle Relaxation [PE], Muscle Relaxant [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3421,HUMAN PRESCRIPTION DRUG,Cyclobenzaprine Hydrochloride,,Cyclobenzaprine Hydrochloride,"TABLET, FILM COATED",ORAL,20210720,,ANDA,ANDA071611,"Teva Pharmaceuticals USA, Inc.",CYCLOBENZAPRINE HYDROCHLORIDE,7.5,mg/1,"Centrally-mediated Muscle Relaxation [PE], Muscle Relaxant [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3422,HUMAN PRESCRIPTION DRUG,Cyclobenzaprine Hydrochloride,,Cyclobenzaprine Hydrochloride,"TABLET, FILM COATED",ORAL,20210720,,ANDA,ANDA071611,"Teva Pharmaceuticals USA, Inc.",CYCLOBENZAPRINE HYDROCHLORIDE,10,mg/1,"Centrally-mediated Muscle Relaxation [PE], Muscle Relaxant [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3425,HUMAN PRESCRIPTION DRUG,Lorazepam,,Lorazepam,TABLET,ORAL,20211011,,ANDA,ANDA072926,"Teva Pharmaceuticals USA, Inc.",LORAZEPAM,0.5,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3426,HUMAN PRESCRIPTION DRUG,Lorazepam,,Lorazepam,TABLET,ORAL,20211209,,ANDA,ANDA072927,"Teva Pharmaceuticals USA, Inc.",LORAZEPAM,1,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3427,HUMAN PRESCRIPTION DRUG,Lorazepam,,Lorazepam,TABLET,ORAL,20210720,,ANDA,ANDA072928,"Teva Pharmaceuticals USA, Inc.",LORAZEPAM,2,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3541,HUMAN PRESCRIPTION DRUG,Estradiol,,Estradiol,CREAM,VAGINAL,20180102,,ANDA,ANDA086069,"Teva Pharmaceuticals USA, Inc.",ESTRADIOL,0.1,mg/g,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3542,HUMAN PRESCRIPTION DRUG,Atomoxetine,,Atomoxetine,CAPSULE,ORAL,20170530,,ANDA,ANDA079022,"Teva Pharmaceuticals USA, Inc.",ATOMOXETINE HYDROCHLORIDE,10,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3543,HUMAN PRESCRIPTION DRUG,Atomoxetine,,Atomoxetine,CAPSULE,ORAL,20170530,,ANDA,ANDA079022,"Teva Pharmaceuticals USA, Inc.",ATOMOXETINE HYDROCHLORIDE,18,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3544,HUMAN PRESCRIPTION DRUG,Atomoxetine,,Atomoxetine,CAPSULE,ORAL,20170530,,ANDA,ANDA079022,"Teva Pharmaceuticals USA, Inc.",ATOMOXETINE HYDROCHLORIDE,25,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3545,HUMAN PRESCRIPTION DRUG,Atomoxetine,,Atomoxetine,CAPSULE,ORAL,20170530,,ANDA,ANDA079022,"Teva Pharmaceuticals USA, Inc.",ATOMOXETINE HYDROCHLORIDE,40,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3546,HUMAN PRESCRIPTION DRUG,Atomoxetine,,Atomoxetine,CAPSULE,ORAL,20170530,,ANDA,ANDA079022,"Teva Pharmaceuticals USA, Inc.",ATOMOXETINE HYDROCHLORIDE,60,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3547,HUMAN PRESCRIPTION DRUG,Atomoxetine,,Atomoxetine,CAPSULE,ORAL,20170530,,ANDA,ANDA079022,"Teva Pharmaceuticals USA, Inc.",ATOMOXETINE HYDROCHLORIDE,80,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3548,HUMAN PRESCRIPTION DRUG,Atomoxetine,,Atomoxetine,CAPSULE,ORAL,20170530,,ANDA,ANDA079022,"Teva Pharmaceuticals USA, Inc.",ATOMOXETINE HYDROCHLORIDE,100,mg/1,"Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3560,HUMAN PRESCRIPTION DRUG,"PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID",,"PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID",KIT,,20200831,,ANDA,ANDA090145,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3607,HUMAN PRESCRIPTION DRUG,Fluticasone Propionate and Salmeterol,,Fluticasone Propionate and Salmeterol,"POWDER, METERED",RESPIRATORY (INHALATION),20170428,,NDA AUTHORIZED GENERIC,NDA208799,"Teva Pharmaceuticals USA, Inc.",FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE,55; 14,ug/1; ug/1,"Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3608,HUMAN PRESCRIPTION DRUG,Fluticasone Propionate and Salmeterol,,Fluticasone Propionate and Salmeterol,"POWDER, METERED",RESPIRATORY (INHALATION),20170428,,NDA AUTHORIZED GENERIC,NDA208799,"Teva Pharmaceuticals USA, Inc.",FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE,113; 14,ug/1; ug/1,"Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3609,HUMAN PRESCRIPTION DRUG,Fluticasone Propionate and Salmeterol,,Fluticasone Propionate and Salmeterol,"POWDER, METERED",RESPIRATORY (INHALATION),20170428,,NDA AUTHORIZED GENERIC,NDA208799,"Teva Pharmaceuticals USA, Inc.",FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE,232; 14,ug/1; ug/1,"Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3630,HUMAN PRESCRIPTION DRUG,Acyclovir,,acyclovir,CREAM,TOPICAL,20190829,,NDA AUTHORIZED GENERIC,NDA021478,"Teva Pharmaceuticals USA, Inc.",ACYCLOVIR,50,mg/g,"DNA Polymerase Inhibitors [MoA], Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-3655,HUMAN PRESCRIPTION DRUG,Methylergonovine Maleate,,Methylergonovine Maleate,TABLET,ORAL,20190326,,ANDA,ANDA211455,"Teva Pharmaceuticals USA, Inc.",METHYLERGONOVINE MALEATE,0.2,mg/1,"Ergolines [CS], Ergot Derivative [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3656,HUMAN PRESCRIPTION DRUG,Buprenorphine,,Buprenorphine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20181126,,ANDA,ANDA204937,"Teva Pharmaceuticals USA, Inc.",BUPRENORPHINE,5,ug/h,"Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]",CIII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3657,HUMAN PRESCRIPTION DRUG,Buprenorphine,,Buprenorphine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20181126,,ANDA,ANDA204937,"Teva Pharmaceuticals USA, Inc.",BUPRENORPHINE,10,ug/h,"Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]",CIII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3658,HUMAN PRESCRIPTION DRUG,Buprenorphine,,Buprenorphine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20181126,,ANDA,ANDA204937,"Teva Pharmaceuticals USA, Inc.",BUPRENORPHINE,15,ug/h,"Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]",CIII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3659,HUMAN PRESCRIPTION DRUG,Buprenorphine,,Buprenorphine,"PATCH, EXTENDED RELEASE",TRANSDERMAL,20181126,,ANDA,ANDA204937,"Teva Pharmaceuticals USA, Inc.",BUPRENORPHINE,20,ug/h,"Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]",CIII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-3727,HUMAN PRESCRIPTION DRUG,diclofenac epolamine,,diclofenac epolamine,SYSTEM,TOPICAL,20200501,,NDA AUTHORIZED GENERIC,NDA021234,Teva Pharmaceuticals USA Inc.,DICLOFENAC EPOLAMINE,0.013,g/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Prostaglandin Production [PE], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-3750,HUMAN PRESCRIPTION DRUG,Tobramycin,,Tobramycin,SOLUTION,RESPIRATORY (INHALATION),20200915,,ANDA,ANDA210915,"Teva Pharmaceuticals USA, Inc.",TOBRAMYCIN,300,mg/4mL,"Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4000,HUMAN PRESCRIPTION DRUG,Vestura,,Drospirenone and Ethinyl Estradiol,KIT,,20210302,20260531,ANDA,ANDA078833,"Teva Pharmaceuticals USA, Inc.",,,,,,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4059,HUMAN PRESCRIPTION DRUG,Cefadroxil,,Cefadroxil,TABLET,ORAL,20070131,,ANDA,ANDA062774,"Teva Pharmaceuticals USA, Inc.",CEFADROXIL,1000,mg/1,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4061,HUMAN PRESCRIPTION DRUG,Formoterol fumarate,,Formoterol fumarate,SOLUTION,RESPIRATORY (INHALATION),20210622,,ANDA,ANDA091141,"Teva Pharmaceuticals USA, Inc.",FORMOTEROL FUMARATE,20,ug/2mL,"Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4067,HUMAN PRESCRIPTION DRUG,Prazosin Hydrochloride,,Prazosin Hydrochloride,CAPSULE,ORAL,20070222,,ANDA,ANDA071745,"Teva Pharmaceuticals USA, Inc.",PRAZOSIN HYDROCHLORIDE,1,mg/1,"Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4068,HUMAN PRESCRIPTION DRUG,Prazosin Hydrochloride,,Prazosin Hydrochloride,CAPSULE,ORAL,20070222,,ANDA,ANDA071745,"Teva Pharmaceuticals USA, Inc.",PRAZOSIN HYDROCHLORIDE,2,mg/1,"Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4069,HUMAN PRESCRIPTION DRUG,Prazosin Hydrochloride,,Prazosin Hydrochloride,CAPSULE,ORAL,20070118,,ANDA,ANDA071745,"Teva Pharmaceuticals USA, Inc.",PRAZOSIN HYDROCHLORIDE,5,mg/1,"Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4085,HUMAN PRESCRIPTION DRUG,Tobramycin,,Tobramycin,SOLUTION,RESPIRATORY (INHALATION),20131119,,ANDA,ANDA091589,"Teva Pharmaceuticals USA, Inc.",TOBRAMYCIN,300,mg/5mL,"Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4125,HUMAN PRESCRIPTION DRUG,Penicillin V Potassium,,Penicillin V Potassium,"POWDER, FOR SOLUTION",ORAL,19900930,,ANDA,ANDA060456,"Teva Pharmaceuticals USA, Inc.",PENICILLIN V POTASSIUM,125,mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4127,HUMAN PRESCRIPTION DRUG,Penicillin V Potassium,,Penicillin V Potassium,"POWDER, FOR SOLUTION",ORAL,19900930,,ANDA,ANDA060456,"Teva Pharmaceuticals USA, Inc.",PENICILLIN V POTASSIUM,250,mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4136,HUMAN PRESCRIPTION DRUG,Cefdinir,,Cefdinir,"POWDER, FOR SUSPENSION",ORAL,20070508,,ANDA,ANDA065332,"Teva Pharmaceuticals USA, Inc.",CEFDINIR MONOHYDRATE,125,mg/5mL,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4137,HUMAN PRESCRIPTION DRUG,Cefdinir,,Cefdinir,"POWDER, FOR SUSPENSION",ORAL,20070508,,ANDA,ANDA065332,"Teva Pharmaceuticals USA, Inc.",CEFDINIR MONOHYDRATE,250,mg/5mL,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4145,HUMAN PRESCRIPTION DRUG,Levalbuterol,,Levalbuterol,SOLUTION,RESPIRATORY (INHALATION),20130429,,ANDA,ANDA090297,"Teva Pharmaceuticals USA, Inc.",LEVALBUTEROL HYDROCHLORIDE,0.31,mg/3mL,"Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC]",,N,20251231,J45.9,"[{""icd10_code"":""J45.9"",""description"":""Asthma, unspecified"",""confidence"":0.7,""context"":""asthma rescue""},{""icd10_code"":""J44.1"",""description"":""Chronic obstructive pulmonary disease with acute exacerbation"",""confidence"":0.2,""context"":""COPD exacerbation""},{""icd10_code"":""J44.0"",""description"":""Chronic obstructive pulmonary disease with acute lower respiratory infection"",""confidence"":0.1,""context"":""COPD with infection""}]",0.70
0093-4146,HUMAN PRESCRIPTION DRUG,Levalbuterol,,Levalbuterol,SOLUTION,RESPIRATORY (INHALATION),20130429,,ANDA,ANDA090297,"Teva Pharmaceuticals USA, Inc.",LEVALBUTEROL HYDROCHLORIDE,0.63,mg/3mL,"Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC]",,N,20251231,J45.9,"[{""icd10_code"":""J45.9"",""description"":""Asthma, unspecified"",""confidence"":0.7,""context"":""asthma rescue""},{""icd10_code"":""J44.1"",""description"":""Chronic obstructive pulmonary disease with acute exacerbation"",""confidence"":0.2,""context"":""COPD exacerbation""},{""icd10_code"":""J44.0"",""description"":""Chronic obstructive pulmonary disease with acute lower respiratory infection"",""confidence"":0.1,""context"":""COPD with infection""}]",0.70
0093-4148,HUMAN PRESCRIPTION DRUG,Levalbuterol,,Levalbuterol,SOLUTION,RESPIRATORY (INHALATION),20130429,,ANDA,ANDA090297,"Teva Pharmaceuticals USA, Inc.",LEVALBUTEROL HYDROCHLORIDE,1.25,mg/3mL,"Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC]",,N,20251231,J45.9,"[{""icd10_code"":""J45.9"",""description"":""Asthma, unspecified"",""confidence"":0.7,""context"":""asthma rescue""},{""icd10_code"":""J44.1"",""description"":""Chronic obstructive pulmonary disease with acute exacerbation"",""confidence"":0.2,""context"":""COPD exacerbation""},{""icd10_code"":""J44.0"",""description"":""Chronic obstructive pulmonary disease with acute lower respiratory infection"",""confidence"":0.1,""context"":""COPD with infection""}]",0.70
0093-4155,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,"POWDER, FOR SUSPENSION",ORAL,19900930,,ANDA,ANDA061931,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,250,mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4160,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,"POWDER, FOR SUSPENSION",ORAL,20030402,,ANDA,ANDA065119,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,200,mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4161,HUMAN PRESCRIPTION DRUG,Amoxicillin,,Amoxicillin,"POWDER, FOR SUSPENSION",ORAL,20030226,,ANDA,ANDA065119,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,400,mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4175,HUMAN PRESCRIPTION DRUG,Cephalexin,,Cephalexin,"POWDER, FOR SUSPENSION",ORAL,19900930,,ANDA,ANDA062703,"Teva Pharmaceuticals USA, Inc.",CEPHALEXIN,125,mg/5mL,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-4177,HUMAN PRESCRIPTION DRUG,Cephalexin,,Cephalexin,"POWDER, FOR SUSPENSION",ORAL,19900930,,ANDA,ANDA062703,"Teva Pharmaceuticals USA, Inc.",CEPHALEXIN,250,mg/5mL,"Cephalosporin Antibacterial [EPC], Cephalosporins [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5002,HUMAN PRESCRIPTION DRUG,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide",,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide","TABLET, FILM COATED",ORAL,20161114,,ANDA,ANDA202491,"Teva Pharmaceuticals USA, Inc.",AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL,10; 25; 40,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5003,HUMAN PRESCRIPTION DRUG,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide",,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide","TABLET, FILM COATED",ORAL,20161114,,ANDA,ANDA202491,"Teva Pharmaceuticals USA, Inc.",AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL,10; 12.5; 40,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5004,HUMAN PRESCRIPTION DRUG,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide",,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide","TABLET, FILM COATED",ORAL,20161114,,ANDA,ANDA202491,"Teva Pharmaceuticals USA, Inc.",AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL,5; 25; 40,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5005,HUMAN PRESCRIPTION DRUG,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide",,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide","TABLET, FILM COATED",ORAL,20161114,,ANDA,ANDA202491,"Teva Pharmaceuticals USA, Inc.",AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL,5; 12.5; 20,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5006,HUMAN PRESCRIPTION DRUG,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide",,"Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide","TABLET, FILM COATED",ORAL,20161114,,ANDA,ANDA202491,"Teva Pharmaceuticals USA, Inc.",AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL,5; 12.5; 40,mg/1; mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5030,HUMAN PRESCRIPTION DRUG,Tiagabine Hydrochloride,,Tiagabine Hydrochloride,"TABLET, FILM COATED",ORAL,20160603,,NDA AUTHORIZED GENERIC,NDA020646,"Teva Pharmaceuticals USA, Inc.",TIAGABINE HYDROCHLORIDE,2,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5031,HUMAN PRESCRIPTION DRUG,Tiagabine Hydrochloride,,Tiagabine Hydrochloride,"TABLET, FILM COATED",ORAL,20160603,,NDA AUTHORIZED GENERIC,NDA020646,"Teva Pharmaceuticals USA, Inc.",TIAGABINE HYDROCHLORIDE,4,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5045,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20170705,,ANDA,ANDA202731,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,25,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5046,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20170705,,ANDA,ANDA202731,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,35,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5056,HUMAN PRESCRIPTION DRUG,Atorvastatin Calcium,,Atorvastatin Calcium,"TABLET, FILM COATED",ORAL,20170504,,ANDA,ANDA205300,"Teva Pharmaceuticals USA, Inc.",ATORVASTATIN CALCIUM TRIHYDRATE,10,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-5057,HUMAN PRESCRIPTION DRUG,Atorvastatin Calcium,,Atorvastatin Calcium,"TABLET, FILM COATED",ORAL,20170504,,ANDA,ANDA205300,"Teva Pharmaceuticals USA, Inc.",ATORVASTATIN CALCIUM TRIHYDRATE,80,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-5058,HUMAN PRESCRIPTION DRUG,Atorvastatin Calcium,,Atorvastatin Calcium,"TABLET, FILM COATED",ORAL,20170504,,ANDA,ANDA205300,"Teva Pharmaceuticals USA, Inc.",ATORVASTATIN CALCIUM TRIHYDRATE,40,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-5059,HUMAN PRESCRIPTION DRUG,Atorvastatin Calcium,,Atorvastatin Calcium,"TABLET, FILM COATED",ORAL,20170504,,ANDA,ANDA205300,"Teva Pharmaceuticals USA, Inc.",ATORVASTATIN CALCIUM TRIHYDRATE,20,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-5060,HUMAN PRESCRIPTION DRUG,Hydroxyzine Hydrochloride,,Hydroxyzine Hydrochloride,"TABLET, FILM COATED",ORAL,20130219,,ANDA,ANDA088617,"Teva Pharmaceuticals USA, Inc.",HYDROXYZINE DIHYDROCHLORIDE,10,mg/1,"Antihistamine [EPC], Histamine Receptor Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5061,HUMAN PRESCRIPTION DRUG,Hydroxyzine Hydrochloride,,Hydroxyzine Hydrochloride,"TABLET, FILM COATED",ORAL,20121009,,ANDA,ANDA088618,"Teva Pharmaceuticals USA, Inc.",HYDROXYZINE DIHYDROCHLORIDE,25,mg/1,"Antihistamine [EPC], Histamine Receptor Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5062,HUMAN PRESCRIPTION DRUG,Hydroxyzine Hydrochloride,,Hydroxyzine Hydrochloride,"TABLET, FILM COATED",ORAL,20121022,,ANDA,ANDA088619,"Teva Pharmaceuticals USA, Inc.",HYDROXYZINE DIHYDROCHLORIDE,50,mg/1,"Antihistamine [EPC], Histamine Receptor Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5150,HUMAN PRESCRIPTION DRUG,Moexipril Hydrochloride,,Moexipril Hydrochloride,"TABLET, FILM COATED",ORAL,20030508,,ANDA,ANDA076204,"Teva Pharmaceuticals USA, Inc.",MOEXIPRIL HYDROCHLORIDE,15,mg/1,"Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5200,HUMAN PRESCRIPTION DRUG,Buspirone Hydrochloride,,Buspirone Hydrochloride,TABLET,ORAL,20040326,,ANDA,ANDA075022,"Teva Pharmaceuticals USA, Inc.",BUSPIRONE HYDROCHLORIDE,30,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5234,HUMAN PRESCRIPTION DRUG,"Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate",,"Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate","TABLET, FILM COATED",ORAL,20201001,,ANDA,ANDA091215,"Teva Pharmaceuticals USA, Inc.",EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE,600; 200; 300,mg/1; mg/1; mg/1,"Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleosides [CS], Nucleosides [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5245,HUMAN PRESCRIPTION DRUG,Olanzapine,,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20120217,,ANDA,ANDA077243,"Teva Pharmaceuticals USA, Inc.",OLANZAPINE,5,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5246,HUMAN PRESCRIPTION DRUG,Olanzapine,,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20120217,,ANDA,ANDA077243,"Teva Pharmaceuticals USA, Inc.",OLANZAPINE,10,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5247,HUMAN PRESCRIPTION DRUG,Olanzapine,,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20120124,,ANDA,ANDA077243,"Teva Pharmaceuticals USA, Inc.",OLANZAPINE,15,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5248,HUMAN PRESCRIPTION DRUG,Olanzapine,,Olanzapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20120124,,ANDA,ANDA077243,"Teva Pharmaceuticals USA, Inc.",OLANZAPINE,20,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5260,HUMAN PRESCRIPTION DRUG,Almotriptan Malate,,Almotriptan Malate,"TABLET, FILM COATED",ORAL,20150707,,ANDA,ANDA078027,"Teva Pharmaceuticals USA, Inc.",ALMOTRIPTAN MALATE,6.25,mg/1,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5261,HUMAN PRESCRIPTION DRUG,Almotriptan Malate,,Almotriptan Malate,"TABLET, FILM COATED",ORAL,20150707,,ANDA,ANDA078027,"Teva Pharmaceuticals USA, Inc.",ALMOTRIPTAN MALATE,12.5,mg/1,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5328,HUMAN PRESCRIPTION DRUG,Junel Fe,24,Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate,KIT,,20150608,,ANDA,ANDA090938,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5341,HUMAN PRESCRIPTION DRUG,Sildenafil,,Sildenafil,"TABLET, FILM COATED",ORAL,20171211,,ANDA,ANDA077342,"Teva Pharmaceuticals USA, Inc.",SILDENAFIL CITRATE,25,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5342,HUMAN PRESCRIPTION DRUG,Sildenafil,,Sildenafil,"TABLET, FILM COATED",ORAL,20171211,,ANDA,ANDA077342,"Teva Pharmaceuticals USA, Inc.",SILDENAFIL CITRATE,50,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5343,HUMAN PRESCRIPTION DRUG,Sildenafil,,Sildenafil,"TABLET, FILM COATED",ORAL,20171211,,ANDA,ANDA077342,"Teva Pharmaceuticals USA, Inc.",SILDENAFIL CITRATE,100,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5346,HUMAN PRESCRIPTION DRUG,Methylphenidate Hydrochloride,(LA),Methylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20120716,,ANDA,ANDA079031,"Teva Pharmaceuticals USA, Inc.",METHYLPHENIDATE HYDROCHLORIDE,20,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5347,HUMAN PRESCRIPTION DRUG,Methylphenidate Hydrochloride,(LA),Methylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20120716,,ANDA,ANDA079031,"Teva Pharmaceuticals USA, Inc.",METHYLPHENIDATE HYDROCHLORIDE,30,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5348,HUMAN PRESCRIPTION DRUG,Methylphenidate Hydrochloride,(LA),Methylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20120716,,ANDA,ANDA079031,"Teva Pharmaceuticals USA, Inc.",METHYLPHENIDATE HYDROCHLORIDE,40,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5376,HUMAN PRESCRIPTION DRUG,Clozapine,,Clozapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20200730,,ANDA,ANDA090308,"Teva Pharmaceuticals USA, Inc.",CLOZAPINE,150,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5377,HUMAN PRESCRIPTION DRUG,Clozapine,,Clozapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20200730,,ANDA,ANDA090308,"Teva Pharmaceuticals USA, Inc.",CLOZAPINE,200,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5416,HUMAN PRESCRIPTION DRUG,Clozapine,,Clozapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20180417,,ANDA,ANDA090308,"Teva Pharmaceuticals USA, Inc.",CLOZAPINE,12.5,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5417,HUMAN PRESCRIPTION DRUG,Clozapine,,Clozapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20170725,,ANDA,ANDA090308,"Teva Pharmaceuticals USA, Inc.",CLOZAPINE,25,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5419,HUMAN PRESCRIPTION DRUG,Clozapine,,Clozapine,"TABLET, ORALLY DISINTEGRATING",ORAL,20170725,,ANDA,ANDA090308,"Teva Pharmaceuticals USA, Inc.",CLOZAPINE,100,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5420,HUMAN PRESCRIPTION DRUG,Cabergoline,,Cabergoline,TABLET,ORAL,20070307,,ANDA,ANDA077750,"Teva Pharmaceuticals USA, Inc.",CABERGOLINE,0.5,mg/1,"Ergolines [CS], Ergot Derivative [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5455,HUMAN PRESCRIPTION DRUG,Mimvey,,Estradiol and Norethindrone Acetate,"TABLET, FILM COATED",ORAL,20100602,,ANDA,ANDA079193,"Teva Pharmaceuticals USA, Inc.",ESTRADIOL; NORETHINDRONE ACETATE,1; .5,mg/1; mg/1,"Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC], Progesterone Congeners [CS], Progestin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5503,HUMAN PRESCRIPTION DRUG,Olanzapine and Fluoxetine,,Olanzapine and Fluoxetine,CAPSULE,ORAL,20130410,,ANDA,ANDA202074,"Teva Pharmaceuticals USA, Inc.",FLUOXETINE HYDROCHLORIDE; OLANZAPINE,25; 3,mg/1; mg/1,"Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5504,HUMAN PRESCRIPTION DRUG,Olanzapine and Fluoxetine,,Olanzapine and Fluoxetine,CAPSULE,ORAL,20120619,,ANDA,ANDA077528,"Teva Pharmaceuticals USA, Inc.",FLUOXETINE HYDROCHLORIDE; OLANZAPINE,25; 6,mg/1; mg/1,"Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5505,HUMAN PRESCRIPTION DRUG,Olanzapine and Fluoxetine,,Olanzapine and Fluoxetine,CAPSULE,ORAL,20120619,,ANDA,ANDA077528,"Teva Pharmaceuticals USA, Inc.",FLUOXETINE HYDROCHLORIDE; OLANZAPINE,50; 6,mg/1; mg/1,"Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5506,HUMAN PRESCRIPTION DRUG,Olanzapine and Fluoxetine,,Olanzapine and Fluoxetine,CAPSULE,ORAL,20120619,,ANDA,ANDA077528,"Teva Pharmaceuticals USA, Inc.",FLUOXETINE HYDROCHLORIDE; OLANZAPINE,25; 12,mg/1; mg/1,"Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5507,HUMAN PRESCRIPTION DRUG,Olanzapine and Fluoxetine,,Olanzapine and Fluoxetine,CAPSULE,ORAL,20120619,,ANDA,ANDA077528,"Teva Pharmaceuticals USA, Inc.",FLUOXETINE HYDROCHLORIDE; OLANZAPINE,50; 12,mg/1; mg/1,"Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5517,HUMAN PRESCRIPTION DRUG,Sildenafil,,Sildenafil,"TABLET, FILM COATED",ORAL,20130531,,ANDA,ANDA078380,"Teva Pharmaceuticals USA, Inc.",SILDENAFIL CITRATE,20,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5526,HUMAN PRESCRIPTION DRUG,Atazanavir Sulfate,,Atazanavir Sulfate,CAPSULE,ORAL,20171227,,ANDA,ANDA091673,"Teva Pharmaceuticals USA, Inc.",ATAZANAVIR SULFATE,150,mg/1,"Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5527,HUMAN PRESCRIPTION DRUG,Atazanavir Sulfate,,Atazanavir Sulfate,CAPSULE,ORAL,20171227,,ANDA,ANDA091673,"Teva Pharmaceuticals USA, Inc.",ATAZANAVIR SULFATE,200,mg/1,"Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5528,HUMAN PRESCRIPTION DRUG,Atazanavir Sulfate,,Atazanavir Sulfate,CAPSULE,ORAL,20171227,,ANDA,ANDA091673,"Teva Pharmaceuticals USA, Inc.",ATAZANAVIR SULFATE,300,mg/1,"Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5537,HUMAN PRESCRIPTION DRUG,Eszopiclone,,Eszopiclone,"TABLET, FILM COATED",ORAL,20140414,,ANDA,ANDA091169,"Teva Pharmaceuticals USA, Inc.",ESZOPICLONE,1,mg/1,,CIV,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5538,HUMAN PRESCRIPTION DRUG,Eszopiclone,,Eszopiclone,"TABLET, FILM COATED",ORAL,20140414,,ANDA,ANDA091169,"Teva Pharmaceuticals USA, Inc.",ESZOPICLONE,2,mg/1,,CIV,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5539,HUMAN PRESCRIPTION DRUG,Eszopiclone,,Eszopiclone,"TABLET, FILM COATED",ORAL,20140414,,ANDA,ANDA091169,"Teva Pharmaceuticals USA, Inc.",ESZOPICLONE,3,mg/1,,CIV,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5550,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20141110,,ANDA,ANDA078908,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,5,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5551,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20150202,,ANDA,ANDA078908,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,10,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5552,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20140521,,ANDA,ANDA078908,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,15,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5553,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20150622,,ANDA,ANDA078908,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,20,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5554,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20140522,,ANDA,ANDA202731,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,30,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5562,HUMAN PRESCRIPTION DRUG,Dexmethylphenidate Hydrochloride,,Dexmethylphenidate Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20131121,,ANDA,ANDA202731,"Teva Pharmaceuticals USA, Inc.",DEXMETHYLPHENIDATE HYDROCHLORIDE,40,mg/1,"Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE]",CII,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5571,HUMAN PRESCRIPTION DRUG,Erythromycin,,Erythromycin,"TABLET, FILM COATED",ORAL,20210504,,ANDA,ANDA214549,"Teva Pharmaceuticals USA, Inc.",ERYTHROMYCIN,250,mg/1,"Decreased Sebaceous Gland Activity [PE], Macrolide Antimicrobial [EPC], Macrolide [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5572,HUMAN PRESCRIPTION DRUG,Erythromycin,,Erythromycin,"TABLET, FILM COATED",ORAL,20210504,,ANDA,ANDA214549,"Teva Pharmaceuticals USA, Inc.",ERYTHROMYCIN,500,mg/1,"Decreased Sebaceous Gland Activity [PE], Macrolide Antimicrobial [EPC], Macrolide [EPC], Macrolides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5907,HUMAN PRESCRIPTION DRUG,Mesalamine,,Mesalamine,"CAPSULE, DELAYED RELEASE",ORAL,20190509,,ANDA,ANDA207873,"Teva Pharmaceuticals USA, Inc.",MESALAMINE,400,mg/1,"Aminosalicylate [EPC], Aminosalicylic Acids [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5938,HUMAN PRESCRIPTION DRUG,Lanthanum carbonate,,Lanthanum carbonate,"TABLET, CHEWABLE",ORAL,20220525,,ANDA,ANDA090977,"Teva Pharmaceuticals USA, Inc.",LANTHANUM CARBONATE,500,mg/1,"Phosphate Binder [EPC], Phosphate Chelating Activity [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5939,HUMAN PRESCRIPTION DRUG,Lanthanum carbonate,,Lanthanum carbonate,"TABLET, CHEWABLE",ORAL,20220525,,ANDA,ANDA090977,"Teva Pharmaceuticals USA, Inc.",LANTHANUM CARBONATE,750,mg/1,"Phosphate Binder [EPC], Phosphate Chelating Activity [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5940,HUMAN PRESCRIPTION DRUG,Lanthanum carbonate,,Lanthanum carbonate,"TABLET, CHEWABLE",ORAL,20220525,,ANDA,ANDA090977,"Teva Pharmaceuticals USA, Inc.",LANTHANUM CARBONATE,1000,mg/1,"Phosphate Binder [EPC], Phosphate Chelating Activity [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5955,HUMAN PRESCRIPTION DRUG,Arformoterol tartrate,,Arformoterol tartrate,SOLUTION,RESPIRATORY (INHALATION),20211206,,ANDA,ANDA200293,"Teva Pharmaceuticals USA, Inc.",ARFORMOTEROL TARTRATE,15,ug/2mL,"Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5985,HUMAN PRESCRIPTION DRUG,Epinephrine,,Epinephrine,INJECTION,INTRAMUSCULAR; SUBCUTANEOUS,20190819,,ANDA,ANDA090589,"Teva Pharmaceuticals USA, Inc.",EPINEPHRINE,0.15,mg/.3mL,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Catecholamine [EPC], Catecholamines [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-5986,HUMAN PRESCRIPTION DRUG,Epinephrine,,Epinephrine,INJECTION,INTRAMUSCULAR; SUBCUTANEOUS,20181127,,ANDA,ANDA090589,"Teva Pharmaceuticals USA, Inc.",EPINEPHRINE,0.3,mg/.3mL,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Catecholamine [EPC], Catecholamines [CS], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-6031,HUMAN PRESCRIPTION DRUG,Rivelsa,,Levonorgestrel/Ethinyl Estradiol and Ethinyl Estradiol,KIT,,20170403,,NDA AUTHORIZED GENERIC,NDA204061,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-6148,HUMAN PRESCRIPTION DRUG,camrese Lo,,Levonorgestrel/Ethinyl Estradiol and Ethinyl Estradiol,KIT,,20111207,,NDA AUTHORIZED GENERIC,NDA022262,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-6815,HUMAN PRESCRIPTION DRUG,Budesonide,,Budesonide,SUSPENSION,RESPIRATORY (INHALATION),20190111,,ANDA,ANDA077519,"Teva Pharmaceuticals USA, Inc.",BUDESONIDE,0.25,mg/2mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-6815,HUMAN PRESCRIPTION DRUG,Budesonide,,Budesonide,SUSPENSION,RESPIRATORY (INHALATION),20081119,,ANDA,ANDA077519,"Teva Pharmaceuticals USA, Inc.",BUDESONIDE,0.25,mg/2mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-6816,HUMAN PRESCRIPTION DRUG,Budesonide,,Budesonide,SUSPENSION,RESPIRATORY (INHALATION),20190111,,ANDA,ANDA077519,"Teva Pharmaceuticals USA, Inc.",BUDESONIDE,0.5,mg/2mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-6816,HUMAN PRESCRIPTION DRUG,Budesonide,,Budesonide,SUSPENSION,RESPIRATORY (INHALATION),20081119,,ANDA,ANDA077519,"Teva Pharmaceuticals USA, Inc.",BUDESONIDE,0.5,mg/2mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-6817,HUMAN PRESCRIPTION DRUG,Budesonide,,Budesonide,SUSPENSION,RESPIRATORY (INHALATION),20160311,,ANDA,ANDA204548,"Teva Pharmaceuticals USA, Inc.",BUDESONIDE,1,mg/2mL,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7113,HUMAN PRESCRIPTION DRUG,Nefazodone Hydrochloride,,Nefazodone Hydrochloride,TABLET,ORAL,20030916,,ANDA,ANDA076037,"Teva Pharmaceuticals USA, Inc.",NEFAZODONE HYDROCHLORIDE,150,mg/1,Serotonin Reuptake Inhibitor [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7163,HUMAN PRESCRIPTION DRUG,Tolterodine Tartrate,,Tolterodine Tartrate,"CAPSULE, EXTENDED RELEASE",ORAL,20170320,,ANDA,ANDA079141,"Teva Pharmaceuticals USA, Inc.",TOLTERODINE TARTRATE,2,mg/1,"Cholinergic Muscarinic Antagonist [EPC], Cholinergic Muscarinic Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7164,HUMAN PRESCRIPTION DRUG,Tolterodine Tartrate,,Tolterodine Tartrate,"CAPSULE, EXTENDED RELEASE",ORAL,20170320,,ANDA,ANDA079141,"Teva Pharmaceuticals USA, Inc.",TOLTERODINE TARTRATE,4,mg/1,"Cholinergic Muscarinic Antagonist [EPC], Cholinergic Muscarinic Antagonists [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7172,HUMAN PRESCRIPTION DRUG,Etodolac,,Etodolac,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20000811,,ANDA,ANDA075665,"Teva Pharmaceuticals USA, Inc.",ETODOLAC,500,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7178,HUMAN PRESCRIPTION DRUG,Nefazodone Hydrochloride,,Nefazodone Hydrochloride,TABLET,ORAL,20030916,,ANDA,ANDA076037,"Teva Pharmaceuticals USA, Inc.",NEFAZODONE HYDROCHLORIDE,50,mg/1,Serotonin Reuptake Inhibitor [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7198,HUMAN PRESCRIPTION DRUG,Fluoxetine,,Fluoxetine,CAPSULE,ORAL,20020130,,ANDA,ANDA075452,"Teva Pharmaceuticals USA, Inc.",FLUOXETINE HYDROCHLORIDE,40,mg/1,"Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7201,HUMAN PRESCRIPTION DRUG,Pravastatin Sodium,,Pravastatin Sodium,TABLET,ORAL,20060425,20261231,ANDA,ANDA076056,"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,20,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-7202,HUMAN PRESCRIPTION DRUG,Pravastatin Sodium,,Pravastatin Sodium,TABLET,ORAL,20060425,20260930,ANDA,ANDA076056,"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,40,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-7271,HUMAN PRESCRIPTION DRUG,Pioglitazone,,Pioglitazone,TABLET,ORAL,20150204,,ANDA,ANDA077210,"Teva Pharmaceuticals USA, Inc.",PIOGLITAZONE HYDROCHLORIDE,15,mg/1,"Peroxisome Proliferator Receptor alpha Agonist [EPC], Peroxisome Proliferator Receptor gamma Agonist [EPC], Peroxisome Proliferator-activated Receptor alpha Agonists [MoA], Peroxisome Proliferator-activated Receptor gamma Agonists [MoA], Thiazolidinedione [EPC], Thiazolidinediones [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7272,HUMAN PRESCRIPTION DRUG,Pioglitazone,,Pioglitazone,TABLET,ORAL,20150204,,ANDA,ANDA077210,"Teva Pharmaceuticals USA, Inc.",PIOGLITAZONE HYDROCHLORIDE,30,mg/1,"Peroxisome Proliferator Receptor alpha Agonist [EPC], Peroxisome Proliferator Receptor gamma Agonist [EPC], Peroxisome Proliferator-activated Receptor alpha Agonists [MoA], Peroxisome Proliferator-activated Receptor gamma Agonists [MoA], Thiazolidinedione [EPC], Thiazolidinediones [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7273,HUMAN PRESCRIPTION DRUG,Pioglitazone,,Pioglitazone,TABLET,ORAL,20150522,,ANDA,ANDA077210,"Teva Pharmaceuticals USA, Inc.",PIOGLITAZONE HYDROCHLORIDE,45,mg/1,"Peroxisome Proliferator Receptor alpha Agonist [EPC], Peroxisome Proliferator Receptor gamma Agonist [EPC], Peroxisome Proliferator-activated Receptor alpha Agonists [MoA], Peroxisome Proliferator-activated Receptor gamma Agonists [MoA], Thiazolidinedione [EPC], Thiazolidinediones [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7290,HUMAN PRESCRIPTION DRUG,Raloxifene Hydrochloride,,Raloxifene Hydrochloride,"TABLET, FILM COATED",ORAL,20140328,,ANDA,ANDA078193,"Teva Pharmaceuticals USA, Inc.",RALOXIFENE HYDROCHLORIDE,60,mg/1,"Estrogen Agonist/Antagonist [EPC], Selective Estrogen Receptor Modulators [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7295,HUMAN PRESCRIPTION DRUG,Carvedilol,,Carvedilol,"TABLET, FILM COATED",ORAL,20070906,,ANDA,ANDA076373,"Teva Pharmaceuticals USA, Inc.",CARVEDILOL,12.5,mg/1,"Adrenergic alpha-Antagonists [MoA], Adrenergic beta1-Antagonists [MoA], Adrenergic beta2-Antagonists [MoA], alpha-Adrenergic Blocker [EPC], beta-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7296,HUMAN PRESCRIPTION DRUG,Carvedilol,,Carvedilol,"TABLET, FILM COATED",ORAL,20070906,,ANDA,ANDA076373,"Teva Pharmaceuticals USA, Inc.",CARVEDILOL,25,mg/1,"Adrenergic alpha-Antagonists [MoA], Adrenergic beta1-Antagonists [MoA], Adrenergic beta2-Antagonists [MoA], alpha-Adrenergic Blocker [EPC], beta-Adrenergic Blocker [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7314,HUMAN PRESCRIPTION DRUG,Clopidogrel,,Clopidogrel,"TABLET, FILM COATED",ORAL,20120517,,ANDA,ANDA076999,"Teva Pharmaceuticals USA, Inc.",CLOPIDOGREL BISULFATE,75,mg/1,"Cytochrome P450 2C8 Inhibitors [MoA], Decreased Platelet Aggregation [PE], P2Y12 Platelet Inhibitor [EPC], P2Y12 Receptor Antagonists [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7334,HUMAN PRESCRIPTION DRUG,Mycophenolate Mofetil,,Mycophenolate Mofetil,CAPSULE,ORAL,20090506,,ANDA,ANDA065491,"Teva Pharmaceuticals USA, Inc.",MYCOPHENOLATE MOFETIL,250,mg/1,Antimetabolite Immunosuppressant [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7350,HUMAN PRESCRIPTION DRUG,Lansoprazole,,Lansoprazole,"CAPSULE, DELAYED RELEASE",ORAL,20091111,,ANDA,ANDA077255,"Teva Pharmaceuticals USA, Inc.",LANSOPRAZOLE,15,mg/1,"Inhibition Gastric Acid Secretion [PE], Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7351,HUMAN PRESCRIPTION DRUG,Lansoprazole,,Lansoprazole,"CAPSULE, DELAYED RELEASE",ORAL,20091111,,ANDA,ANDA077255,"Teva Pharmaceuticals USA, Inc.",LANSOPRAZOLE,30,mg/1,"Inhibition Gastric Acid Secretion [PE], Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7352,HUMAN PRESCRIPTION DRUG,Calcitriol,,Calcitriol,"CAPSULE, LIQUID FILLED",ORAL,20160825,,ANDA,ANDA075765,"Teva Pharmaceuticals USA, Inc.",CALCITRIOL,0.25,ug/1,"Cholecalciferol [CS], Vitamin D3 Analog [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7353,HUMAN PRESCRIPTION DRUG,Calcitriol,,Calcitriol,"CAPSULE, LIQUID FILLED",ORAL,20160701,,ANDA,ANDA075765,"Teva Pharmaceuticals USA, Inc.",CALCITRIOL,0.5,ug/1,"Cholecalciferol [CS], Vitamin D3 Analog [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7355,HUMAN PRESCRIPTION DRUG,Finasteride,,Finasteride,"TABLET, FILM COATED",ORAL,20061215,,ANDA,ANDA076511,"Teva Pharmaceuticals USA, Inc.",FINASTERIDE,5,mg/1,"5-alpha Reductase Inhibitor [EPC], 5-alpha Reductase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7367,HUMAN PRESCRIPTION DRUG,Losartan Potassium and Hydrochlorothiazide,,Losartan Potassium and Hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20100406,,ANDA,ANDA077157,"Teva Pharmaceuticals USA, Inc.",HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM,12.5; 50,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7368,HUMAN PRESCRIPTION DRUG,Losartan Potassium and Hydrochlorothiazide,,Losartan Potassium and Hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20100406,,ANDA,ANDA077157,"Teva Pharmaceuticals USA, Inc.",HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM,25; 100,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7369,HUMAN PRESCRIPTION DRUG,Losartan Potassium and Hydrochlorothiazide,,Losartan Potassium and Hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20100406,,ANDA,ANDA077157,"Teva Pharmaceuticals USA, Inc.",HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM,12.5; 100,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7384,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20100701,,ANDA,ANDA076565,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,37.5,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7385,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20100701,,ANDA,ANDA076565,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,75,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7386,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,"CAPSULE, EXTENDED RELEASE",ORAL,20100701,,ANDA,ANDA076565,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,150,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7442,HUMAN PRESCRIPTION DRUG,Fluvastatin,,Fluvastatin,CAPSULE,ORAL,20120705,,ANDA,ANDA078407,"Teva Pharmaceuticals USA, Inc.",FLUVASTATIN SODIUM,20,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-7443,HUMAN PRESCRIPTION DRUG,Fluvastatin,,Fluvastatin,CAPSULE,ORAL,20120705,,ANDA,ANDA078407,"Teva Pharmaceuticals USA, Inc.",FLUVASTATIN SODIUM,40,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-7446,HUMAN PRESCRIPTION DRUG,Fluvastatin Sodium,,Fluvastatin Sodium,"TABLET, FILM COATED, EXTENDED RELEASE",ORAL,20160602,,ANDA,ANDA079011,"Teva Pharmaceuticals USA, Inc.",FLUVASTATIN SODIUM,80,mg/1,"HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]",,N,20251231,E78.5,"[{""icd10_code"":""E78.5"",""description"":""Hyperlipidemia, unspecified"",""confidence"":0.6,""context"":""primary hyperlipidemia""},{""icd10_code"":""E78.0"",""description"":""Pure hypercholesterolemia"",""confidence"":0.25,""context"":""high cholesterol""},{""icd10_code"":""Z79.899"",""description"":""Other long term drug therapy"",""confidence"":0.1,""context"":""CVD prevention""},{""icd10_code"":""I25.10"",""description"":""Atherosclerotic heart disease without angina pectoris"",""confidence"":0.05,""context"":""CAD treatment""}]",0.60
0093-7455,HUMAN PRESCRIPTION DRUG,Glipizide and Metformin Hydrochloride,,Glipizide and Metformin Hydrochloride,"TABLET, FILM COATED",ORAL,20051028,,ANDA,ANDA077270,"Teva Pharmaceuticals USA, Inc.",GLIPIZIDE; METFORMIN HYDROCHLORIDE,2.5; 250,mg/1; mg/1,"Biguanide [EPC], Biguanides [CS], Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,E11.9,"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.85,""context"":""first-line T2DM""},{""icd10_code"":""E11.65"",""description"":""Type 2 diabetes with hyperglycemia"",""confidence"":0.1,""context"":""glucose control""},{""icd10_code"":""Z79.84"",""description"":""Long term use of oral hypoglycemic drugs"",""confidence"":0.05,""context"":""maintenance therapy""}]",0.85
0093-7456,HUMAN PRESCRIPTION DRUG,Glipizide and Metformin Hydrochloride,,Glipizide and Metformin Hydrochloride,"TABLET, FILM COATED",ORAL,20051028,,ANDA,ANDA077270,"Teva Pharmaceuticals USA, Inc.",GLIPIZIDE; METFORMIN HYDROCHLORIDE,2.5; 500,mg/1; mg/1,"Biguanide [EPC], Biguanides [CS], Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,E11.9,"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.85,""context"":""first-line T2DM""},{""icd10_code"":""E11.65"",""description"":""Type 2 diabetes with hyperglycemia"",""confidence"":0.1,""context"":""glucose control""},{""icd10_code"":""Z79.84"",""description"":""Long term use of oral hypoglycemic drugs"",""confidence"":0.05,""context"":""maintenance therapy""}]",0.85
0093-7457,HUMAN PRESCRIPTION DRUG,Glipizide and Metformin Hydrochloride,,Glipizide and Metformin Hydrochloride,"TABLET, FILM COATED",ORAL,20051028,,ANDA,ANDA077270,"Teva Pharmaceuticals USA, Inc.",GLIPIZIDE; METFORMIN HYDROCHLORIDE,5; 500,mg/1; mg/1,"Biguanide [EPC], Biguanides [CS], Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,E11.9,"[{""icd10_code"":""E11.9"",""description"":""Type 2 diabetes mellitus without complications"",""confidence"":0.85,""context"":""first-line T2DM""},{""icd10_code"":""E11.65"",""description"":""Type 2 diabetes with hyperglycemia"",""confidence"":0.1,""context"":""glucose control""},{""icd10_code"":""Z79.84"",""description"":""Long term use of oral hypoglycemic drugs"",""confidence"":0.05,""context"":""maintenance therapy""}]",0.85
0093-7471,HUMAN PRESCRIPTION DRUG,Rizatriptan Benzoate,,Rizatriptan Benzoate,TABLET,ORAL,20130212,,ANDA,ANDA077263,"Teva Pharmaceuticals USA, Inc.",RIZATRIPTAN BENZOATE,5,mg/1,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7472,HUMAN PRESCRIPTION DRUG,Rizatriptan Benzoate,,Rizatriptan Benzoate,TABLET,ORAL,20130212,,ANDA,ANDA077263,"Teva Pharmaceuticals USA, Inc.",RIZATRIPTAN BENZOATE,10,mg/1,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7473,HUMAN PRESCRIPTION DRUG,Capecitabine,,Capecitabine,"TABLET, FILM COATED",ORAL,20140307,,ANDA,ANDA091649,"Teva Pharmaceuticals USA, Inc.",CAPECITABINE,150,mg/1,"Nucleic Acid Synthesis Inhibitors [MoA], Nucleoside Metabolic Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7474,HUMAN PRESCRIPTION DRUG,Capecitabine,,Capecitabine,"TABLET, FILM COATED",ORAL,20140307,,ANDA,ANDA091649,"Teva Pharmaceuticals USA, Inc.",CAPECITABINE,500,mg/1,"Nucleic Acid Synthesis Inhibitors [MoA], Nucleoside Metabolic Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7516,HUMAN PRESCRIPTION DRUG,fluticasone propionate and salmeterol,,fluticasone propionate and salmeterol,POWDER,RESPIRATORY (INHALATION),20220323,,ANDA,ANDA213948,"Teva Pharmaceuticals USA, Inc.",FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE,500; 50,ug/1; ug/1,"Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7517,HUMAN PRESCRIPTION DRUG,fluticasone propionate and salmeterol,,fluticasone propionate and salmeterol,POWDER,RESPIRATORY (INHALATION),20220323,,ANDA,ANDA213948,"Teva Pharmaceuticals USA, Inc.",FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE,100; 50,ug/1; ug/1,"Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7518,HUMAN PRESCRIPTION DRUG,fluticasone propionate and salmeterol,,fluticasone propionate and salmeterol,POWDER,RESPIRATORY (INHALATION),20220323,,ANDA,ANDA213948,"Teva Pharmaceuticals USA, Inc.",FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE,250; 50,ug/1; ug/1,"Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7536,HUMAN PRESCRIPTION DRUG,Anastrozole,,Anastrozole,"TABLET, FILM COATED",ORAL,20100628,,ANDA,ANDA078058,"Teva Pharmaceuticals USA, Inc.",ANASTROZOLE,1,mg/1,"Aromatase Inhibitor [EPC], Aromatase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7620,HUMAN PRESCRIPTION DRUG,Letrozole,,Letrozole,"TABLET, FILM COATED",ORAL,20110603,,ANDA,ANDA090289,"Teva Pharmaceuticals USA, Inc.",LETROZOLE,2.5,mg/1,"Aromatase Inhibitor [EPC], Aromatase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7629,HUMAN PRESCRIPTION DRUG,Imatinib Mesylate,,Imatinib Mesylate,"TABLET, FILM COATED",ORAL,20160804,,ANDA,ANDA204285,"Teva Pharmaceuticals USA, Inc.",IMATINIB MESYLATE,100,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7630,HUMAN PRESCRIPTION DRUG,Imatinib Mesylate,,Imatinib Mesylate,"TABLET, FILM COATED",ORAL,20160804,,ANDA,ANDA204285,"Teva Pharmaceuticals USA, Inc.",IMATINIB MESYLATE,400,mg/1,"Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7652,HUMAN PRESCRIPTION DRUG,Vardenafil Hydrochloride,,Vardenafil Hydrochloride,"TABLET, FILM COATED",ORAL,20190103,,ANDA,ANDA091347,"Teva Pharmaceuticals USA, Inc.",VARDENAFIL HYDROCHLORIDE,2.5,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7653,HUMAN PRESCRIPTION DRUG,Vardenafil Hydrochloride,,Vardenafil Hydrochloride,"TABLET, FILM COATED",ORAL,20190103,,ANDA,ANDA091347,"Teva Pharmaceuticals USA, Inc.",VARDENAFIL HYDROCHLORIDE,5,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7654,HUMAN PRESCRIPTION DRUG,Vardenafil Hydrochloride,,Vardenafil Hydrochloride,"TABLET, FILM COATED",ORAL,20190103,,ANDA,ANDA091347,"Teva Pharmaceuticals USA, Inc.",VARDENAFIL HYDROCHLORIDE,10,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7655,HUMAN PRESCRIPTION DRUG,Vardenafil Hydrochloride,,Vardenafil Hydrochloride,"TABLET, FILM COATED",ORAL,20190103,,ANDA,ANDA091347,"Teva Pharmaceuticals USA, Inc.",VARDENAFIL HYDROCHLORIDE,20,mg/1,"Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7662,HUMAN PRESCRIPTION DRUG,Erlotinib,,Erlotinib,"TABLET, FILM COATED",ORAL,20211208,,ANDA,ANDA091059,"Teva Pharmaceuticals USA, Inc.",ERLOTINIB HYDROCHLORIDE,25,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7663,HUMAN PRESCRIPTION DRUG,Erlotinib,,Erlotinib,"TABLET, FILM COATED",ORAL,20190509,,ANDA,ANDA091059,"Teva Pharmaceuticals USA, Inc.",ERLOTINIB HYDROCHLORIDE,100,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7664,HUMAN PRESCRIPTION DRUG,Erlotinib,,Erlotinib,"TABLET, FILM COATED",ORAL,20190509,,ANDA,ANDA091059,"Teva Pharmaceuticals USA, Inc.",ERLOTINIB HYDROCHLORIDE,150,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7679,HUMAN PRESCRIPTION DRUG,Etonogestrel and Ethinyl Estradiol,,Etonogestrel and Ethinyl Estradiol,"INSERT, EXTENDED RELEASE",VAGINAL,20210119,,ANDA,ANDA204305,"Teva Pharmaceuticals USA, Inc.",ETHINYL ESTRADIOL; ETONOGESTREL,.015; .12,mg/d; mg/d,"Estrogen Receptor Agonists [MoA], Estrogen [EPC], Progesterone Congeners [CS], Progestin [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7701,HUMAN PRESCRIPTION DRUG,Levocetirizine Dihydrochloride,,Levocetirizine Dihydrochloride,"TABLET, FILM COATED",ORAL,20110906,,ANDA,ANDA090199,"Teva Pharmaceuticals USA, Inc.",LEVOCETIRIZINE DIHYDROCHLORIDE,5,mg/1,"Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7704,HUMAN PRESCRIPTION DRUG,Emtricitabine and Tenofovir Disoproxil Fumarate,,Emtricitabine and Tenofovir Disoproxil Fumarate,"TABLET, FILM COATED",ORAL,20210120,,ANDA,ANDA090894,"Teva Pharmaceuticals USA, Inc.",EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE,200; 300,mg/1; mg/1,"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleosides [CS], Nucleosides [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7766,HUMAN PRESCRIPTION DRUG,Everolimus,,Everolimus,TABLET,ORAL,20200610,,ANDA,ANDA210050,"Teva Pharmaceuticals USA, Inc.",EVEROLIMUS,2.5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7767,HUMAN PRESCRIPTION DRUG,Everolimus,,Everolimus,TABLET,ORAL,20200610,,ANDA,ANDA210050,"Teva Pharmaceuticals USA, Inc.",EVEROLIMUS,5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7768,HUMAN PRESCRIPTION DRUG,Everolimus,,Everolimus,TABLET,ORAL,20200610,,ANDA,ANDA210050,"Teva Pharmaceuticals USA, Inc.",EVEROLIMUS,7.5,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7769,HUMAN PRESCRIPTION DRUG,Everolimus,,Everolimus,TABLET,ORAL,20231023,,ANDA,ANDA210050,"Teva Pharmaceuticals USA, Inc.",EVEROLIMUS,10,mg/1,"Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7865,HUMAN PRESCRIPTION DRUG,Fentanyl Citrate,,Fentanyl Citrate,LOZENGE,ORAL; TRANSMUCOSAL,20151208,20260531,NDA AUTHORIZED GENERIC,NDA020747,"Teva Pharmaceuticals USA, Inc.",FENTANYL CITRATE,200,ug/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7866,HUMAN PRESCRIPTION DRUG,Fentanyl Citrate,,Fentanyl Citrate,LOZENGE,ORAL; TRANSMUCOSAL,20151208,20260831,NDA AUTHORIZED GENERIC,NDA020747,"Teva Pharmaceuticals USA, Inc.",FENTANYL CITRATE,400,ug/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7867,HUMAN PRESCRIPTION DRUG,Fentanyl Citrate,,Fentanyl Citrate,LOZENGE,ORAL; TRANSMUCOSAL,20151208,20250731,NDA AUTHORIZED GENERIC,NDA020747,"Teva Pharmaceuticals USA, Inc.",FENTANYL CITRATE,600,ug/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7868,HUMAN PRESCRIPTION DRUG,Fentanyl Citrate,,Fentanyl Citrate,LOZENGE,ORAL; TRANSMUCOSAL,20151208,20260831,NDA AUTHORIZED GENERIC,NDA020747,"Teva Pharmaceuticals USA, Inc.",FENTANYL CITRATE,800,ug/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7869,HUMAN PRESCRIPTION DRUG,Fentanyl Citrate,,Fentanyl Citrate,LOZENGE,ORAL; TRANSMUCOSAL,20151208,20251031,NDA AUTHORIZED GENERIC,NDA020747,"Teva Pharmaceuticals USA, Inc.",FENTANYL CITRATE,1200,ug/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7870,HUMAN PRESCRIPTION DRUG,Fentanyl Citrate,,Fentanyl Citrate,LOZENGE,ORAL; TRANSMUCOSAL,20151208,20260531,NDA AUTHORIZED GENERIC,NDA020747,"Teva Pharmaceuticals USA, Inc.",FENTANYL CITRATE,1600,ug/1,"Full Opioid Agonists [MoA], Opioid Agonist [EPC]",CII,N,,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-7909,HUMAN PRESCRIPTION DRUG,Tiopronin,,Tiopronin,"TABLET, SUGAR COATED",ORAL,20210517,,ANDA,ANDA214326,"Teva Pharmaceuticals USA, Inc.",TIOPRONIN,100,mg/1,"Cystine Disulfide Reduction [MoA], N-substituted Glycines [CS], Reducing and Complexing Thiol [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8034,HUMAN PRESCRIPTION DRUG,Glyburide,,Glyburide,TABLET,ORAL,19990511,,ANDA,ANDA074686,"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,1.5,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8035,HUMAN PRESCRIPTION DRUG,Glyburide,,Glyburide,TABLET,ORAL,19990511,,ANDA,ANDA074686,"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,3,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8036,HUMAN PRESCRIPTION DRUG,Glyburide,,Glyburide,TABLET,ORAL,19990512,,ANDA,ANDA074686,"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,6,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8072,HUMAN PRESCRIPTION DRUG,Tiagabine Hydrochloride,,Tiagabine Hydrochloride,"TABLET, FILM COATED",ORAL,20180309,,NDA AUTHORIZED GENERIC,NDA020646,"Teva Pharmaceuticals USA, Inc.",TIAGABINE HYDROCHLORIDE,12,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8073,HUMAN PRESCRIPTION DRUG,Kelnor 1/50,,Ethynodiol Diacetate and Ethinyl Estradiol,KIT,,20180301,,ANDA,ANDA072723,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8076,HUMAN PRESCRIPTION DRUG,Tiagabine Hydrochloride,,Tiagabine Hydrochloride,"TABLET, FILM COATED",ORAL,20180309,,NDA AUTHORIZED GENERIC,NDA020646,"Teva Pharmaceuticals USA, Inc.",TIAGABINE HYDROCHLORIDE,16,mg/1,"Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8117,HUMAN PRESCRIPTION DRUG,Famciclovir,,Famciclovir,"TABLET, FILM COATED",ORAL,20070905,,ANDA,ANDA077487,"Teva Pharmaceuticals USA, Inc.",FAMCICLOVIR,125,mg/1,"DNA Polymerase Inhibitors [MoA], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8118,HUMAN PRESCRIPTION DRUG,Famciclovir,,Famciclovir,"TABLET, FILM COATED",ORAL,20070905,,ANDA,ANDA077487,"Teva Pharmaceuticals USA, Inc.",FAMCICLOVIR,250,mg/1,"DNA Polymerase Inhibitors [MoA], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8119,HUMAN PRESCRIPTION DRUG,Famciclovir,,Famciclovir,"TABLET, FILM COATED",ORAL,20070905,,ANDA,ANDA077487,"Teva Pharmaceuticals USA, Inc.",FAMCICLOVIR,500,mg/1,"DNA Polymerase Inhibitors [MoA], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8162,HUMAN PRESCRIPTION DRUG,Quetiapine,,Quetiapine,"TABLET, FILM COATED",ORAL,20120327,,ANDA,ANDA077745,"Teva Pharmaceuticals USA, Inc.",QUETIAPINE FUMARATE,100,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8163,HUMAN PRESCRIPTION DRUG,Quetiapine,,Quetiapine,"TABLET, FILM COATED",ORAL,20120327,,ANDA,ANDA077745,"Teva Pharmaceuticals USA, Inc.",QUETIAPINE FUMARATE,200,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8164,HUMAN PRESCRIPTION DRUG,Quetiapine,,Quetiapine,"TABLET, FILM COATED",ORAL,20120327,,ANDA,ANDA077745,"Teva Pharmaceuticals USA, Inc.",QUETIAPINE FUMARATE,300,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8165,HUMAN PRESCRIPTION DRUG,Quetiapine,,Quetiapine,"TABLET, FILM COATED",ORAL,20120327,,ANDA,ANDA077745,"Teva Pharmaceuticals USA, Inc.",QUETIAPINE FUMARATE,400,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8166,HUMAN PRESCRIPTION DRUG,Quetiapine,,Quetiapine,"TABLET, FILM COATED",ORAL,20120327,,ANDA,ANDA077745,"Teva Pharmaceuticals USA, Inc.",QUETIAPINE FUMARATE,50,mg/1,Atypical Antipsychotic [EPC],,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8180,HUMAN PRESCRIPTION DRUG,Oseltamivir Phosphate,,Oseltamivir Phosphate,"POWDER, FOR SUSPENSION",ORAL,20190710,,ANDA,ANDA211125,"Teva Pharmaceuticals USA, Inc.",OSELTAMIVIR PHOSPHATE,6,mg/mL,"Neuraminidase Inhibitor [EPC], Neuraminidase Inhibitors [MoA]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8192,HUMAN PRESCRIPTION DRUG,Cimetidine,,Cimetidine,"TABLET, FILM COATED",ORAL,20031124,,ANDA,ANDA074151,"Teva Pharmaceuticals USA, Inc.",CIMETIDINE,300,mg/1,"Histamine H2 Receptor Antagonists [MoA], Histamine-2 Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8199,HUMAN PRESCRIPTION DRUG,Sunitinib Malate,,Sunitinib Malate,CAPSULE,ORAL,20211222,,ANDA,ANDA213803,"Teva Pharmaceuticals USA, Inc.",SUNITINIB MALATE,12.5,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8204,HUMAN PRESCRIPTION DRUG,Cimetidine,,Cimetidine,"TABLET, FILM COATED",ORAL,20040202,,ANDA,ANDA074151,"Teva Pharmaceuticals USA, Inc.",CIMETIDINE,400,mg/1,"Histamine H2 Receptor Antagonists [MoA], Histamine-2 Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8210,HUMAN PRESCRIPTION DRUG,Finzala,,norethindrone acetate and ethinyl estradiol and ferrous fumarate,KIT,,20220804,,ANDA,ANDA210087,"Teva Pharmaceuticals USA, Inc.",,,,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8224,HUMAN PRESCRIPTION DRUG,Sunitinib Malate,,Sunitinib Malate,CAPSULE,ORAL,20211222,,ANDA,ANDA213803,"Teva Pharmaceuticals USA, Inc.",SUNITINIB MALATE,25,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8229,HUMAN PRESCRIPTION DRUG,Sunitinib Malate,,Sunitinib Malate,CAPSULE,ORAL,20211222,,ANDA,ANDA213803,"Teva Pharmaceuticals USA, Inc.",SUNITINIB MALATE,37.5,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8231,HUMAN PRESCRIPTION DRUG,Sunitinib Malate,,Sunitinib Malate,CAPSULE,ORAL,20211222,,ANDA,ANDA213803,"Teva Pharmaceuticals USA, Inc.",SUNITINIB MALATE,50,mg/1,"Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8232,HUMAN PRESCRIPTION DRUG,Irbesartan and Hydrochlorothiazide,,Irbesartan and Hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20130827,,ANDA,ANDA077369,"Teva Pharmaceuticals USA, Inc.",HYDROCHLOROTHIAZIDE; IRBESARTAN,12.5; 300,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8238,HUMAN PRESCRIPTION DRUG,Irbesartan and Hydrochlorothiazide,,Irbesartan and Hydrochlorothiazide,"TABLET, FILM COATED",ORAL,20130124,,ANDA,ANDA077369,"Teva Pharmaceuticals USA, Inc.",HYDROCHLOROTHIAZIDE; IRBESARTAN,12.5; 150,mg/1; mg/1,"Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8305,HUMAN PRESCRIPTION DRUG,Cimetidine,,Cimetidine,"TABLET, FILM COATED",ORAL,20031206,,ANDA,ANDA074463,"Teva Pharmaceuticals USA, Inc.",CIMETIDINE,800,mg/1,"Histamine H2 Receptor Antagonists [MoA], Histamine-2 Receptor Antagonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8310,HUMAN PRESCRIPTION DRUG,Eletriptan Hydrobromide,,Eletriptan Hydrobromide,"TABLET, FILM COATED",ORAL,20170721,,ANDA,ANDA202040,"Teva Pharmaceuticals USA, Inc.",ELETRIPTAN HYDROBROMIDE,20,mg/1,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8311,HUMAN PRESCRIPTION DRUG,Eletriptan Hydrobromide,,Eletriptan Hydrobromide,"TABLET, FILM COATED",ORAL,20170721,,ANDA,ANDA202040,"Teva Pharmaceuticals USA, Inc.",ELETRIPTAN HYDROBROMIDE,40,mg/1,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8342,HUMAN PRESCRIPTION DRUG,Glyburide,,Glyburide,TABLET,ORAL,19950830,,ANDA,ANDA074388,"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,1.25,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8343,HUMAN PRESCRIPTION DRUG,Glyburide,,Glyburide,TABLET,ORAL,19950830,,ANDA,ANDA074388,"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,2.5,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8344,HUMAN PRESCRIPTION DRUG,Glyburide,,Glyburide,TABLET,ORAL,19950830,,ANDA,ANDA074388,"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,5,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8675,HUMAN PRESCRIPTION DRUG,Amoxicillin and Clavulanate Potassium,,Amoxicillin and Clavulanate Potassium,"POWDER, FOR SUSPENSION",ORAL,20040923,,ANDA,ANDA065162,"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN; CLAVULANATE POTASSIUM,600; 42.9,mg/5mL; mg/5mL,"Penicillin-class Antibacterial [EPC], Penicillins [CS], beta Lactamase Inhibitor [EPC], beta Lactamase Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8739,HUMAN PRESCRIPTION DRUG,Mexiletine Hydrochloride,,Mexiletine Hydrochloride,CAPSULE,ORAL,19950605,,ANDA,ANDA074377,"Teva Pharmaceuticals USA, Inc.",MEXILETINE HYDROCHLORIDE,150,mg/1,Antiarrhythmic [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8740,HUMAN PRESCRIPTION DRUG,Mexiletine Hydrochloride,,Mexiletine Hydrochloride,CAPSULE,ORAL,19950605,,ANDA,ANDA074377,"Teva Pharmaceuticals USA, Inc.",MEXILETINE HYDROCHLORIDE,200,mg/1,Antiarrhythmic [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-8741,HUMAN PRESCRIPTION DRUG,Mexiletine Hydrochloride,,Mexiletine Hydrochloride,CAPSULE,ORAL,19950605,,ANDA,ANDA074377,"Teva Pharmaceuticals USA, Inc.",MEXILETINE HYDROCHLORIDE,250,mg/1,Antiarrhythmic [EPC],,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9018,HUMAN PRESCRIPTION DRUG,Cyclosporine,Modified,Cyclosporine,"CAPSULE, LIQUID FILLED",ORAL,20210608,,ANDA,ANDA065110,"Teva Pharmaceuticals USA, Inc.",CYCLOSPORINE,25,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9019,HUMAN PRESCRIPTION DRUG,Cyclosporine,Modified,Cyclosporine,"CAPSULE, LIQUID FILLED",ORAL,20210608,,ANDA,ANDA065110,"Teva Pharmaceuticals USA, Inc.",CYCLOSPORINE,50,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9020,HUMAN PRESCRIPTION DRUG,Cyclosporine,Modified,Cyclosporine,"CAPSULE, LIQUID FILLED",ORAL,20210608,,ANDA,ANDA065110,"Teva Pharmaceuticals USA, Inc.",CYCLOSPORINE,100,mg/1,"Calcineurin Inhibitor Immunosuppressant [EPC], Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",,N,20261231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9147,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,TABLET,ORAL,20060804,,ANDA,ANDA076690,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,25,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9148,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,TABLET,ORAL,20060804,,ANDA,ANDA076690,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,37.5,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9149,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,TABLET,ORAL,20060804,,ANDA,ANDA076690,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,50,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9157,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,TABLET,ORAL,20060804,,ANDA,ANDA076690,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,75,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9163,HUMAN PRESCRIPTION DRUG,Venlafaxine Hydrochloride,,Venlafaxine Hydrochloride,TABLET,ORAL,20060804,,ANDA,ANDA076690,"Teva Pharmaceuticals USA, Inc.",VENLAFAXINE HYDROCHLORIDE,100,mg/1,"Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9222,HUMAN PRESCRIPTION DRUG,Diflunisal,,Diflunisal,"TABLET, FILM COATED",ORAL,20210630,,ANDA,ANDA073673,"Teva Pharmaceuticals USA, Inc.",DIFLUNISAL,500,mg/1,"Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9224,HUMAN PRESCRIPTION DRUG,mesalamine,,mesalamine,"CAPSULE, EXTENDED RELEASE",ORAL,20210105,,NDA AUTHORIZED GENERIC,NDA022301,"Teva Pharmaceuticals USA, Inc.",MESALAMINE,375,mg/1,"Aminosalicylate [EPC], Aminosalicylic Acids [CS]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9290,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,"TABLET, ORALLY DISINTEGRATING",ORAL,20220302,,ANDA,ANDA077194,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,0.125,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9291,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,"TABLET, ORALLY DISINTEGRATING",ORAL,20220302,,ANDA,ANDA077194,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,0.25,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9292,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,"TABLET, ORALLY DISINTEGRATING",ORAL,20220302,,ANDA,ANDA077194,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,0.5,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9293,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,"TABLET, ORALLY DISINTEGRATING",ORAL,20211122,,ANDA,ANDA077194,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,1,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9294,HUMAN PRESCRIPTION DRUG,Clonazepam,,Clonazepam,"TABLET, ORALLY DISINTEGRATING",ORAL,20220302,,ANDA,ANDA077194,"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,2,mg/1,"Benzodiazepine [EPC], Benzodiazepines [CS]",CIV,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9364,HUMAN PRESCRIPTION DRUG,Glyburide,,glyburide,TABLET,ORAL,19840501,,NDA AUTHORIZED GENERIC,NDA017532,TEVA Pharmaceuticals USA Inc,GLYBURIDE,5,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9433,HUMAN PRESCRIPTION DRUG,Glyburide,,glyburide,TABLET,ORAL,19840501,,NDA AUTHORIZED GENERIC,NDA017532,TEVA Pharmaceuticals USA Inc,GLYBURIDE,2.5,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9477,HUMAN PRESCRIPTION DRUG,Glyburide,,glyburide,TABLET,ORAL,19840501,,NDA AUTHORIZED GENERIC,NDA017532,TEVA Pharmaceuticals USA Inc,GLYBURIDE,1.25,mg/1,"Sulfonylurea Compounds [CS], Sulfonylurea [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9609,HUMAN PRESCRIPTION DRUG,doxepin hydrochloride,,doxepin hydrochloride,CREAM,TOPICAL,20230217,,ANDA,ANDA215408,"Teva Pharmaceuticals USA, Inc.",DOXEPIN HYDROCHLORIDE,50,mg/g,Tricyclic Antidepressant [EPC],,N,20251231,F32.9,"[{""icd10_code"":""F32.9"",""description"":""Major depressive disorder, single episode, unspecified"",""confidence"":0.5,""context"":""depression""},{""icd10_code"":""F33.9"",""description"":""Major depressive disorder, recurrent, unspecified"",""confidence"":0.25,""context"":""recurrent depression""},{""icd10_code"":""F41.9"",""description"":""Anxiety disorder, unspecified"",""confidence"":0.15,""context"":""anxiety/panic""},{""icd10_code"":""F43.10"",""description"":""Post-traumatic stress disorder, unspecified"",""confidence"":0.05,""context"":""PTSD""},{""icd10_code"":""F50.00"",""description"":""Anorexia nervosa, unspecified"",""confidence"":0.05,""context"":""eating disorders""}]",0.50
0093-9614,HUMAN PRESCRIPTION DRUG,Silver Nitrate,,Silver Nitrate,SOLUTION,TOPICAL,19910101,20270630,UNAPPROVED DRUG OTHER,,"Teva Pharmaceuticals USA, Inc.",SILVER NITRATE,0.005,g/mL,,,N,,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0093-9701,HUMAN PRESCRIPTION DRUG,Carbidopa and levodopa,,Carbidopa and levodopa,TABLET,ORAL,20220118,,ANDA,ANDA074260,"Teva Pharmaceuticals USA, Inc.",CARBIDOPA; LEVODOPA,10; 100,mg/1; mg/1,"Amino Acids, Aromatic [CS], Aromatic Amino Acid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9702,HUMAN PRESCRIPTION DRUG,Carbidopa and levodopa,,Carbidopa and levodopa,TABLET,ORAL,20220118,,ANDA,ANDA074260,"Teva Pharmaceuticals USA, Inc.",CARBIDOPA; LEVODOPA,25; 100,mg/1; mg/1,"Amino Acids, Aromatic [CS], Aromatic Amino Acid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0093-9703,HUMAN PRESCRIPTION DRUG,Carbidopa and levodopa,,Carbidopa and levodopa,TABLET,ORAL,20231215,,ANDA,ANDA074260,"Teva Pharmaceuticals USA, Inc.",CARBIDOPA; LEVODOPA,25; 250,mg/1; mg/1,"Amino Acids, Aromatic [CS], Aromatic Amino Acid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0096-0682,HUMAN OTC DRUG,Solbar Shield SPF40,,Solbar Shield SPF40,CREAM,TOPICAL,19960601,,OTC MONOGRAPH DRUG,M020,Person and Covey,TITANIUM DIOXIDE; ZINC OXIDE,.05; .075,g/g; g/g,"Copper Absorption Inhibitor [EPC], Decreased Copper Ion Absorption [PE]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0685,HUMAN OTC DRUG,Solbar Thirty SPF 30,,Solbar Thirty SPF30,CREAM,TOPICAL,19960601,,OTC MONOGRAPH DRUG,M020,Person and Covey,AVOBENZONE; HOMOSALATE; OCTINOXATE; OCTOCRYLENE; OXYBENZONE,.03; .12; .075; .015; .06,g/g; g/g; g/g; g/g; g/g,,,N,20261231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0687,HUMAN OTC DRUG,Solbar Avo SPF35,,Solbar Avo SPF35,CREAM,TOPICAL,19960601,,OTC MONOGRAPH DRUG,M020,Person and Covey,AVOBENZONE; HOMOSALATE; OCTINOXATE; OXYBENZONE,.03; .08; .075; .06,g/g; g/g; g/g; g/g,,,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0688,HUMAN OTC DRUG,Solbar Zinc SPF38,,Solbar Zinc SPF38,CREAM,TOPICAL,19960601,,OTC MONOGRAPH DRUG,M020,Person and Covey,HOMOSALATE; OCTINOXATE; ZINC OXIDE,.1015; .077; .077,g/g; g/g; g/g,"Copper Absorption Inhibitor [EPC], Decreased Copper Ion Absorption [PE]",,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0709,HUMAN OTC DRUG,Xerac AC,,Xerac AC,LIQUID,TOPICAL,19960601,,OTC MONOGRAPH DRUG,M019,Person and Covey,ALUMINUM CHLORIDE,0.0625,g/g,,,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0721,HUMAN OTC DRUG,Daily Facial Moisturizer,SPF 25,Sunscreen,CREAM,TOPICAL,19910801,,OTC MONOGRAPH DRUG,M020,Person and Covey,AVOBENZONE; HOMOSALATE; OCTINOXATE; OCTOCRYLENE,.03; .06; .075; .015,g/g; g/g; g/g; g/g,,,N,20261231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0732,HUMAN OTC DRUG,Aquanil HC,,Hydrocortisone,LOTION,TOPICAL,19950108,,OTC MONOGRAPH DRUG,M017,Person and Covey,HYDROCORTISONE,0.01,g/g,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20261231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0736,HUMAN OTC DRUG,DHS tar gel,,coal tar,SHAMPOO,TOPICAL,19960601,,OTC MONOGRAPH DRUG,M032,Person and Covey,COAL TAR,0.005,g/g,,,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0737,HUMAN OTC DRUG,DHS TAR,,coal tar,SHAMPOO,TOPICAL,19950601,,OTC MONOGRAPH DRUG,M032,Person and Covey,COAL TAR,0.005,g/g,,,N,20251231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0738,HUMAN OTC DRUG,DHS SAL,4 oz.,DHS SAL,SHAMPOO,TOPICAL,19950601,,OTC MONOGRAPH DRUG,M032,Person and Covey,SALICYLIC ACID,0.035,g/g,,,N,20261231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0096-0741,HUMAN OTC DRUG,Solbar Fifty SPF50,,Solbar Fifty SPF50,CREAM,TOPICAL,19960601,,OTC MONOGRAPH DRUG,M020,Person and Covey,AVOBENZONE; OCTINOXATE; OCTOCRYLENE; OXYBENZONE,.011; .08; .1; .06,g/g; g/g; g/g; g/g,,,N,20261231,L30.9,"[{""icd10_code"":""L30.9"",""description"":""Dermatitis, unspecified"",""confidence"":0.6,""context"":""skin condition""},{""icd10_code"":""L20.9"",""description"":""Atopic dermatitis, unspecified"",""confidence"":0.2,""context"":""eczema""},{""icd10_code"":""L40.9"",""description"":""Psoriasis, unspecified"",""confidence"":0.2,""context"":""psoriasis""}]",0.60
0113-0019,HUMAN OTC DRUG,Good Sense Severe NightTime,,"Acetaminophen, dextromethorphan HBr, doxylamine succinate, phenylephrine HCl",SOLUTION,ORAL,20151021,,OTC MONOGRAPH DRUG,M012,L. Perrigo Company,ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; DOXYLAMINE SUCCINATE; PHENYLEPHRINE HYDROCHLORIDE,650; 20; 12.5; 10,mg/30mL; mg/30mL; mg/30mL; mg/30mL,"Adrenergic alpha1-Agonists [MoA], Antihistamine [EPC], Histamine Receptor Antagonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0113-0020,HUMAN OTC DRUG,good sense childrens pain and fever,,Acetaminophen,SUSPENSION,ORAL,20140320,,OTC MONOGRAPH DRUG,M013,L. Perrigo Company,ACETAMINOPHEN,160,mg/5mL,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0113-0025,HUMAN OTC DRUG,Good Sense Pain Relief,,Acetaminophen,"TABLET, FILM COATED",ORAL,20151006,,OTC MONOGRAPH DRUG,M013,L. Perrigo Company,ACETAMINOPHEN,500,mg/1,,,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
0113-0028,HUMAN OTC DRUG,Good Sense 24 hour allergy nasal,,Fluticasone propionate,"SPRAY, METERED",NASAL,20160803,,ANDA,ANDA207957,L. Perrigo Company,FLUTICASONE PROPIONATE,50,ug/1,"Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",,N,20251231,Z51.81,"[{""icd10_code"":""Z51.81"",""description"":""Encounter for therapeutic drug level monitoring"",""confidence"":0.1,""context"":""generic drug therapy""}]",0.10
